Modifications of soybean transgenic event mon87751 and methods thereof

Abstract

Modified soybean event MON87751 and plants, plant cells, seeds, plant parts, progeny plants, commodity products comprising detectable amounts of modified soybean event MON87751 DNA are provided. Polynucleotides and sequences specific for a modified soybean event MON87751 and methods for making and using plants, plant cells, seeds, plant parts, progeny plants, and commodity products comprising a modified soybean event MON87751, and methods for detecting a modified soybean event MON87751, in a DNA molecule or sample, are provided.

Description

MODIFICATIONS OF SOYBEAN TRANSGENIC EVENT MON87751AND METHODS THEREOFREFERENCE TO RELATED APPLICATION

[0001] This application claims the priority of U.S. Provisional Appl. Ser. 63 / 554,393, filed February 16, 2024, the entire disclosure of which is incorporated herein by reference.INCORPORATION OF SEQUENCE LISTING

[0002] The sequence listing contained in the file named BCS246027_SEQLIST_ST26.xml, which is 288,838 bytes (size as measured in Microsoft Windows®), and was created on January 16, 2025, is filed herewith by electronic submission and is incorporated by reference herein.FIELD OF THE INVENTION

[0003] The present invention relates to recombinant DNA molecules present in and / or isolated from a modified soybean event MON87751. The invention also relates to soybean plants, plant parts, plant seeds, plant cells, progeny plants, and agricultural products containing a modified soybean event MON87751, as well as methods of using the same, and making and detecting the presence of a modified soybean event MON87751. Transgenic soybean plants, plant parts, seed and cells containing a modified soybean event MON87751 DNA may exhibit resistance to infestations by insects in the Lepidoptera family.BACKGROUND

[0004] Soybean (Glycine max) is an important crop in many areas of the world, and biotechnology methods have been applied to this crop in order to produce soybean varieties with desirable traits. One such desirable trait is insect resistance. The expression of an insect resistance transgene in a plant can confer the desirable trait of insect resistance on the plant, but expression of the transgene may be influenced by many different factors including the orientation and composition of the cassettes driving expression of the individual genes transferred to the plant chromosome, the chromosomal location, and the genomic result of the transgene insertion. For example, it has been observed in plants that there is variation in the level and pattern of transgene expression amongindividual events that differ in the chromosomal insertion site of the transgene but are otherwise identical. There can also be phenotypic or agronomic differences between events. Therefore, it is often necessary to produce and analyze a large number of individual plant cell transformation events in order to select an event having both the desirable trait and the optimal phenotypic and agricultural characteristics suitable for commercial success. Selecting the preferred transgenic event requires extensive molecular characterization, as well as greenhouse and field trials with many events over multiple years, in multiple locations, and under a variety of conditions. A significant amount of efficacy, phenotypic, and molecular data is collected, and the resulting data and observations are then analyzed by teams of scientists and agronomists with the goal of selecting one or more commercially suitable events. Such an event, once selected, is then used for introgression of the desirable transgenic trait into other genetic backgrounds using plant breeding methods, thus producing a number of different crop varieties that contain the desirable trait and are suitably adapted to specific local agronomic conditions.

[0005] Transgenic soybeans which rely upon expression of a single toxin for insecticidal control of insect infestation may be at risk of limited durability because of the increased likelihood of development of resistance to the toxin by the insect pests. Similarly, transgenic soybeans containing toxic agents that do not provide multiple unique modes of action could also be at risk of limited durability. The first available soybean that produces a protein toxic to lepidopterans contains a single toxin protein, CrylAc. A recent soybean transgenic event has been disclosed that contains CrylAc and CrylF toxin proteins. If resistance to CrylAc occurs, the CrylAc and CrylF transgenic event would be left with only the CrylF toxin as its source of efficacy. It is therefore necessary to provide for a soybean plant that has two or more toxic agents that control the pests controlled by CrylAc in which none of the toxic agents bind the same or substantially the same receptors in the target insect midgut that are bound by CrylAc. The invention described herein provides for a transgenic soybean event MON87751 that overcomes the durability problem described above for the soybean transgenic events described in the prior art, by providing two or more agents toxic to lepidopteran pest species, in which neither toxic agent has previously been included in any soybean plant for the purpose of targeting for control the lepidopteran pests of soybean.

[0006] There is a continuing need in the art to provide novel transgenic events in soybean that exhibit resistance to insect infestation, and preferably the novel transgenic events confer resistanceto the target insects, including those races that have evolved resistance to the exi sting commercially deployed traits, using modes of action that are not overlapping with or similar to the modes of action previously deployed in earlier commercial embodiments. The present disclosure provides for modifications of a novel transgenic event that confers resistance to soybean Lepidopteran infestations.SUMMARY

[0007] In one aspect, the present disclosure provides a recombinant DNA molecule comprising: (a) a first nucleotide sequence (i) comprising an expression cassette that encodes a Cry 1 A. 105 or Cry2Ab protein, and / or (ii) selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8; and (b) a second nucleotide sequence that (i) comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47, or (ii) or is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47, or (iii) is selected from the group consisting of SEQ ID NOs: 49-148. In some embodiments, the first nucleotide sequence of the recombinant DNA molecule comprises at least one expression cassette, wherein the expression cassette encodes Cry2Ab or Cry 1A. 105. In some embodiments, the first nucleotide sequence of the recombinant DNA molecule comprises at least two expression cassettes comprising a first expression cassette and a second expression cassette, wherein the first expression cassette encodes Cry2Ab, and the second expression cassette encodes Cry 1 A. 105. In some embodiments, the recombinant DNA moleculemay further comprise (c) a third nucleotide sequence that (i) comprises at least 10, at least 1 1 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or (ii) is at at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or (iii) is selected from the group consisting of SEQ ID NOs: 149-248. The third nucleotide sequence, in certain embodiments, is selected from the group consisting of SEQ ID NOs: 149-248. The recombinant DNA molecule, in particular embodiments, has a deletion of one or more consecutive nucleotides between the second nucleotide sequence and the third nucleotide sequence relative to SEQ ID NO: 10, 28, or 48.

[0008] In another aspect, the present disclosure provides a recombinant DNA molecule comprising: (a) a first nucleotide sequence (i) comprising an expression cassette that encodes a Cry2Ab or CrylA.105 protein, and / or (ii) selected from the group consisting of of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8; and (b) a second nucleotide sequence that (i) comprises at least 10, at least 1 1, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or (ii) is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13,at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21 , at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or (iii) is selected from the group consisting of SEQ ID NOs: 149-248. In some embodiments, the first nucleotide sequence of the recombinant DNA molecule comprises at least one expression cassette, wherein the expression cassette encodes Cry2Ab or Cry 1A.105. In some embodiments, the first nucleotide sequence of the recombinant DNA molecule comprises at least two expression cassettes comprising a first expression cassette and a second expression cassette, wherein the first expression cassette encodes Cry2Ab, and the second expression cassette encodes Cry 1 A.105. In certain embodiment, the second nucleotide sequence is selected from the group consisting of SEQ ID NOs: 149-248. The recombinant DNA molecule, in some embodiments, has a deletion of one or more consecutive nucleotides between the first nucleotide sequence and the second nucleotide sequence relative to SEQ ID NO: 10, 28, or 48. In particular embodiments, the recombinant DNA molecule may further comprise nucleotides 1- 1,334 or 10, 120-12,640 of SEQ ID NO: 10.

[0009] In many embodiments, a recombinant DNA molecule is comprised in a soybean plant, soybean plant part, soybean plant cell, soybean plant seed, soybean progeny plant, or commodity or fuel product made from soybean and soybean plant parts.

[0010] In yet another aspect, the present disclosure provides a recombinant DNA molecule comprising a polynucleotide segment of sufficient length to function as a DNA probe that hybridizes specifically under stringent hybridization conditions with a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 47, and SEQ ID NO: 48. In still yet another aspect, the present disclosure provides a pair of DNA molecules that can function as DNA primers when used together in an amplification reaction comprising a first DNA molecule and a second DNA molecule, wherein the first DNA molecule and the second DNA molecule are different, (a) wherein the first DNA molecule is: (i) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%,at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 1 1 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof, or (ii) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 1 1, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; and (b) wherein the second DNA molecule is: (i) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof, or (ii) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof, or (iii) at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof. In certain embodiments, the first DNA molecule and the second DNA molecule can be used together in an amplification reaction with a sample from a plant, plant part, plant seed, plant cell, food or animal feed, or commodity or fuel product made from a plant or plant part to produce an amplicon diagnostic for the presence of a modified soybean event MON87551 DNA in said sample. The amplicon, in some embodiments, comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

[0011] In one aspect, the present disclosure provides a method of detecting the presence of a DNA segment diagnostic for a modified soybean event MON87551 DNA in a sample, said method comprising: contacting the sample with the DNA molecule that functions as a DNA probe of the present disclosure; subjecting the sample and the DNA molecule to stringent hybridization conditions; and detecting hybridization of the DNA molecule to the DNA segment in the sample, wherein the detection is diagnostic for the presence of the modified soybean event MON87551 DNA in the sample. In another aspect, the present disclosure provides a method of detecting the presence of a DNA segment diagnostic for a modified soybean event MON87551 DNA in a sample, the method comprising: contacting the sample with a pair of DNA molecules capable of functioning as DNA primers when used together in an amplification reaction provided by the present disclosure; performing an amplification reaction sufficient to produce a DNA amplicon; and detecting the presence of the DNA amplicon in the reaction, wherein the presence of the DNA amplicon is diagnostic for the presence of the modified soybean event MON87551 DNA in the sample. In yet another aspect, the present disclosure provides a method of detecting the presence of a DNA segment diagnostic for a modified soybean event MON87551 DNA in a sample, the method comprising performing a sequencing reaction with the sample, wherein the production in the sequencing reaction of a target nucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof, is diagnostic for the modified soybean event MON87551 DNA in the sample.In particular embodiments, the modified soybean event MON87551 is a further modified soybean event MON87551. In yet another embodiment, the present disclosure provides a DNA detection kit comprising: (a) a DNA probe of the present disclosure; and / or (b) a pair of DNA molecules that function as DNA primers as provided by the present disclosure.

[0012] In another aspect, the present disclosure provides a modified soybean plant, soybean plant part, soybean seed, or soybean cell comprise a recombinant DNA molecule or DNA segment comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, or a complement thereof; or recombinant DNA molecule or DNA segment comprising a nucleotide sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 47, or SEQ ID NO: 48, or a complement thereof. According to present embodiments, soybean plant, soybean plant part, soybean seed, or soybean cell exhibits resistance to Lepidopteran insect pest species. In particular embodiments, the soybean plant, soybean plant part, soybean seed, or soybean cell is further defined as a progeny plant of any generation of a soybean plant comprising a modified soybean event MON87751, or a soybean plant, soybean plant part, soybean seed, or soybean cell derived therefrom. In some embodiments, a recombinant DNA molecule comprises all or part of chromosome 2 of a soybean genome, or a DNA segment is present in chromosome 2 of a modified soybean plant, soybean plant part, soybean seed, or soybean cell. According to some embodiments, a modified soybean event MON87751 of a modified soybean plant, soybean plant part, soybean seed, or soybean cell comprises a genetic modification, mutation or edit, relative to the soybean event MON87751, introduced via a mutagenesis or targeted genome editing technique.

[0013] In yet another aspect, the present disclosure provides a method of producing a progeny soybean plant comprising a modified soybean event MON87751 comprising: (a) sexually crossing a first modified soybean plant that comprises a modified soybean event MON87751 with itself or a second soybean plant; (b) collecting one or more seeds produced from said cross; (c) growing said seed to produce one or more progeny plants; and (d) selecting at least a first progeny plant or seed comprising a modified soybean event MON87751. The present disclosure, in additional embodiments, provides a hybrid modified soybean plant or seed comprising a modified soybean event MON87751 produced by the methods described herein. In a further embodiment, the method described herein further comprises: (e) collecting seed from said at least first progeny plant comprising a modified soybean event MON87751. In some embodiments, modified soybean plant or seed event MON87751 is a further modified soybean event MON87751.

[0014] Aspects of the present disclosure provide a nonliving soybean plant material comprising a detectable amount of a recombinant DNA molecule as described herein. In some embodiments, the present disclosure provides microorganisms and commodity products comprising a recombinant DNA molecule of the present disclosure. The microorganism, in a number of embodiments, is a plant cell. In some embodiments, a commodity product is produced from a modified soybean plant, soybean plant part, soybean seed, or soybean tissue or cell comprising a modified soybean event MON87751. The modified soybean event MON87751, in certain embodiments, is a further modified soybean event MON87751. In certain aspects, the present disclosure provides a method of producing a commodity product, the method comprising: (a) obtaining a modified soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751; and (b) producing a commodity product from the transgenic soybean plant, soybean plant part, or soybean seed.

[0015] In aspects of the present disclosure, a modified soybean event MON87551 may be a further modified soybean event MON87551.

[0016] In one aspect, the present disclosure provides a soybean plant, soybean plant part, or soybean seed comprising a DNA molecule or segment functional as a template when tested in a DNA amplification method to produce an amplicon diagnostic for the presence of a modified soybean event MON87751 DNA.

[0017] In another aspect, the present disclosure provides a method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: (a) contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with a pair of DNA molecules that function as DNA primers, as provided by the present disclosure; performing a nucleic acid amplification reaction with the sample and the pair of DNA molecules; and detecting in the nucleic acid amplification reaction a first amplicon diagnostic for a modified soybean event MON87551 and a second amplicon diagnostic for native soybean genomic DNA not comprising the modified soybean event MON87751, wherein the presence of only the first amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed homozygous for the modified soybean event MON87751, and the presence of both the first amplicon and the second amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed heterozygous for the modified soybean event MON88751. In yet another aspect, the present disclosure provides a method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 and a second primer pair that can produce a second amplicon of a standard genomic sequence known to be single copy and homozygous in the soybean plant, soybean plant part, or soybean seed; contacting the sample with a first probe that specifically hybridizes to the first amplicon and / or all or part of the modified soybean event MON87751, performing a DNA amplification reaction using real-time PCR with the sample and determining the cycle thresholds (Ct values) of the first amplicon and the second amplicon; calculating the difference (ACt) between the Ct values of the second amplicon and the first amplicon; and determining the zygosity of the modified soybean event MON87751, wherein a ACt of about zero (0) indicates homozygosity of the modified soybean event MON87751 and a ACt of about one (1) indicates heterozygosity of the modified soybean event MON87751. In some embodiments, the first and second primer pairs comprise SEQ ID NO: 11 combined with SEQ ID NO: 12, and SEQ ID NO: 249 combined with SEQ ID NO: 250.

[0018] In still yet another aspect, the present disclosure provides a method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with a primer pair capable of producing a first amplicon diagnostic for the modified soybean event MON87751 and a second amplicon diagnostic for nativesoybean genomic DNA not comprising the modified soybean event MON87751 ; performing a nucleic acid amplification reaction with the sample and the set of primer pairs; and detecting the first amplicon and the second amplicon, wherein the presence of only the first amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed homozygous for the modified soybean event MON87751, the presence of only the second amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed homozygous for native soybean genomic DNA not comprising the modified soybean event MON87751, and the presence of both the first amplicon and the second amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed heterozygous for the modified soybean event MON87751. In one aspect, the present disclosure provides a method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with a probe set which contains at least a first probe that specifically hybridizes to the modified soybean event MON87751 and at least a second probe that specifically hybridizes to soybean genomic DNA that was disrupted by insertion of the heterologous DNA of soybean event MON87751 and is disrupted by the modified soybean event MON87751, wherein the second probe does not hybridize to the modified soybean event MON87751 DNA; and hybridizing the probe set with the sample under stringent hybridization conditions, wherein detecting hybridization of only the first probe under the hybridization conditions is diagnostic for a soybean plant, soybean plant part, or soybean seed homozygous for the modified soybean event MON87751. The probe set, in particular embodiments, comprises SEQ ID NO: 13 and SEQ ID NO: 16. In some embodiments, the modified soybean event MON8775 l is a further modified soybean event MON87751.

[0019] Aspects of the present disclosure provide a population of transgenic soybean plants, wherein each transgenic soybean plant comprises a modified soybean event MON87751. In some embodiments, the population of soybean plants have an increased resistance to Lepidopteran insect pest species on average relative to a population of control soybean plants lacking the modified soybean event MON87751. The modified soybean event MON87751, in additional embodiments, is a further modified soybean event MON87751. In particular embodiments, the population of soybean plants has an increased resistance to a Lepidopteran insect pest species on average relative to a population of control soybean plants lacking the modified soybean event MON87751.

[0020] In some aspect, the present disclosure provides a method of modifying a soybean plant, the method comprising: (a) introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site-specific nuclease into at least one cell of an explant of a soybean plant comprising soybean event MON87751, or a plant part thereof, to produce a modified soybean event MON87751 via a targeted genome editing technique; and (b) developing or regenerating a modified soybean plant from the explant, wherein the modified soybean plant comprises the modified soybean event MON87751. The modified soybean event MON87751, in additional embodiments, is a further modified soybean event MON87751. Nonlimiting examples site-specific nucleases include a zinc-finger nuclease (ZFN), a meganuclease, an RNA-guided endonuclease, a TALE-endonuclease (TALEN), a recombinase, and a transposase. In some embodiments, the site-specific nuclease is an RNA-guided endonuclease or a CRISPR / Cas nuclease. The introducing step (a), in particular embodiments, comprises introducing the recombinant DNA construct into the at least one cell of the explant, wherein the recombinant DNA construct further comprises an expression cassette encoding a first guide RNA (gRNA). The recombinant DNA construct, in additional embodiments, further comprises an expression cassette encoding a second guide RNA (gRNA). The introducing step (a), in certain embodiments, further comprises introducing a first guide RNA (gRNA) or a second recombinant DNA construct comprising an expression cassette encoding a first guide RNA (gRNA) into the at least one cell of the explant. The introducing step (a), in some embodiments, comprises introducing at least two guide RNAs (gRNAs) comprising the first gRNA and a second gRNA into the at least one cell of the explant. In a number of embodiments, the second recombinant DNA construct further comprises an expression cassette encoding a second guide RNA (gRNA). The introducing step (a), in many embodiments, comprises introducing a first gRNA and second recombinant DNA construct comprising an expression cassette encoding a second guide RNA (gRNA) into the at least one cell of the explant. In some embodiments, the site-specific nuclease has a first target site in the genome of the soybean plant at or near soybean event MON87751. In particular embodiments, the site-specific nuclease has a second target site in the genome of the soybean plant at or near soybean event MON87751. The introducing step (a), in certain embodiments, comprises introducing a second site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a second site-specific nuclease into at least one cell of the explant, and wherein the second site-specific nuclease has a second target site inthe genome of the soybean plant at or near soybean event MON87751 . In some embodiments, the first gRNA has a first target site in a flanking DNA sequence, 5' flank, 3 ' flank, junction sequence, or insertion sequence of soybean event MON87751, or a complement thereof. In particular embodiments, the first gRNA has a first target site comprising a target sequence that is: (i) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or (ii) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 1 1, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides SEQ ID NO: 28 or 48, or a complement thereof;; or (iii) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof. In some embodiments, the first gRNA has a second target site comprising a target sequence that is: (i) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotidesof SEQ ID NO: 27 or 47, or a complement thereof; or (ii) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or (iii) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof. In certain embodiments, (i) the first gRNA has a first target site comprising a target sequence that is: (1) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or (2) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or (3) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least99.9% or 100% identical to at least 10, at least 1 1 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof; and (ii) the second gRNA has a second target site comprising a target sequence that is: (ii) wherein the second gRNA has a second target site comprising a target sequence that is: (1) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or (2) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or (3) at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof. In some embodiments, the modified soybean event MON87751 comprises a deletion or excision of intervening genomic DNA between the first target site and the second target site, relative to the soybean event MON87751 . In certain embodiments, the methods of the present disclosure may further comprise selecting the modified soybean plant comprising the modified soybean event MON87751, andsexually crossing the modified soybean plant with itself or a second soybean plant to produce one or more modified progeny soybean plants.

[0021] Aspect of the present disclosure provide a method of introducing a target site into a soybean plant, the method comprising: (a) introducing a cognate target site into the soybean event MON87751 locus of at least one cell of a soybean plant or soybean plant part comprising the soybean event MON87751 or an explant thereof via a targeted genome editing technique, wherein the cognate target site is identical or similar to an originator target site for a site-specific nuclease present in the soybean event MON87751 locus, and (b) developing or regenerating a modified soybean plant comprising a modified soybean event MON87751 comprising the cognate target site. In some embodiments, the methods of the present disclosure may further comprise: (c) introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site-specific nuclease into at least one cell of an explant of a soybean plant comprising the modified soybean event MON87751 or a plant part thereof, to produce a further modified soybean event MON87751 via a targeted genome editing technique, wherein the target site of the site-specific nuclease includes the cognate target site and the originator target site; and (d) developing or regenerating a second modified soybean plant comprising the further modified soybean event MON87751.

[0022] In certain aspects, the present disclosure provides a method of introducing a target site into a soybean plant, the method comprising: (a) introducing a cognate target site into the soybean event MON87751 locus of at least one cell of a soybean plant or soybean plant part comprising the soybean event MON87751 or an explant thereof via a targeted genome editing technique to produce a modified soybean event MON87751 comprising the cognate target site, wherein the cognate target site is identical or similar to an originator target site for a site-specific nuclease present in the soybean event MON87751 locus, and (b) introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site-specific nuclease into at least one cell of an explant of a modified soybean plant comprising the modified soybean event MON87751, or a plant part thereof, to produce a further modified soybean event MON87751 via a targeted genome editing technique, wherein the target site of the site-specific nuclease includes the cognate target site and the originator target site; and (c) developing or regenerating a second modified soybean plant comprising the further modified soybean event MON87751. In some embodiments, the further modified soybean event MON87751 of the second modifiedsoybean plant comprises a deletion or excision of intervening genomic DNA between the originator target site and the cognate target site, relative to the soybean event MON87751 or modified soybean event MON87751. In certain embodiments, the methods of the present disclosure may further comprise selecting the second modified soybean plant or a progeny plant of the second modified soybean plant comprising the further modified soybean event MON87751, and sexually crossing the second modified soybean plant or the progeny plant with itself or another soybean plant to produce one or more modified progeny soybean plants comprising the further modified soybean event MON87751. In some embodiments, the modified soybean event MON87751 is a further modified soybean event MON87751.

[0023] In some aspects, the present disclosure provides a method of modifying an explant of a soybean plant or plant part, the method comprising: introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site-specific nuclease into at least one cell of an explant of a soybean plant or plant part comprising soybean event MON87751 to produce a modified soybean event MON87751 into the at least one cell of the explant. In certain embodiments, the modified soybean event MON87751 is a further modified soybean event MON87751.BRIEF DESCRIPTION OF THE DRAWINGS

[0024] FIG. 1 is a diagrammatic representation of the relative positions, illustrated by each horizontal line, of the segments of the heterologous transgenic DNA, the flanking genomic DNA, the arbitrarily designated 5' and 3' genomic / inserted DNA junctions, and relative positions of sequence unique to event MON87751 within the heterologous transgenic DNA which may be used to identify soybean event MON87751; the horizontal lines labeled [1], [2], [3], [4], [5], [6], [7], [8], [9],

[0010] ,

[0017] ,

[0018] ,

[0019] ,

[0020] ,

[0021] ,

[0022] ,

[0023] ,

[0024] ,

[0025] , and

[0026] correspond to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively; the horizontal line with a thick bar represents the composite of the heterologous transgenic DNA inserted in event MON87751 (SEQ ID NO: 9) and both the 5' and 3 ' flanking genomic DNA and is a representation of SEQ ID NO: 10 containing SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 8; the thick horizontal arrows designatedSQ26901 , SQ20267, SQ25826, and SQ271 15, correspond to SEQ ID NO: 15, SEQ ID NO: 11 , SEQ ID NO: 12, and SEQ ID NO: 14, respectively; the thin horizontal arrows represent the relative organization of the two separate expression cassettes of the heterologous transgenic inserted DNA of event MON87751, P represents a promoter element, L represents a leader, P-L represents a promoter and leader, I represents an intron, CTP represents a chloroplast transit peptide, Cry2Ab represents the coding region for Cry2Ab protein, T=3' transcription termination and polyadenylation element (3' UTR), and CrylA.105 represents the coding region for CrylA.105 protein.

[0025] FIG. 2 illustrates the T-DNA segment encoding the Cry protein expression cassette(s) in the eleven transformation constructs used to generate transgenic soybean events evaluated during selection of soybean event MON87751, and the composition of each Cry protein expression cassette within each construct.

[0026] FIG. 3 is a graphical representation of the results of ELISA analysis of Cry protein expression in events generated with construct 1, construct 2, and construct 3, compared to a non- transgenic soybean line (A3555). Panel A. shows Cry2Ab protein levels in leaf tissue collected at R1 and R3 stage of plant growth. Panel B. shows CrylA.105 protein levels in leaf tissue collected at R1 and R3 stage of plant growth.

[0027] FIG. 4 is a graphical representation of the results of ELISA analysis of Cry protein expression in events generated with construct 1, construct 5, construct 6, and construct 4, compared to a non-transgenic soybean line (A3555). Panel A. shows Cry2Ab protein levels in leaf tissue collected at the R3 stage of plant growth from plants grown in two separate screenhouse trials. Panel B. shows CrylA.105 protein levels in leaf tissue collected at the R3 stage of plant growth from plants grown in two separate screenhouse trials.

[0028] FIG. 5 is a graphical representation of the results of ELISA analysis of Cry2Ab protein expression in events generated with construct 1, construct 2, construct 3, construct, 4, construct 5, construct 6, construct 9, construct 7, and construct 11 for leaf samples collected at the R3 and R5 stage of plant growth.

[0029] FIG. 6 is a graphical representation of the results of ELISA analysis of Cry21 A.105 protein expression in events generated with construct 1, construct 2, construct 3, construct, 4, construct 5, construct 6, construct 9, construct 7, and construct 11 for leaf samples collected at the R3 and R5stage of plant growth. Panel A Y-axis plotted at 0 - 5000 ppm dry weight and Panel B Y-axis plotted at 0-500 ppm dry weight to better illustrate in Panel B the data for the R3 stage.BRIEF DESCRIPTION OF THE SEQUENCES

[0030] SEQ ID NO: 1 is a 20-nucleotide sequence representing the 5' junction region of soybean genomic DNA and the integrated transgenic expression cassette. SEQ ID NO: 1 is positioned in SEQ ID NO: 10 at nucleotide position 1325-1344.

[0031] SEQ ID NO: 2 is a 20-nucleotide sequence representing the 3 ' junction region of soybean genomic DNA and the integrated transgenic expression cassette. SEQ ID NO: 2 is positioned in SEQ ID NO: 10 at nucleotide position 11444-11463.

[0032] SEQ ID NO: 3 is a 60-nucleotide sequence representing the 5 ' junction region of soybean genomic DNA and the integrated transgenic expression cassette. SEQ ID NO: 3 is positioned in SEQ ID NO: 10 at nucleotide position 1305-1364.

[0033] SEQ ID NO: 4 is a 60-nucleotide sequence representing the 3 ' junction region of soybean genomic DNA and the integrated transgenic expression cassette. SEQ ID NO: 4 is positioned in SEQ ID NO: 10 at nucleotide position 11424-11483.

[0034] SEQ ID NO: 5 is a 100-nucleotide sequence representing the 5' junction region of soybean genomic DNA and the integrated transgenic expression cassette. SEQ ID NO: 5 is positioned in SEQ ID NO: 10 at nucleotide position 1285-1384.

[0035] SEQ ID NO: 6 is a 100-nucleotide sequence representing the 3 ' junction region of soybean genomic DNA and the integrated transgenic expression cassette. SEQ ID NO: 6 is positioned in SEQ ID NO: 10 at nucleotide position 11404-11503.

[0036] SEQ ID NO: 7 is a 1,626-nucleotide sequence representing the 5' flanking soybean genomic sequence up to and including the junction of the genomic DNA and transgenic inserted DNA, and includes (5' to 3') 1,334 of flanking genomic DNA and 292 nucleotides of the arbitrarily designated 5' end of the inserted transgenic DNA.

[0037] SEQ ID NO: 8 is a 1,452-nucleotide sequence representing the flanking soybean genomic sequence up to and including the junction of the genomic DNA and transgenic inserted DNA, andincludes (5' to 3') 265 nucleotides of the arbitrarily designated 3' end of the inserted transgenic DNA and 1,187 nucleotides of 3' flanking genomic DNA.

[0038] SEQ ID NO: 9 is a 10,119-nucleotide sequence corresponding to the transgenic DNA inserted in the genome of soybean event MON87751.

[0039] SEQ ID NO: 10 is a 12,640-nucleotide sequence corresponding the composite nucleotide sequence of the transgenic genomic DNA inserted in event MON87751 and the 5' flanking genomic DNA nucleotide sequences and the 3 ' flanking genomic DNA nucleotide sequence and includes SEQ ID NO: 7 and SEQ ID NO: 9 and SEQ ID NO: 8.

[0040] SEQ ID NO: 11 is a 27-nucleotide sequence corresponding to a thermal amplification primer referred to as SQ20267 used to identify soybean event MON87751 DNA in a sample, and is identical to the nucleotide sequence corresponding to positions 11400 to 11426 of SEQ ID NO: 10.

[0041] SEQ ID NO: 12 is a 26-nucleotide sequence corresponding to a thermal amplification primer referred to as SQ25826 used to identify soybean event MON87751 DNA in a sample, and is identical to the reverse compliment of the nucleotide sequence corresponding to positions 11454 to 11479 of SEQ ID NO: 10.

[0042] SEQ ID NO: 13 is a 19-nucleotide sequence corresponding to a probe referred to as PB10263 used to identify soybean event MON87751 DNA in a sample, and is identical to the nucleotide sequence corresponding to positions 11428 to 11446 of SEQ ID NO: 10.

[0043] SEQ ID NO: 14 is a 24-nucleotide sequence corresponding to a thermal amplification primer referred to as SQ27115 used to identify the presence of soybean wild-type allele DNA and / or soybean event MON87751 DNA in a sample, and is identical to the reverse compliment of the nucleotide sequence corresponding to positions 11458 to 11481 of SEQ ID NO: 10.

[0044] SEQ ID NO: 15 is a 30-nucleotide sequence corresponding to a thermal amplification primer referred to as SQ26901 used in a zygosity assay to identify the presence of wild-type allele DNA in a sample derived from soybean, and is identical to the nucleotide sequence corresponding to positions 1288 to 1317 of SEQ ID NO: 10.

[0045] SEQ ID NO: 16 is a 18-nucleotide sequence corresponding to a probe referred to as PB11254 and is used in a zygosity assay to identify the presence of a wild-type allele DNA in a sample derived from soybean.

[0046] SEQ ID NO: 17 is a 112-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is identical to positions 36-147 in SEQ ID NO: 9, and to positions 1,370-1,481 in SEQ ID NO: 10.

[0047] SEQ ID NO: 18 is a 52-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is identical to positions 1,305-1,356 in SEQ ID NO: 9, and to positions 1,639-1,690 in SEQ ID NO: 10.

[0048] SEQ ID NO: 19 is a 283-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is identical to positions 1,561-1,843 in SEQ ID NO: 9, and to positions 2,895-3,177 in SEQ ID NO: 10.

[0049] SEQ ID NO: 20 is a 486-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is identical to positions 2,340-2,825 in SEQ ID NO: 9, and to positions 3,674-4,159 in SEQ ID NO: 10.

[0050] SEQ ID NO: 21 is a 179-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is identical to positions 3,326-3,504 in SEQ ID NO: 9, and to positions 4,660-48,38 in SEQ ID NO: 10.

[0051] SEQ ID NO: 22 is a 106-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is useful for identifying event MON87751 DNA in a sample, and is identical to positions 3,749-3,854 in SEQ ID NO: 9, and to positions 5,083-5,188 in SEQ ID NO: 10.

[0052] SEQ ID NO: 23 is a 60-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is useful for identifying event MON87751 DNA in a sample, and is identical to positions 9,320- 9,379 in SEQ ID NO: 9, and to positions 10,654-10,713 in SEQ ID NO: 10.

[0053] SEQ ID NO: 24 is a 66-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is useful for identifying event MON87751 DNA in a sample, and is identical to positions 9,620-685 in SEQ ID NO: 9, and to positions 10,954-11,019 in SEQ ID NO: 10.

[0054] SEQ ID NO: 25 is a 156-nucleotide sequence corresponding to a unique nucleotide sequence in the transgenic DNA (SEQ ID NO: 9) inserted in soybean event MON87751, and is useful for identifying event MON87751 DNA in a sample, and is identical to positions 9,720-9,875 in SEQ ID NO: 9, and to positions 11,054-1,1209 in SEQ ID NO: 10.

[0055] SEQ ID NO: 26 is a 1,905-nucleotide sequence corresponding to the open reading frame encoding the Cry2Ab protein expressed in soybean event MON87751.

[0056] SEQ ID NO: 27 is a 1,334-nucleotide sequence representing the 5' flanking soybean genomic DNA up to the inserted T-DNA.

[0057] SEQ ID NO: 28 is a 1,187-nucleotide sequence representing the 3' flanking soybean genomic DNA after the inserted T-DNA.

[0058] SEQ ID NO: 29 is a 27-nucleotide sequence corresponding to an OgRRS, OgRRS_5-l.

[0059] SEQ ID NO: 30 is a 27-nucleotide sequence corresponding to an OgRRS, OgRRS_5-2.

[0060] SEQ ID NO: 31 is a 27-nucleotide sequence corresponding to an OgRRS, OgRRS In- 1.

[0061] SEQ ID NO: 32 is a 27-nucleotide sequence corresponding to an OgRRS, OgRRS_3-l.

[0062] SEQ ID NO: 33 is a 27-nucleotide sequence corresponding to an OgRRS, OgRRS_3-2.

[0063] SEQ ID NO: 34 is a 51-nucleotide sequence corresponding to a gRNA, gRNA_OgRRS_5- 1 comprised of a Casl2a protospacer adjacent motif (PAM) site operably linked to a guide-RNA hybridization site.

[0064] SEQ ID NO: 35 is a 51-nucleotide sequence corresponding to a gRNA, gRNA_OgRRS_5- 2.

[0065] SEQ ID NO: 36 is a 51 -nucleotide sequence corresponding to a gRNA, gRNA OgRRS In- 1.

[0066] SEQ ID NO: 37 is a 51 -nucleotide sequence corresponding to a gRNA, gRNA_OgRRS_3- 1.

[0067] SEQ ID NO: 38 is a 51-nucleotide sequence corresponding to a gRNA, gRNA_OgRRS_3- 2.

[0068] SEQ ID NO: 39 is a sequence of a synthetic DNA coding sequence designed for expression in a plant cell encoding a nuclear targeted LbCasl2a CRISPR-associated protein.

[0069] SEQ ID NO: 40 is an amino acid sequence of a nuclear targeted LbCasl2a CRISPR- associated protein encoded by SEQ ID NO: 39.

[0070] SEQ ID NO: 41 is a sequence of a synthetic DNA coding sequence designed for expression in a plant cell encoding a nuclear targeted LbCasl2a-TYCV CRISPR-associated protein.

[0071] SEQ ID NO: 42 is an amino acid sequence of a nuclear targeted LbCasl2a-TYCV CRISPR-associated protein encoded by SEQ ID NO:41.

[0072] SEQ ID NO: 43 is a sequence of a synthetic DNA coding sequence designed for expression in a plant cell encoding a nuclear targeted LbCasl2a-TATV CRISPR-associated protein.

[0073] SEQ ID NO: 44 is an amino acid sequence of a nuclear targeted LbCasl2a-TATV CRISPR-associated protein encoded by SEQ ID NO:43.

[0074] SEQ ID NO: 45 is a sequence of a synthetic DNA coding sequence designed for expression in a plant cell encoding a nuclear targeted FnCasl2a CRISPR-associated protein.

[0075] SEQ ID NO: 46 is an amino acid sequence of a nuclear targeted FnCasl2a CRISPR- associated protein encoded by SEQ ID NO:45.

[0076] SEQ ID NO: 47 is a 5,000-nucleotide sequence representing soybean genomic DNA that flanks the transgenic insert at the 5' end of the insert. Nucleotides 3,667-5,000 of Nucleotides of SEQ ID NO:47 are identical to nucleotides 1-1,334 of SEQ ID NO:27. 1-3,666 are based on the genomic sequence of the Williams 82 cultivar.

[0077] SEQ ID NO: 48 is a 5,000-nucleotide sequence representing soybean genomic DNA that flanks the transgenic insert at the 3' end of the insert. Nucleotides 1-1,187 of SEQ ID NO: 48 are identical to nucleotides 1-1,187 of SEQ ID NO:28. Nucleotides 1,188-5,000 are based on the genomic sequence of the Williams 82 cultivar.

[0078] SEQ ID NOs: 49-121 are 50-nucleotide sequences in the 5' flank genomic sequence of soybean event MON87751 based on the genomic sequence of the Williams 82 cultivar.

[0079] SEQ ID NO: 122 is 50-nucleotide sequence in the 5' flank of event MON87751 based on the genomic sequence of Williams 82 cultivar and the genomic flank sequence of MON87751.

[0080] SEQ ID NOs: 123-148 are 50-nucleotide sequences in the 5' flank genomic sequence of soybean event MON87751.

[0081] SEQ ID NOs: 149-171 are 50-nucleotide sequences in the 3' flank genomic sequence of soybean event MON87751.

[0082] SEQ ID NO: 172 is a 50-nucleotide sequence in the 3' flank of event MON87751 based on the genomic flank sequence of MON87751 and the genomic sequence of Williams 82 cultivar.

[0083] SEQ ID NOs: 173-248 are 50-nucleotide sequences in the 3' flank of event MON87751 based on the genomic sequence of the Williams 82 cultivar.

[0084] SEQ ID NO: 249 is a 20-nucleotide sequence corresponding to a thermal amplification primer referred to as SQ549 used as an internal control for the event and zygosity assay for soybean event GM_CSM63770 and hybridizes to a region of the soybean genome.

[0085] SEQ ID NO: 250 is a 20-nucleotide sequence corresponding to a thermal amplification primer referred to as SQ546 used as an internal control for the event and zygosity assay for soybean event GM_CSM63770 and hybridizes to a region of the soybean genome.

[0086] SEQ ID NO: 251 is a 28-nucleotide sequence corresponding to a probe referred to as PB0004 used as an internal control for the event and zygosity assay for soybean event GM_CSM63770 and hybridizes to a region of the soybean genome.DETAILED DESCRIPTION

[0087] The inventors have identified a transgenic soybean event MON87751 that exhibits commercially acceptable resistance to agriculturally important insect pests in the order Lepidoptera such as Spodoptera frugiperda (fall armyworm, FAW), Spodoptera eridania (southern armyworm, SAW), Spodoptera exigua (beet armyworm, BAW), Spodoptera omithogalli (yellowstriped army worm, YSAW), Crocidosema aporema (bean shoot moth, BSM), Rachiplusia mi (sunflower looper, SFL), Anticarsia gemmatalis (velvetbean caterpillar, VBC),Chrysodeixis includens (soybean looper, SBL), Helicoverpci zect (soybean podworm, SPW), Helicoverpa gelotopeon (South American bollworm ), Elasmopalpus lignosellus, (lesser cornstalk borer), Estigmene acrea (saltmarsh caterpillar), and Plathypena scabra (green cloverworm), amongst others. The event provides two different operably linked expression cassettes, one encoding Cry2Ab, and the other encoding Cry 1 A.105 insecticidal proteins, and provides two different modes of action for resistance to soybean from lepidopteran infestations. Other transgenic soybean events are known in the art, i.e., MON 88701, which expresses a CrylAc Bacillus thuringiensis (Bt) toxin protein (MacRae et al. 2005, Fischhoff & Perlak 1995). MON 88701 provides a single mode of action for resistance to major lepidopteran insect pests of soybean, though efficacy against Spodoptera spp. is not significant. It would be preferable to provide transgenic soybean expressing two or more different insecticidal proteins exhibiting efficacy to major pests of soybean and including control of Spodoptera spp. The inventors provide at least one solution to this problem in the form of the soybean event MON87751, which combines two covalently linked expression cassettes in one locus within the soybean genome, these cassettes conferring the traits of expanded lepidopteran species resistance, and additionally, provides to the soybean cells, soybean tissues, soybean leaves, soybean pods, soybean seed, and soybean plants more than one mode of action to prevent or delay development of resistance among species of Lepidoptera.

[0088] The soybean event MON87751 was produced by an Agrobacterium mediated transformation process of soybean meristem tissue with the plasmid construct 1. This plasmid construct contains two regions, each bounded by Agrobacterium border segments (T-DNA segment). The first T-DNA segment contains two linked plant expression cassettes, one expression cassette encoding a selectable marker and one expression cassette encoding a scorable marker. The second T-DNA segment contains two linked plant expression cassettes with the regulatory genetic elements necessary for expression in soybean plant cells of two different insecticidal proteins, Cry2Ab and Cry 1 A.105. Due to the two T-DNA segments in the plasmid construct 1, the T-DNA segment containing the selection / scorable marker genes inserted randomly into the soybean genome and at a site separate from the site of integration of the T-DNA segment containing the Cry2Ab and Cryl A.105 expression cassettes, thus allowing for segregation of the two T-DNA segments within the genome of the transformed soybean plants during the process of selfing and / or backcrossing, e.g. screening R1 and higher generation of transgenic plants. The transformedsoybean cells were regenerated into intact soybean plants and individual plants were selected from the population of plants that showed integrity of the second T-DNA segment encoding the Cry2Ab and CrylA.105 proteins. InRl and subsequent generations, events were selected based on integrity of the second T-DNA segment encoding the Cry2Ab and Cryl A.105 proteins, and on the absence (i.e., segregation) of the first T-DNA segment encoding the selectable / scorable marker cassettes, and for plants not containing any plasmid backbone sequence. The expression of the Cry2Ab and Cryl A.105 insecticidal toxic proteins in the cells of the soybean event MON87751 confers resistance to lepidopteran insect pests when the soybean cells of event MON87751 are provided in the diet the insects.

[0089] The plasmid DNA inserted into the genome of soybean event MON87751 was characterized by detailed molecular analyses. These analyses included: the insert number (number of integration sites within the soybean genome), the genomic insert location (the specific site in the soybean genome where the insertion occurred), the copy number (the number of copies of the T-DNA within one locus), and the integrity of the transgenic inserted DNA. The plasmid construct containing the two linked expression cassettes inserted into the soybean genome giving rise to the event MON87751 contains multiple segments (junction sequences between elements used to build or construct the several expression cassettes) that are not known to appear naturally in the soybean genome nor in other vectors or transgenic events of soybean or otherwise (for example, sequences as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26). In addition, the transformation event that gave rise to the inserted transgenic DNA in the event MON87751 is characterized herein as an insertion into a single locus in the soybean genome, resulting in two new loci or junction sequences between the inserted DNA and the soybean genome DNA. Also characterized herein are additional unique sequences within the heterologous DNA inserted into the soybean genome of event MON87751 and that are of sufficient length to be unique only to a soybean genome comprising of the event MON87751 DNA. These junction sequences are useful for detecting the presence of the event MON87751 DNA in soybean cells, soybean tissue, soybean seed and soybean plants or soybean plant products (soybean commodity products). DNA molecular probes and primer pairs are described herein that have been developed for use in identifying the presence of these variousjunction segments in biological samples containing or suspected of containing soybean cells, soybean seed, soybean plant parts or soybean plant tissue that contain the event MON87751 DNA. The data show that event MON87751 contains a single T-DNA insertion with one copy of the inserted transgenic DNA. No additional elements from the transformation construct 1 other than portions of the Agrobacterium tumefaciens left and right border regions used for transgenic DNA transfer from the plant transformation plasmid to the soybean genome have been identified in event MON87751 DNA. Finally, thermal amplification producing specific amplicons diagnostic for the presence of such event MON87751 DNA in a sample, and DNA sequence analyses were performed to determine the arbitrarily assigned 5 ' and 3 ' insert-to-plant genome junctions, confirm the organization of the elements within the insert, and determine the complete DNA sequence of the inserted transgene DNA (SEQ ID NO: 9) in soybean event MON87751.

[0090] Dozens of transgenic events were produced using the transformation construct 1 used to produce the transgenic soybean event MON87751, and ten additional transformation constructs were generated and used to produce many dozens of other transgenic soybean events which were compared to the soybean event MON87751 and similar soybean events. These events were tested by ELISA assay for expression in leaf tissue of the two insecticidal proteins, Cry2Ab and Cry 1A.105. A subset of the events produced from each transformation, and most of the constructs, were tested for efficacy for controlling lepidopteran insect pests in small-plot screenhouse trials. It was determined that the plant expression elements, and relative orientation of the Cry2Ab and Cry 1A.105 expression cassettes in the transformation construct 1, provided the events with the best efficacy against the broadest spectrum of lepidopteran insect pests tested.

[0091] As used herein, a “soybean event MON87751 locus” refers to the genomic locus of the soybean event MON87751 or a modified soybean event MON87751 or a further modified soybean event MON87751, wherein the soybean event MON87751 locus includes the flanking, junction and insertion sequences of the soybean event MON87751 or the modified soybean event MON87751 or further modified soybean event MON87751. A modified soybean event MON87751 or a further modified soybean event MON87751 comprises one or more mutations, edits and / or genetic modifications in the soybean event MON87751 locus, such as one or more mutations, edits and / or genetic modifications in a flanking, junction and / or insertion sequence(s) of the soybean event MON87751 locus, relative to the soybean event MON87751.

[0092] According to present embodiments, a modified soybean event MON87751 and methods of making a modified soybean event MON87751 are provided. As is described further herein, various mutagenesis or targeted genome editing techniques and related tools are known and could be made or engineered to permit genetic modification or mutation of the transgenic insert, junction and / or the flanking genomic DNA of soybean event MON87751, such as by deletion, insertion, transposition, inversion, and / or substitution of nucleic acid sequence(s), and / or by insertion or introduction of a guide RNA target site or a cognate target site or CgRRS, and the transgenic event as modified may still be uniquely characterized by the presence of heterologous DNA and / or one or more sequences of the insertion, junction(s) and / or flanking sequence(s) described herein at the same position or location in the genome previously occupied by the unmodified soybean event MON87751 relative to flanking portions or sequences of the native soybean genome. According to present embodiments, a modified transgenic event derived from soybean event MON87751 may comprise all or part of the insertion sequence and / or transgene cassette of soybean event MON87751, one or more of the junction sequence(s) of soybean event MON87751, and / or one or more flanking sequence(s) described herein.

[0093] As used herein, a “modified soybean event MON87751” refers to any genomic DNA or sequence of the soybean event MON87751 locus comprising one or more mutations, edits or genetic modifications relative to the genomic DNA or sequence of the soybean event MON87751 , wherein such mutations or edits are introduced or made by a mutagenesis or targeted genome editing technique of a soybean plant, plant part, tissue or cell comprising the soybean event MON87751. A “modified soybean event MON87751” includes, as a type of modified soybean event MON87751, a “further modified soybean eventMON87751” made by first inserting a target site or cognate target site or CgRRS into the soybean event MON87751 locus and then further modifying the soybean event MON87751 locus as described herein. For clarity, a “modified soybean event MON87751” includes genomic DNA or sequences of the soybean event MON87751 locus comprising one or more mutations, edits or genetic modifications relative to the genomic DNA or sequence of the soybean event MON87751, wherein such mutations or edits are introduced or made by a mutagenesis or targeted genome editing technique of a soybean plant, plant part, tissue or cell comprising the soybean event MON87751, wherein such modified soybean event MON87751 is not a further modified soybean event MON87751. Methods and techniques of mutagenesis are known in the art and include, for example, chemical mutagenesis (i.e., treatmentwith a chemical mutagen, such as an azide, hydroxyl amine, nitrous acid, acridine, nucleotide base analog, or alkylating agent - e.g. , EMS (ethylmethane sulfonate), MNU (N-methyl-N-nitrosourea), etc.), physical mutagenesis (e.g., gamma rays, X-rays, UV, ion beam, other forms of radiation, etc.), and insertional mutagenesis e.g., transposon or T-DNA insertion). As used herein, a “modified soybean plant” refers to a soybean or Glycine genus plant comprising a modified soybean event MON87751 or a further modified soybean event MON87751. Thus, a modified soybean plant part, plant seed, plant tissue, or plant cell comprising a modified soybean event MON87751 or a further modified soybean event MON87751 that is derived, taken or descended from a modified soybean plant and / or created by genetic modification, mutation or editing of the transgenic insert, junction and / or the flanking genomic DNA of soybean event MON87751 in a soybean plant part, plant seed, plant tissue, or plant cell using a mutagenesis or targeted genome editing technique.

[0094] As used herein, a “target site” for genome editing refers to the location of a polynucleotide sequence within a plant genome, which may be within or near soybean event MON87751, that is bound and cleaved by a site-specific nuclease introducing a double stranded break (or singlestranded nick) into the nucleic acid backbone of the polynucleotide sequence and / or its complementary DNA strand. A target site may comprise at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 29, or at least 30 consecutive nucleotides. A “target site” for a RNA-guided nuclease may comprise the sequence of either complementary strand of a double-stranded nucleic acid (DNA) molecule or chromosome at the target site that is bound or hybridized to a guide RNA of a ribonucleoprotein complex comprising the RNA-guided nuclease. A site-specific nuclease may bind to a target site, such as via a non-coding guide RNA (e.g., without being limiting, a CRISPR RNA (crRNA) or a singleguide RNA (sgRNA) as described further below). A non-coding guide RNA (gRNA) provided herein may be complementary to a target site (e.g., complementary to either strand of a doublestranded nucleic acid molecule or chromosome at the target site). It will be appreciated that perfect identity or complementarity may not be required for a non-coding guide RNA to bind or hybridize to a target site. For example, at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 mismatches (or more) between a target site and a non-coding RNA may be tolerated. A “target site” also refers to the location of a polynucleotide sequence within a plant genome,which may be within or near soybean event MON87751 or a modified soybean event MON87751 , that is bound and cleaved by another site-specific nuclease that may not be guided by a non-coding RNA molecule, such as a meganuclease, zinc finger nuclease (ZFN), or a transcription activatorlike effector nuclease (TALEN), to introduce a double stranded break (or single-stranded nick) into the polynucleotide sequence and / or its complementary DNA strand. As used herein, a “target region” or a “targeted region” refers to a polynucleotide sequence or region that is flanked by two or more target sites. Without being limiting, in some embodiments a target region may be subjected to a mutation, deletion, insertion or inversion. As used herein, “flanked” when used to describe a target region of a polynucleotide sequence or molecule, refers to two or more target sites of the polynucleotide sequence or molecule surrounding the target region, with one target site on each side of the target region.

[0095] As used herein, a “donor molecule”, “donor template”, or “donor template molecule” (collectively a “donor template”), which may be a recombinant DNA donor template, is defined as a nucleic acid molecule having a nucleic acid template or insertion sequence for site-directed, targeted insertion or recombination into the genome of a plant cell via repair of a nick or doublestranded DNA break in the genome of a plant cell. For example, a “donor template” may be used for site-directed integration of a guide RNA target site or a cognate target site or CgRRS into a target site within the genome of a plant. A targeted genome editing technique provided herein may comprise the use of one or more, two or more, three or more, four or more, or five or more donor molecules or templates. A “donor template” may be a single-stranded or double-stranded DNA or RNA molecule or plasmid. An “insertion sequence” of a donor template is a sequence designed for targeted insertion into the genome of a plant cell, which may be of any suitable length, such as to include a guide RNA target site or a cognate target site or CgRRS. Such an insertion sequence of a donor template is distinct and different from the transgenic insertion or insert of soybean event MON87751, although they may potentially have sequence(s) in common. A donor template may also have at least one homology sequence or homology arm, such as two homology arms, to direct the integration of a mutation or insertion sequence into a target site within the genome of a plant via homologous recombination, wherein the homology sequence or homology arm(s) are identical or complementary, or have a percent identity or percent complementarity, to a sequence at or near the target site within the genome of the plant. When a donor template comprises homology arm(s)and an insertion sequence, the homology arm(s) will flank or surround the insertion sequence of the donor template.

[0096] As used herein, a “targeted genome editing technique” refers to any method, protocol, or technique that can be used to make a targeted mutation or edit, such as one or more insertions, deletions, substitutions, inversions, transpositions, mutations and / or other genetic modifications at or near a target site in the genome of a plant, and / or a deletion or excision of a target region between two target sites in the genome of a plant, using a site-specific nuclease, such as a meganuclease, a zine-finger nuclease (ZFN), an RNA-guided endonuclease (e.g., the CRISPR / Cas9 system), a TALE-endonuclease (TALEN), a recombinase, or a transposase. A site-specific nuclease may introduce a double stranded break (or single-stranded nick) into the nucleic acid backbone of the polynucleotide sequence and / or its complementary DNA strand. Following the introduction of the single or double-stranded break or nick or cleavage of DNA at or near the target site(s) by the sitespecific nuclease, the genomic sequence can be repaired via a double strand break repair pathway, which may include, for example, non-homologous end-joining (NHEJ), microhomology-mediated end joining (MMEJ), homologous recombination, synthesis-dependent strand annealing (SDSA), single-strand annealing (SSA), or a combination of any thereof, at or near the target site(s). However, if the repair is imperfect, a mutation or edit may be introduced at or near the target site(s), and a target region between two or more target sites may be deleted or excised.

[0097] A “site-specific nuclease” provided herein may be selected from the group consisting of a zinc-finger nuclease (ZFN), a meganuclease, an RNA-guided endonuclease, a TALE- endonuclease (TALEN), a recombinase, a transposase, or any combination thereof. See, e.g., Khandagale, K. et al., “Genome editing for targeted improvement in plants,” Plant Biotechnol Rep 10: 327-343 (2016); and Gaj, T. et al., “ZFN, TALEN and CRISPR / Cas-based methods for genome engineering,” Trends Biotechnol. 31(7): 397-405 (2013), the contents and disclosures of which are incorporated herein by reference. A recombinase may be a serine recombinase attached to a DNA recognition motif, a tyrosine recombinase attached to a DNA recognition motif or other recombinase enzyme known in the art. A recombinase or transposase may be a DNA transposase or recombinase attached to a DNA binding domain. A tyrosine recombinase attached to a DNA recognition motif may be selected from the group consisting of a Cre recombinase, a Flp recombinase, and a Tnpl recombinase. According to some embodiments, a Cre recombinase or a Gin recombinase provided herein is tethered to a zinc-finger DNA binding domain. In anotherembodiment, a serine recombinase attached to a DNA recognition motif provided herein is selected from the group consisting of a PhiC31 integrase, an R4 integrase, and a TP-901 integrase. In another embodiment, a DNA transposase attached to a DNA binding domain provided herein is selected from the group consisting of a TALE-piggyBac and TALE-Mutator.

[0098] According to embodiments of the present disclosure, an RNA-guided endonuclease may be selected from the group consisting of Cast, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, Casl2a, Cpfl, CasX, CasY, and homologs or modified versions thereof, Argonaute (non-limiting examples of Argonaute proteins include Thermits thermophilus Argonaute (TtAgo), Pyrococcus furiosus Argonaute (PfAgo), Natronobacterium gregoryi Argonaute (NgAgo) and homologs or modified versions thereof. According to some embodiments, an RNA-guided endonuclease may be a Cas9 or Cast 2a or Cpfl enzyme.

[0099] In an aspect, a site-specific nuclease provided herein is selected from the group consisting of a zinc-finger nuclease, a meganuclease, an RNA-guided nuclease, a TALE-nuclease, a recombinase, a transposase, or any combination thereof. In another aspect, a site-specific nuclease provided herein is selected from the group consisting of a Cas9 or a Casl2a or Cpfl. In another aspect, a site-specific nuclease provided herein is selected from the group consisting of a Casl , a CaslB, a Cas2, a Cas3, a Cas4, a Cas5, a Cas6, a Cas7, a Cas8, a Cas9, a CaslO, a Casl2a, a Csyl, a Csy2, a Csy3, a Csel, a Cse2, a Cscl, a Csc2, a Csa5, a Csn2, a Csm2, a Csm3, a Csm4, a Csm5, a Csm6, a Cmrl, a Cmr3, a Cmr4, a Cmr5, a Cmr6, a Csbl, a Csb2, a Csb3, a Csxl7, a Csxl4, a CsxlO, a Csxl6, a CsaX, a Csx3, a Csxl, a Csxl5, a Csfl, a Csf2, a Csf3, a Csf4, a Cpfl, CasX, CasY, a homolog thereof, or a modified version thereof. In another aspect, an RNA-guided nuclease provided herein is selected from the group consisting of a Cas9 or a Casl2a or Cpfl. In another aspect, an RNA guided nuclease provided herein is selected from the group consisting of a Casl, a CaslB, a Cas2, a Cas3, a Cas4, a Cas5, a Cas6, a Cas7, a Cas8, a Cas9, a CaslO, a Casl2a, a Csyl, a Csy2, a Csy3, a Csel, a Cse2, a Cscl, a Csc2, a Csa5, a Csn2, a Csm2, a Csm3, a Csm4, a Csm5, a Csm6, a Cmrl, a Cmr3, a Cmr4, a Cmr5, a Cmr6, a Csbl, a Csb2, a Csb3, a Csxl7, a Csxl4, a CsxlO, a Csxl6, a CsaX, a Csx3, a Csxl, a Csxl5, a Csfl, a Csf2, a Csf3, a Csf4, a Cpfl, CasX, CasY, a homolog thereof, or a modified version thereof. In another aspect, amethod and / or a composition provided herein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten sitespecific nucleases. In yet another aspect, a method and / or a composition provided herein comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten polynucleotides encoding at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten site-specific nucleases.

[0100] For RNA-guided endonucleases, a guide RNA (gRNA) molecule is further provided to direct the endonuclease to a target site in the genome of the plant via base-pairing or hybridization to cause a DSB or nick at or near the target site. The gRNA may be transformed or introduced into a plant cell or tissue (perhaps along with a nuclease, or nuclease-encoding DNA molecule, construct or vector) as a gRNA molecule, or as a recombinant DNA molecule, construct, or vector comprising a polynucleotide or transcribable DNA sequence encoding the guide RNA operably linked to a plant-expressible promoter. As understood in the art, a “guide RNA” may comprise, for example, a CRISPR RNA (crRNA), a single-chain guide RNA (sgRNA), or any other RNA molecule that may guide or direct an endonuclease to a specific target site in the genome. A “single-chain guide RNA” (or “sgRNA”) is a RNA molecule comprising a crRNA covalently linked a tracrRNA by a linker sequence, which may be expressed as a single RNA transcript or molecule. The guide RNA comprises a guide or targeting sequence that is identical or complementary to a target site within the plant genome, such as within or near soybean event MON87751 or a modified soybean event MON87751. A protospacer-adjacent motif (PAM) may be present in the genome immediately adjacent and upstream or downstream of the genomic target site sequence complementary to the targeting sequence of the guide RNA as known in the art. See, e.g., Wu, X. et al., “Target specificity of the CRISPR-Cas9 system,” Quant Biol. 2(2): 59-70 (2014), the content and disclosure of which is incorporated herein by reference. The guide RNA may typically be a non-coding RNA molecule that does not encode a protein. The guide sequence of the guide RNA may be at least 10 nucleotides in length, such as 12-40 nucleotides, 12-30 nucleotides, 12-20 nucleotides, 12-35 nucleotides, 12-30 nucleotides, 15-30 nucleotides, 17-30 nucleotides, or 17-25 nucleotides in length, or about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25 or more nucleotides in length. The guide sequence may be at least 95%, at least 96%, at least 97%, at least 99% or 100% identical or complementary to at least 10, at least 11, at least 12,at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, or more consecutive nucleotides of a DNA sequence at the genomic target site. As used herein, the term “consecutive” in reference to a polynucleotide or protein sequence means without deletions or gaps in the sequence.

[0101] In addition to the guide sequence, a guide RNA may further comprise one or more other structural or scaffold sequence(s), which may bind or interact with an RNA-guided endonuclease. Such scaffold or structural sequences may further interact with other RNA molecules (e.g., tracrRNA). Methods and techniques for designing targeting constructs and guide RNAs for genome editing and site-directed integration at a target site within the genome of a plant using an RNA-guided endonuclease are known in the art.

[0102] According to some embodiments, recombinant DNA molecules, constructs and vectors are provided comprising a polynucleotide or transcribable DNA sequence encoding a site-specific nuclease, such as a zinc-finger nuclease (ZFN), a meganuclease, an RNA-guided endonuclease, a TALE-endonuclease (TALEN), a recombinase, or a transposase, wherein the coding sequence is operably linked to a plant expressible promoter. For RNA-guided endonucleases, recombinant DNA molecules, constructs and vectors are further provided comprising a polynucleotide or transcribable DNA sequence encoding a guide RNA, wherein the guide RNA comprises a guide sequence of sufficient length having a percent identity or complementarity to a target site within the genome of a plant. According to some embodiments, recombinant DNA molecules, constructs and vectors are provided comprising a first polynucleotide or transcribable DNA sequence encoding a site-specific nuclease and a second polynucleotide or transcribable DNA sequence encoding one or more gRNAs. According to some embodiments, each polynucleotide or transcribable DNA sequence of a recombinant DNA molecule, construct and vector that encodes a site-specific nuclease and / or a guide RNA may be operably linked to a plant expressible promoter, such as an inducible promoter, a constitutive promoter, a tissue-specific promoter, etc.

[0103] According to some embodiments, recombinant DNA molecules, constructs and vectors are provided comprising a polynucleotide or transcribable DNA sequence encoding a site-specific nuclease, such as a zinc-finger nuclease (ZFN), a meganuclease, an RNA-guided endonuclease, a TALE-endonuclease (TALEN), a recombinase, or a transposase, wherein the coding sequence is operably linked to a plant expressible promoter. For RNA-guided endonucleases, recombinantDNA molecules, constructs and vectors are further provided comprising a polynucleotide or transcribable DNA sequence encoding a guide RNA, wherein the guide RNA comprises a guide sequence of sufficient length having a percent identity or complementarity to a target site within the genome of a plant. According to some embodiments, recombinant DNA molecules, constructs and vectors are provided comprising a first polynucleotide or transcribable DNA sequence encoding a site-specific nuclease and a second polynucleotide or transcribable DNA sequence encoding one or more gRNAs. According to some embodiments, each polynucleotide or transcribable DNA sequence of a recombinant DNA molecule, construct and vector that encodes a site-specific nuclease and / or a guide RNA may be operably linked to a plant expressible promoter, such as an inducible promoter, a constitutive promoter, a tissue-specific promoter, etc.

[0104] According to some embodiments, a recombinant DNA molecule, construct or vector may comprise a first polynucleotide sequence encoding a site-specific nuclease and a second polynucleotide sequence encoding a guide RNA(s) that may be introduced into a plant cell together via plant transformation techniques. Alternatively, two recombinant DNA molecules, constructs or vectors may be provided including a first recombinant DNA molecule, construct or vector and a second DNA molecule, construct or vector that may be introduced into a plant cell together or sequentially via plant transformation techniques, wherein the first recombinant DNA molecule, construct or vector comprises a polynucleotide sequence encoding a site-specific nuclease and the second recombinant DNA molecule, construct or vector comprises a polynucleotide sequence encoding a guide RNA(s). According to some embodiments, a recombinant DNA molecule, construct or vector comprising a polynucleotide sequence encoding a site-specific nuclease may be introduced via plant transformation techniques into a plant cell that already comprises (or is transformed with) a recombinant DNA construct or vector comprising a polynucleotide sequence encoding a guide RNA(s). Alternatively, a recombinant DNA molecule, construct or vector comprising a polynucleotide sequence encoding a guide RNA may be introduced via plant transformation techniques into a plant cell that already comprises (or is transformed with) a recombinant DNA construct or vector comprising a polynucleotide sequence encoding a sitespecific nuclease. According to yet further embodiments, a first plant comprising (or transformed with) a recombinant DNA construct or vector comprising a polynucleotide sequence encoding a site-specific nuclease may be crossed with a second plant comprising (or transformed with) a recombinant DNA construct or vector comprising a polynucleotide sequence encoding a guideRNA(s). Such recombinant DNA molecules, constructs or vectors may be transiently transformed into a plant cell or stably transformed or more preferably integrated into the genome of a plant cell.

[0105] In an aspect, molecules or vectors comprising polynucleotides encoding a site-specific nuclease, and optionally one or more, two or more, three or more, or four or more gRNAs are provided to a plant cell by transformation methods known in the art (e.g., without being limiting, particle bombardment, PEG-mediated protoplast transfection or Agrobacterium-mediated transformation). In an aspect, molecules or vectors comprising polynucleotides encoding a Cas9 nuclease, and optionally one or more, two or more, three or more, or four or more gRNAs are provided to a plant cell by transformation methods known in the art (e.g., without being limiting, particle bombardment, PEG-mediated protoplast transfection or Agrobacterium-mediated transformation). In another aspect, vectors comprising polynucleotides encoding a Casl2a and, optionally one or more, two or more, three or more, or four or more crRNAs are provided to a cell by transformation methods known in the art (e.g., without being limiting, viral transfection, particle bombardment, PEG-mediated protoplast transfection or Agrobacterium-mediated transformation).

[0106] Several site-specific nucleases, such as recombinases, zinc finger nucleases (ZFNs), meganucleases, and TALENs, are not RNA-guided and instead rely on their protein structure to determine their target site for causing the DSB or nick, or they are fused, tethered, or attached to a DNA-binding protein domain or motif. The protein structure of the site-specific nuclease (or the fused / attached / tethered DNA binding domain) may target the site-specific nuclease to the target site. According to many of these embodiments, non-RNA-guided site-specific nucleases, such as recombinases, zinc finger nucleases (ZFNs), meganucleases, and TALENs, may be designed, engineered and constructed according to known methods to target and bind to a target site in the genome of a plant, to create a DSB or nick at or near such genomic target site or locus. For example, an engineered site-specific nuclease, such as a recombinase, zinc finger nuclease (ZFN), meganuclease, or TALEN, may be designed to target and bind to a genomic target site within the genome of a plant to create a DSB or nick at the genomic target site.

[0107] In an aspect, a targeted genome editing technique described herein may comprise the use of a zinc finger nuclease (ZFN). ZFNs are synthetic proteins consisting of an engineered zinc finger DNA-binding domain fused to a cleavage domain (or a cleavage half-domain), which maybe derived from a restriction endonuclease (e.g., Fold). The DNA binding domain may be canonical (C2H2) or non-canonical (e.g., C3H or C4). The DNA-binding domain can comprise one or more zinc fingers (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or more zinc fingers) depending on the target site. Multiple zinc fingers in a DNA-binding domain may be separated by linker sequence(s). ZFNs can be designed to cleave almost any stretch of double-stranded DNA by modification of the zinc finger DNA-binding domain. ZFNs form dimers from monomers composed of a nonspecific DNA cleavage domain (e.g., derived from the Fold nuclease) fused to a DNA-binding domain comprising a zinc finger array engineered to bind a target site DNA sequence. The DNA- binding domain of a ZFN may typically be composed of 3-4 (or more) zine-fingers. The amino acids at positions -1, +2, +3, and +6 relative to the start of the zinc finger a-helix, which contribute to site-specific binding to the target site, can be changed and customized to fit specific target sequences. The other amino acids may form a consensus backbone to generate ZFNs with different sequence specificities. Methods and rules for designing ZFNs for targeting and binding to specific target sequences are known in the art. See, e.g., US Patent App. Nos. 2005 / 0064474, 2009 / 0117617, and 2012 / 0142062, the contents and disclosures of which are incorporated herein by reference. The FokI nuclease domain may require dimerization to cleave DNA and therefore two ZFNs with their C-terminal regions are needed to bind opposite DNA strands of the cleavage site (separated by 5-7 bp). The ZFN monomer can cut the target site if the two-ZF-binding sites are palindromic. A ZFN, as used herein, is broad and includes a monomeric ZFN that can cleave double stranded DNA without assistance from another ZFN. The term ZFN may also be used to refer to one or both members of a pair of ZFNs that are engineered to work together to cleave DNA at the same site.

[0108] Without being limited by any scientific theory, because the DNA-binding specificities of zinc finger domains can be re-engineered using one of various methods, customized ZFNs can theoretically be constructed to target nearly any target sequence (e.g., at or near soybean event MON87751 in a plant genome). Publicly available methods for engineering zinc finger domains include Context-dependent Assembly (CoDA), Oligomerized Pool Engineering (OPEN), and Modular Assembly. In an aspect, a method and / or composition provided herein comprises one or more, two or more, three or more, four or more, or five or more ZFNs. In another aspect, a ZFN provided herein is capable of generating a targeted DSB or nick. In an aspect, vectors comprising polynucleotides encoding one or more, two or more, three or more, four or more, or five or moreZFNs are provided to a cell by transformation methods known in the art (e.g., without being limiting, viral transfection, particle bombardment, PEG-mediated protoplast transfection, or Agrobacterium-mediated transformation). The ZFNs may be introduced as ZFN proteins, as polynucleotides encoding ZFN proteins, and / or as combinations of proteins and protein-encoding polynucleotides.

[0109] In an aspect, a targeted genome editing technique described herein may comprise the use of a meganuclease. Meganucleases, which are commonly identified in microbes, such as the LAGLID ADG family of homing endonucleases, are unique enzymes with high activity and long recognition sequences (> 14 bp) resulting in site-specific digestion of target DNA. Engineered versions of naturally occurring meganucleases typically have extended DNA recognition sequences (for example, 14 to 40 bp). According to some embodiments, a meganuclease may comprise a scaffold or base enzyme selected from the group consisting of I-Crel, I-Ceul, I-Msol, I-Scel, I-Anil, and I-Dmol. The engineering of meganucleases can be more challenging than ZFNs and TALENs because the DNA recognition and cleavage functions of meganucleases are intertwined in a single domain. Specialized methods of mutagenesis and high-throughput screening have been used to create novel meganuclease variants that recognize unique sequences and possess improved nuclease activity. Thus, a meganuclease may be selected or engineered to bind to a genomic target site or sequence in a plant. In an aspect, a method and / or composition provided herein comprises one or more, two or more, three or more, four or more, or five or more meganucleases. In another aspect, a meganuclease provided herein is capable of generating a targeted DSB. In an aspect, vectors comprising polynucleotides encoding one or more, two or more, three or more, four or more, or five or more meganucleases are provided to a cell by transformation methods known in the art (e.g., without being limiting, viral transfection, particle bombardment, PEG-mediated protoplast transfection or Agrobacterium-medd&ted transformation).

[0110] In an aspect, a targeted genome editing technique described herein may comprise the use of a transcription activator-like effector nuclease (TALEN). TALENs are artificial restriction enzymes generated by fusing the transcription activator-like effector (TALE) DNA binding domain to a nuclease domain (e.g., FokI). In some aspects, the nuclease is selected from a group consisting of PvuII, MutH, lev! FokI, Alwl, Mlyl, Sbfl, Sdal, StsI, CleDORF, Clo051, and Pept071. For FokI nuclease, when each member of a TALEN pair binds to the DNA sites flanking a target site, the FokI monomers dimerize and cause a double-stranded DNA break at the targetsite. Besides the wild-type FokI cleavage domain, variants of the FokI cleavage domain with mutations have been designed to improve cleavage specificity and cleavage activity. The FokI domain functions as a dimer, requiring two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing. Both the number of amino acid residues between the TALEN DNA binding domain and the FokI cleavage domain and the number of bases between the two individual TALEN binding sites are parameters for achieving high levels of activity. The term TALEN, as used herein, is broad and includes a monomeric TALEN that can cleave double stranded DNA without assistance from another TALEN. The term TALEN also refers to one or both members of a pair of TALENs that work together to cleave DNA at the same site.[0U1] Besides the wild-type FokI cleavage domain, variants of the FokI cleavage domain with mutations have been designed to improve cleavage specificity and cleavage activity. The FokI domain functions as a dimer, requiring two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing. Both the number of amino acid residues between the TALEN DNA binding domain and the FokI cleavage domain and the number of bases between the two individual TALEN binding sites are parameters for achieving high levels of activity. PvuII, MutH, and TevI cleavage domains are useful alternatives to FokI and FokI variants for use with TALEs. PvuII functions as a highly specific cleavage domain when coupled to a TALE (see Yank et al. 2013. PLoS One. 8: e82539). MutH is capable of introducing strand-specific nicks in DNA (see Gabsalilow et al. 2013. Nucleic Acids Research. 41: e83). TevI introduces doublestranded breaks in DNA at targeted sites (see Beurdeley et al., 2013. Nature Communications. 4: 1762).

[0112] Transcription activator-like effectors (TALEs) can be engineered to bind practically any DNA sequence, such as at or near the genomic locus of soybean event MON87751 in a plant. TALE has a central DNA-binding domain composed of 13-28 repeat monomers of 33-34 amino acids. The amino acids of each monomer are highly conserved, except for hypervariable amino acid residues at positions 12 and 13. The two variable amino acids are called repeat-variable diresidues (RVDs). The amino acid pairs NI, NG, HD, and NN of RVDs preferentially recognize adenine, thymine, cytosine, and guanine / adenine, respectively, and modulation of RVDs can recognize consecutive DNA bases. This simple relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DNA binding domains by selectinga combination of repeat segments containing the appropriate RVDs. The relationship between amino acid sequence and DNA recognition of the TALE binding domain allows for designable proteins. Software programs such as DNA Works can be used to design TALE constructs. Other methods of designing TALE constructs are known to those of skill in the art. See Doyle et al., Nucleic Acids Research (2012) 40: W117-122.; Cermak et al., Nucleic Acids Research (2011). 39:e82; and tale-nt.cac.soybeanell.edu / about. In an aspect, a method and / or composition provided herein comprises one or more, two or more, three or more, four or more, or five or more TALENs. In another aspect, a TALEN provided herein is capable of generating a targeted DSB. In an aspect, vectors comprising polynucleotides encoding one or more, two or more, three or more, four or more, or five or more TALENs are provided to a cell by transformation methods known in the art (e.g., without being limiting, viral transfection, particle bombardment, PEG-mediated protoplast transfection or Agrobacterium-mediated transformation). See, e.g., US Patent App. Nos. 2011 / 0145940, 2011 / 0301073, and 2013 / 0117869, the contents and disclosures of which are incorporated herein by reference.

[0113] In an aspect, a targeted genome editing technique described herein may comprise the use of a recombinase. In some embodiments, a tyrosine recombinase attached, etc., to a DNA recognition domain or motif may be selected from the group consisting of a Cre recombinase, a Flp recombinase, and a Tnpl recombinase. In an aspect, a Cre recombinase or a Gin recombinase provided herein may be tethered to a zinc-finger DNA binding domain. The Flp- / '7?7' site-directed recombination system may come from the 2p plasmid from the baker’s yeast Saccharomyces cerevisiae. In this system, Flp recombinase (flippase) may recombine sequences between flippase recognition target (FRT) sites. FRT sites comprise 34 nucleotides. Flp may bind to the “arms” of the FRT sites (one arm is in reverse orientation) and cleaves the FRT site at either end of an intervening nucleic acid sequence. After cleavage, Flp may recombine nucleic acid sequences between two FRT sites. Cre-lox is a site-directed recombination system derived from the bacteriophage Pl that is similar to the Flp-7’7 / 7 recombination system. Cre-lox can be used to invert a nucleic acid sequence, delete a nucleic acid sequence, or translocate a nucleic acid sequence. In this system, Cre recombinase may recombine a pair of lox nucleic acid sequences. Lox sites comprise 34 nucleotides, with the first and last 13 nucleotides (arms) being palindromic. During recombination, Cre recombinase protein binds to two lox sites on different nucleic acids and cleaves at the lox sites. The cleaved nucleic acids are spliced together (reciprocallytranslocated) and recombination is complete. In another aspect, a lox site provided herein is a loxP, lox 2272, loxN, lox 511, lox 5171, lox71, lox66, M2, M3, M7, or Mi l site.

[0114] As used herein, the term “derived” or “derived from” in reference to a particular DNA molecule, amplicon or sequence in relation to a soybean cell, soybean tissue, soybean seed, soybean plant, soybean plant part and / or soybean plant product, such as a soybean commodity product, means that the DNA molecule, amplicon or sequence is taken, purified, isolated, or made, directly or indirectly, from such soybean cell, soybean tissue, soybean seed, soybean plant, soybean plant part and / or soybean plant product, such as a soybean commodity product, as the case may be. Alternatively, the term “derived” or “derived from” in reference to a soybean plant product, such as a soybean commodity product, in relation to a soybean cell, soybean tissue, soybean seed, soybean plant, and / or soybean plant part, means that the soybean plant product is taken, purified, isolated, or made, directly or indirectly, from such soybean cell, soybean tissue, soybean seed, soybean plant, and / or soybean plant part, as the case may be. “Capable of being detected” refers to the ability of a particular DNA molecule, segment, or sequence to be detected in a sample, such as by amplification and determining its presence, size, or sequence such as by DNA sequence analysis, and / or binding of a probe to the target DNA molecule, segment, or sequence.

[0115] A “sample” is intended to refer to any composition comprising or derived from, either directly or indirectly, a biological sample, source or material. The sample may generally comprise soybean DNA and / or substantially or completely pure, purified or isolated soybean DNA. A “biological sample” contains biological materials, including but not limited to DNA obtained or derived from, either directly or indirectly, the genome of a soybean cell(s), soybean tissue(s), soybean seed(s), soybean plant(s), soybean plant part(s) and / or soybean plant product(s), such as a soybean commodity product(s). Such soybean cell(s), soybean tissue(s), soybean seed(s), soybean plant(s), soybean plant part(s) and / or soybean plant product(s), such as a soybean commodity product(s), may comprise soybean event MON87751 or a modified soybean event MON87751 or DNA molecule(s) and / or DNA segment(s) comprising soybean event MON87751 or a modified soybean event MON87751. In some embodiments, a sample or biological sample may comprise soybean cell(s), soybean tissue(s), soybean seed(s), soybean plant(s), soybean plant part(s), and / or soybean plant product(s), whose cells or cellular membranes have been fractured (e.g., disrupted or opened) to release the contents of the soybean cell(s) including genomic DNAand / or make the contents of the soybean cell(s) including genomic DNA accessible or usable for assays or testing. “Directly” refers to directly obtaining DNA by a skilled artisan from the soybean genome by fracturing soybean cells (or by obtaining samples of soybean that contain fractured soybean cells) and exposing or using the genomic DNA from soybean cells for the purposes of detection. “Indirectly” refers to obtaining by a skilled artisan a target or specific reference DNA (i.e.. a novel and unique junction segment(s) described herein as being diagnostic for the presence of the soybean event MON87751 or a modified soybean event MON87751) in a particular sample, by means other than by obtaining directly via fracturing of soybean cells or obtaining a sample of soybean that contains fractured soybean cells. Such indirect means include, but are not limited to, amplification of a DNA segment that contains a DNA sequence targeted by a particular probe(s) and / or primer set(s) designed to bind with specificity to or near the target sequence, or amplification of a DNA segment comprising all or part of a target sequence that can be measured and characterized (e.g., measured by migration or separation from other segments of DNA and / or identification in an effective matrix, such as an agarose or acrylamide gel or the like, or characterized by direct sequence analysis of the amplicon(s), or cloning of the amplicon(s) into a vector(s) and direct sequencing of the inserted amplicon(s) present within such vector(s).

[0116] Detailed molecular analysis demonstrated that event MON87751 contains a single T-DNA insertion with one copy of each of the Cry2Ab and Cry 1 A.105 expression cassettes. No additional elements from the transformation construct other than portions of the Agrobacterium tumefaciens left and right border regions used for transgenic DNA transfer from the plant transformation plasmid to the soybean genome were identified in event MON87751. Finally, thermal amplification producing specific amplicons diagnostic for the presence of event MON87751 in a sample and DNA sequence analyses were performed to determine the arbitrarily assigned 5' and 3 ' insert-to-plant genome junctions, confirm the organization of the elements within the insert, and determine the complete DNA sequence of the inserted transgenic DNA (SEQ ID NO: 9). SEQ ID NO: 27 is a sequence representing the one thousand three hundred thirty-three (1,334) base-pair (bp) 5' A3555 soybean genomic DNA sequence flanking the inserted T-DNA sequence presented as SEQ ID NO: 9. SEQ ID NO: 28 is a sequence representing the one thousand one hundred eighty-seven (1,187) bp 3' A3555 soybean genomic DNA sequence flanking the inserted T-DNA sequence presented as SEQ ID NO: 9. SEQ ID NO: 10 corresponds to soybean event MON87751 and contains a contiguous sequence (contig) comprising the 5' A3555 flanking sequence, thetransgene insert of event MON87751, and the 3' A3555 flanking sequence, and thus contains the insert-to-plant genome junction sequences.

[0117] Unless otherwise noted herein, terms are to be understood according to conventional usage by those of ordinary skill in the relevant art. Definitions of common terms in molecular biology may be found in Rieger etal., Glossary of Genetics: Classical and Molecular, 5thedition, Springer- Verlag: New York, 1991; and Lewin, Genes V, Oxford University Press: New York, 1994, along with other sources known to those of ordinary skill in the art. As used herein, the term “soybean” means species belong to the genus Glycine, preferably Glycine max and includes all plant varieties that can be bred with soybean plants containing event MON87751, including wild soybean species as well as those plants belonging to the genus Zea that permit breeding between species.

[0118] The present invention provides for transgenic plants which have been transformed with a DNA construct that contains expression cassettes expressing toxic amounts of the insecticidal proteins Cry2Ab and CrylA.105. What is meant by toxic amount is an efficacious amount, an insecticidal amount, an insecti ci daily-effective amount, a target insect suppressive amount, an efficacious pesticidal amount, an amount in the diet of insects in the order of Lepidoptera that is insecticidal, and other similar terms to be understood according to conventional usage by those of ordinary skill in the relevant art. Soybean plants transformed according to the methods and with the DNA construct disclosed herein are resistant to Lepidopteran insect pests.

[0119] A transgenic plant is produced by transformation of a plant cell with a recombinant DNA construct that includes the expression cassette(s) and transgene(s) as described herein, which is also heterologous with respect to the plant cell, regeneration of a plant resulting from the insertion of the transgene into the genome of the plant cell, and selection of a particular plant characterized by insertion into a particular genome location and the number of efficacious features of the regenerated transgenic plant. The term “transgenic event” or “event” refers to the inserted transgenic DNA in the plant genome and flanking genomic sequences immediately adjacent to the inserted transgenic DNA in the genome of the transformed plant, but also refers to a DNA molecule comprising the inserted transgenic DNA in the plant genome and flanking genomic sequences. Each event is unique and would be expected to be transferred to progeny plants that receive the transgenic DNA and event through genetic inheritance and / or segregation from a parent as the result of a sexual or self-cross of a first parental line that includes the inserted transgenic DNA andevent either with itself or a second parental line that may or may not contain the same transgenic DNA and event. The parental line that includes the inserted transgenic DNA and event may itself be the original transformant or a progeny plant of said original transformant that may have been generated by “selfing” the transformant with itself or crossing the transformant or a progeny plant of the transformant that includes the inserted transgenic DNA and event with another plant. For purposes of the present disclosure, the “event” refers to soybean event MON87751 or a modified soybean event MON87751.

[0120] As used herein, the term “flanking” in reference to a transgenic event refers to the plant genomic sequence(s) immediately adjacent to the transgenic DNA insertion in the genome of a transformed plant, plant part, plant tissue, or plant cell comprising the transgenic event on the 5' and / or 3' side(s) or end(s) of the transgenic event insertion (e.g., all or part of the transgenic insertion of soybean event MON87751 or a modified soybean event MON87751). Likewise, “flanking DNA”, “flanking sequence” or “flanking DNA sequence” each refers to a length of genomic DNA sequence immediately adjacent to the transgenic DNA insertion in the genome of the transformed plant on the 5' and / or 3' side(s) or end(s) of the insertion. A “5' flank” means the soybean genomic DNA sequence adjacent to and upstream (or on the 5' end) of the transgenic DNA insertion. For example, a “5' flank” can include the soybean genomic DNA sequence immediately adjacent to and upstream (on the 5' end) of the transgenic insertion, or any soybean genomic DNA sequence upstream (on the 5' end) of the transgenic insertion that is not immediately adjacent to the transgenic insertion but is within about 5000 nucleotides, within about 4000 nucleotides, within about 3000 nucleotides, within about 2000 nucleotides, or within about 1000 nucleotides upstream of the transgenic insertion. Likewise, a “3' flank” means the soybean genomic DNA sequence adjacent to and downstream (or on the 3' end) of the transgenic insert. For example, a “3' flank” can include the soybean genomic DNA sequence immediately adjacent to and downstream (on the 3' end) of the transgenic insertion, or any soybean genomic DNA sequence downstream (on the 3 ' end) of the transgenic insertion that is not immediately adjacent to the transgenic insertion but is within about 5000 nucleotides, within about 4000 nucleotides, within about 3000 nucleotides, within about 2000 nucleotides, or within about 1000 nucleotides downstream of the transgenic insertion.

[0121] SEQ ID NOs: 27 and 28 are 1,334 and 1,187 nucleotide sequences representing soybean (Glycine max) genomic DNA that flanks the transgenic insert at the 5 ' and 3 ' ends of the insert insoybean event MON87751, respectively. SEQ ID NOs: 47 and 48 are 5,000 nucleotide sequences representing soybean (Glycine max) genomic DNA that flanks the transgenic insert at the 5 ' and 3' ends of the insert, respectively. Nucleotides 3,667-5,000 of SEQ ID NO: 47 are identical to nucleotides 1-1,337 of SEQ ID NO: 27. Nucleotides 1-3,666 are based on the genomic sequence of the Williams 82 soybean cultivar (Genome assembly Glycine_max_v4.0, NCBI). Similarly, nucleotides 1-1,187 of SEQ ID NO: 48 are identical to nucleotides 1-1,187 of SEQ ID NO: 28. The remaining nucleotides (1,188-5,000) are based on the genomic sequence of the Williams 82 soybean cultivar.

[0122] The present disclosure provides the original transformant plant and progeny of the transformant that include the transgenic DNA and event. Such progeny may be produced by a sexual cross or outcross between plants comprising the same transgenic DNA and event, or between a plant comprising the transgenic DNA and event with another plant, or by any other method known in the art including any cell or tissue culture method, wherein the progeny includes the transgenic DNA and event. Such other plant may be a transgenic plant comprising the same and / or a different transgene or may be a non-transgenic plant, and each parental plant in a cross or outcross may be the same or different germplasm or breeding line. Even after repeated back- crossing to a recurrent parent, the transgenic DNA and event is present in progeny of the cross at the same chromosomal location. Thus, a “transgenic plant” can be the original transformant plant regenerated from the transformed plant cell and comprising the transgenic DNA and event, or a progeny plant of the original transformant plant, which may be separated from the transformant by one or more generations, that retains the transgenic DNA and event at the same specific location and sequence context in the plant’s genome. The transformant or progeny plant may be homozygous or heterozygous for soybean event MON87751 or a modified soybean event MON87751. In addition, a “transgenic plant” can include a plant produced from a transformed plant cell or tissue, or from another transgenic plant or plant part, by or using cell or tissue culture methods known in the art. A “transgenic plant” may comprise a plant having a transgene or transgenic event (including a modified transgenic event) stably inserted in the genome of at least one cell of the plant (z.e., soybean event MON87751 or a modified soybean event MON87751 in at least one cell of the plant), and the plant may be chimeric or non-chimeric with respect to the transgene and / or event or modified event. A transgenic plant is chimeric with respect to atransgene, event, or modified event if not all cells of the plant comprise the transgene, event, or modified event.

[0123] As used herein, the term “recombinant” refers to a non-natural DNA, protein, or combination that would not normally be found in nature, such as a combination of DNA sequences, proteins that would not naturally occur together, and is the result of human intervention. A “recombinant DNA molecule” is a DNA molecule comprising a combination of DNA sequences that would not naturally occur together and is the result of human intervention. Two or more elements of such combination of DNA sequences may be operably linked to one another. For example, a recombinant DNA molecule may comprise a combination of at least two DNA sequences that are heterologous with respect to each other, such as a DNA molecule that comprises a coding or transcribable DNA sequence operably linked to a heterologous promoter and / or other regulatory expression element(s), and / or a plant genomic DNA sequence comprising all or part of a transgene and a heterologous and flanking genomic sequence(s) adjacent to the transgene, and / or a DNA molecule that is artificially synthesized and comprises a polynucleotide sequence that deviates from any polynucleotide sequence that would normally exist in nature. A recombinant DNA molecule may comprise all or part of a junction sequence of the genome of a plant and all or part of the transgene insertion into the genome of the plant, and / or may comprise a recombinant or heterologous DNA fragment of event MON87751 or a modified soybean event MON87751. An example of a recombinant DNA molecule is a DNA molecule comprising at least one of SEQ ID NOs: 1-10. As used herein, a recombinant plant, plant part, plant cell or plant tissue is a plant, plant part, plant cell or plant tissue that would not normally exist in nature, is the result of human intervention, and contains a transgene incorporated into the genome of the plant, plant part, plant cell or plant tissue. As a result of such genomic insertion, the recombinant plant is something new and distinctly different from any related wild-type or naturally occurring plant, plant part, plant cell or plant tissue. An example of a recombinant plant, plant part, plant cell or plant tissue is a soybean or Glycine genus plant, plant part, plant cell or plant tissue containing the event MON87751 or a modified soybean event MON87751.

[0124] As used herein, the term “heterologous” in reference to a combination of two or more DNA sequences or elements means that the two or more DNA sequences or elements do not normally exist together as such combination in nature without human intervention. As used herein, the term “heterologous” in reference to a DNA molecule, construct or sequence in relation to a plant,microorganism, plant cell or plant genome means that the DNA molecule, construct or sequence does not exist in nature as part of such plant, microorganism, plant cell or plant genome, and / or does not exist in the same physical or genomic location, context or orientation as part of such plant, microorganism, plant cell or plant genome in nature, without human intervention.

[0125] The present disclosure provides DNA molecules and fragments and their corresponding DNA sequences. The terms “DNA” and “DNA molecule” as used herein refer to a deoxyribonucleic acid (DNA) molecule. A DNA molecule may be of genomic or synthetic origin and / or comprise a recombinant or heterologous DNA molecule or sequence. A DNA molecule may be described in reference to its 5' (upstream) end and 3' (downstream) end. As used herein, the term “DNA sequence” refers to the polynucleotide sequence of the DNA molecule - i.e., the sequence of consecutive nucleotides in the DNA molecule. As used herein in reference to nucleotides of a polynucleotide or DNA sequence or molecule, the terms “consecutive” and “contiguous” are interchangeable and synonymous and refer to the 5' to 3' order of nucleotides in a polynucleotide or DNA sequence, strand or molecule without any gap or interruption between them. By convention, DNA sequences of the disclosure and fragments thereof are disclosed with reference to the 5' to 3' direction of only one strand of the two, anti-parallel and complementary DNA strands of a DNA molecule. By implication and intent, the complementary sequences of the sequences provided here (i.e., the sequences of the complementary, opposing, or antiparallel strand), also referred to in the art as the reverse complementary or reverse complement sequences, are within the scope of the present disclosure and are expressly intended to be within the potential scope of the subject matter as claimed. A DNA molecule, or a fragment derived therefrom, can also be extracted from plant part(s), plant cell(s) and / or tissue(s) or a homogenate, extract or lysate from plant part(s), plant cell(s) and / or tissue(s), or can be produced as an amplicon from extracted, purified or isolated DNA from plant part(s), plant cell(s) and / or tissue(s), or a homogenate, extract or lysate from plant part(s), plant cell(s) and / or tissue(s), which may further comprise event MON87751.

[0126] As used herein, the term “fragment” refers to a smaller piece or sequence of a larger or whole DNA molecule or sequence. For example, a fragment of SEQ ID NO: 9 or 10 may include a sequence that is at least about 12 consecutive nucleotides, at least about 13 consecutive nucleotides, at least about 14 consecutive nucleotides, at least about 15 consecutive nucleotides, at least about 16 consecutive nucleotides, at least about 17 consecutive nucleotides, at least about18 consecutive nucleotides, at least about 19 consecutive nucleotides, at least about 20 consecutive nucleotides, at least about 21 consecutive nucleotides, at least about 22 consecutive nucleotides, at least about 23 consecutive nucleotides, at least about 24 consecutive nucleotides, at least about 25 consecutive nucleotides, at least about 30 consecutive nucleotides, at least about 35 consecutive nucleotides, at least about 40 consecutive nucleotides, at least about 45 consecutive nucleotides, at least about 50 consecutive nucleotides, at least about 60 consecutive nucleotides, at least about 70 consecutive nucleotides, at least about 80 consecutive nucleotides, at least about 90 consecutive nucleotides, at least about 100 consecutive nucleotides, at least about 200 consecutive nucleotides, at least about 300 consecutive nucleotides, at least about 400 consecutive nucleotides, or at least about 500 consecutive nucleotides of the larger, whole or complete DNA molecule or sequence of SEQ ID NO: 9 or 10.

[0127] According to present embodiments, a fragment of the DNA sequence of the 5' flank (SEQ ID NO: 27 or SEQ ID NO: 47) or the 3' flank (SEQ ID NO: 28 or SEQ ID NO: 48) of soybean event MON87751 can comprise at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, or at least 500 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47 or SEQ ID NO: 28 or SEQ ID NO: 48. It is possible that different soybean germplasms may have differences in their genomic sequences, which may include differences in the flanking sequence(s), 5' flank and / or 3 ' flank of soybean event MON87751. These differences may result from introgression of the soybean event MON87751 or a modified soybean event MON87751 into a different germplasm and / or spontaneous, mutagenic or genome editing changes that occur in a given germplasm or line. According to some embodiments, DNA molecules, constructs or polynucleotides are provided comprising a sequence or flanking sequence, or a 5' flank or 3' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 27 or 47 or SEQ ID NO: 28 or 48, or a fragment of either thereof. According to some embodiments, DNA molecules, constructs or polynucleotides are provided comprising a sequence or flanking sequence, or a 5 ' flank or 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, or at least 500 consecutive nucleotides of SEQ ID NO: 27 or 47 or SEQ ID NO: 28 or 48.

[0128] As used herein, the term “isolated” in reference to a molecule means that the molecule is at least partially separated from other molecules or sequences that are normally associated with the molecule in its native or natural state. In some embodiments, the term “isolated” refers to a DNA molecule that is at least partially separated from the nucleic acids or polynucleotide or DNA sequence(s) that normally flank and are covalently linked to the sequence of the DNA molecule in its native or natural state. An “isolated” DNA molecule may have a DNA sequence corresponding to a portion of the genome of a plant cell without other genomic DNA sequence(s) that normally flank and are covalently linked to the DNA sequence in nature. Such an “isolated” DNA molecule may comprise all or part of a transgene(s) and / or transgenic event, which may comprise all or part of soybean event MON87751 or a modified soybean event MON87751 or the transgene(s) or expression cassette(s) described herein. Nucleic acid sequences or elements, such as a coding sequence, intron sequence, untranslated leader sequence, promoter sequence, transcriptional termination sequence, and the like, that are naturally found within the DNA of the genome of an organism are not considered to be “isolated” so long as the element is within the genome of the organism and at the location within the genome in which it is naturally found. However, each of these elements, and subparts of these elements, would be “isolated” within the scope of this disclosure so long as the element or subpart is not within the genome of the organism, and at the location within the genome of the organism, in which it is naturally found. An “isolated” DNA molecule may be any recombinant DNA molecule or amplification product or amplicon, and / or may comprise any DNA sequence removed from its natural or biological state and covalently fused to another DNA molecule or sequence with which it is not associated in nature. Such an isolated DNA molecule could be created by the use of biotechnology techniques, such as by making a recombinant DNA or integrating a foreign or heterologous DNA molecule into the chromosomeof a cell, plant, or seed. Thus, any DNA molecule comprising a transgenic, recombinant, chimeric or artificial nucleotide sequence, transgene or expression cassette would be considered to be an “isolated” DNA molecule since these sequences are not naturally occurring, regardless of whether the sequence, transgene or expression cassette is present within a plasmid, vector or construct used to transform plant cells, within the genome of a plant, plant part, plant tissue, or plant cell, or is present in detectable amounts in tissues, progeny, biological samples or commodity products derived from a plant, plant part, plant tissue, or plant cell. A recombinant DNA molecule or sequence, or any fragment derived therefrom, comprising all or part of a transgene or junction sequence of soybean event would therefore also be considered to be “isolated.” An “isolated” DNA molecule may be extracted or purified from a transgenic plant(s), plant part(s), plant cell(s) and / or tissue(s), or may be present in a homogenate, extract or lysate from any such transgenic plant(s), plant part(s), plant cell(s) and / or tissue(s), or may be produced as an amplicon or amplification product from plant genomic DNA and / or extracted or purified DNA from transgenic plant(s), plant part(s), plant cell (s) and / or tissue(s), or a homogenate, extract or lysate from plant(s), plant part(s), plant cell(s) and / or tissue(s). For the purposes of this disclosure, any transgenic polynucleotide or DNA sequence, i.e., the nucleotide sequence of the DNA inserted into the genome of a plant or bacterium, or present in an extrachromosomal vector, would be considered to be an “isolated” nucleotide or DNA sequence whether it is present within the plasmid or similar structure used to transform the cells, within the genome of the plant or bacterium, or present in detectable amounts in tissues, progeny, biological samples or commodity products derived from the plant or bacterium. An “isolated” DNA molecule is a chemical or biochemical molecule, regardless of whether the molecule is referred to as a nucleic acid, a nucleic acid sequence, a polynucleotide sequence, a DNA sequence, a nucleic acid molecule, a polynucleotide molecule, a DNA molecule, or the like. An “isolated” molecule can provide industrial applicability when present in a plant cell or in a plant genome or when present outside of a plant cell, and therefore, provides and exhibits (and is intended to provide and exhibit) utility regardless of where the molecule is located.

[0129] The phosphodiester bond linkage between one end of a transgenic insert (or insertion) into the genome of a plant and the flanking soybean genomic DNA is referred to as a “junction.” In other words, a “junction” is the connection point or covalent linkage of one end of a transgenic insert and the flanking genomic DNA. One junction is found at the 5' end of the transgenicinsertion and the other is found at the 3' end of the transgenic insert, referred to herein as the 5' and 3 ' junction, respectively. A “junction sequence” refers to a DNA sequence of any length of consecutive nucleotides that spans the 5' or 3 ' junction of a transgenic event in the plant genome. For a “junction sequence” to be specific to a junction between a transgenic event and a flanking genomic sequence, the junction sequence will generally comprise a sufficient number of consecutive nucleotides at one end of the insertion and a sufficient number of consecutive nucleotides of the flanking genomic sequence. According to some embodiments, a “junction sequence” may comprise (i) at least five (5) consecutive nucleotides, at least ten (10) consecutive nucleotides, at least fifteen (15) consecutive nucleotides, at least twenty (20) consecutive nucleotides, or at least thirty (30) consecutive nucleotides at one end of the insertion and (ii) at least five (5) consecutive nucleotides, at least ten (10) consecutive nucleotides, at least fifteen (15) consecutive nucleotides, at least twenty (20) consecutive nucleotides, or at least thirty (30) consecutive nucleotides of flanking genomic DNA sequence, although it is understood that any length of consecutive nucleotides spanning a junction of a transgenic event in a plant genome may be a junction sequence. A variety of junction sequences of soybean event MON87751 can be determined by one of skill in the art using SEQ ID NO: 10. Examples of junction sequences of event MON87751 are provided as SEQ ID NOs: 1-8. Figure 1 illustrates the physical arrangement and locations of the junction sequences, arranged from 5' to 3' (left to right), relative to SEQ ID NO: 10. The junction sequence(s) of a modified soybean event MON87751 may be modified, mutated or edited relative to such junction sequence(s) of com event MON87751. The junction sequences of soybean event MON87751 or a modified soybean event MON87751 may be present as part of the genome of a soybean plant, plant part, plant seed, or plant tissue or cell containing soybean event MON87751 or a modified soybean event MON87751, a DNA molecule containing all or part of soybean event MON87751 or a modified soybean event MON87751, or a microorganism containing soybean event MON87751 or a modified soybean event MON87751. The identification of any one or more of the junction sequences in a DNA molecule or sample from a plant, plant part, plant seed, or plant tissue or cell indicates that the plant, plant part, plant seed, or plant tissue or cell contains or comprises soybean event MON87751 or a modified soybean event MON87751, or the DNA molecule contains or comprises soybean event MON87751 or a modified soybean event MON87751 or was obtained from a soybean plant, plant part, plant seed, or plant tissue or cell containing or comprising soybean event MON87751 or a modified soybeanevent MON87751, and is diagnostic in each case for the presence of soybean event MON87751 or a modified soybean event MON87751.

[0130] The junction sequences described herein can be diagnostic for the presence of all or part of soybean event MON87751 or a modified soybean event MON87751, or diagnostic for a modified soybean event MON87751 if the junction sequence is unmodified in the modified soybean event MON87751, and / or a DNA molecule comprising all or part of the Cry2Ab and / or CrylA.105- encoding transgene(s), construct(s) and / or expression cassette(s) described herein. Thus, the identification or detection, directly or indirectly, of one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 10 in a sample or DNA molecule derived from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, or a commodity product from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, is diagnostic that the soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, or a commodity product from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell has or comprises all or part of soybean event MON87751 or a modified soybean event MON87751. The identification or detection, directly or indirectly, of a 5' junction sequence and a 3' junction sequence (each as provided or described herein) in a sample or DNA molecule derived from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, or a commodity product from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, is diagnostic that the soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, or a commodity product from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell has or comprises soybean event MON87751 or a modified soybean event MON87751. The present disclosure thus provides a DNA molecule that contains at least one of the nucleotide sequences provided as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. Any segment of DNA derived from transgenic soybean event MON87751 that is sufficient to include at least one of the sequences provided as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 is within the scope of the present disclosure. In addition, any DNA or polynucleotide molecule or sequence comprising a sequence complementary to any of the sequences described herein is also within the scope of the present disclosure.

[0131] The disclosure provides DNA, polynucleotide or nucleic acid molecules, which may be single or double stranded, that can be used either as primers or probes for detecting the presence of DNA comprising all or part of soybean event MON87751 or a modified soybean event MON87751 in a sample derived from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell, or a commodity product from a soybean plant, soybean plant part, soybean seed, or soybean tissue or cell. Such primers or probes are specific for a target nucleic acid, polynucleotide or DNA sequence and, as such, are useful for the identification of soybean event MON87751 nucleic acid, polynucleotide or DNA sequence, or a nucleic acid, polynucleotide or DNA sequence of a modified soybean event MON87751, by the methods described herein. A primer or probe can hybridize to a target nucleic acid, polynucleotide or DNA sequence to allow for specific detection or amplification of a nucleic acid, polynucleotide or DNA molecule or sequence that comprises, or is covalently linked and associated with, the target nucleic acid, polynucleotide or DNA sequence. According to present embodiments, the primers and / or probe may be chosen to identify and distinguish detection of a particular transgenic event and not only the presence of a transgene in a plant genome. The target nucleic acid, polynucleotide or DNA molecule or sequence may comprise all or part of soybean event MON87751 a modified soybean event MON87751, a junction sequence and / or flanking genomic DNA. Probes and primers according to the present disclosure may have (i) complete or 100% sequence complementarity (i.e., 100% complementary) to a target DNA sequence or (ii) incomplete sequence complementarity to a target DNA sequence, such as at least 60% complementary, at least 65% complementary, at least 70% complementary, at least 75% complementary, at least 80% complementary, at least 85% complementary, at least 90% complementary, at least 95% complementary, or at least 99% complementary to the target DNA sequence as long as the probe or primer has sufficient complementarity to the target DNA sequence to hybridize to the target DNA sequence under stringent hybridization conditions that are suitable and necessary for use of the probe or primer in the relevant amplification or detection assay, reaction or method. As understood in the art, the percentage complementarity of a primer or probe may be lower if the length of the primer or probe is longer and depends on the stringency and use.

[0132] A “probe” is a nucleic acid molecule that is complementary to a strand of target nucleic acid and is useful in hybridization methods. A probe may be attached a conventional detectable label or reporter molecule, e.g., a radioactive isotope, ligand, chemiluminescent agent, or enzyme.Such a probe is complementary to a strand of a target nucleic acid and, in the case of the present invention, to a strand of DNA from event MON87751 or a modified soybean event MON87751 whether from an event MON87751 containing plant or from a plant containing a modified soybean event MON87751, or from a sample that includes event MON87751 DNA or DNA from a modified soybean event MON87751. Probes according to the present invention include not only deoxyribonucleic or ribonucleic acids, but also polyamides and other probe materials that bind specifically to a target DNA sequence and can be used to detect the presence of that target DNA sequence. Examples of DNA sequences that may be useful as a probe for detecting soybean event MON87751 or a modified soybean event MON87751 are provided as: SEQ ID NO: 13 (PB10263) and SEQ ID NO: 16 (PB11254). A “probe” may also be used to bind a template DNA in a sample comprising all or part of a DNA or nucleotide sequence of soybean eventMON87751 or a modified soybean event MON87751 to purify the template DNA from the remainder of the sample using purification methods or techniques known in the art, for example, if the probe is bound or can be bound to a substrate or a particle or bead that can be purified or separated. Such a template DNA may comprise all or part of a DNA or nucleotide sequence of soybean event MON87751 or a modified soybean event MON87751, or a portion or fragment thereof, such as a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, or a complement thereof.

[0133] A “primer” is typically a DNA molecule that is designed for use in specific annealing or hybridization methods that involve thermal amplification. A pair of primers may be used with template DNA (such as a sample of soybean genomic DNA) in a thermal amplification (such as polymerase chain reaction (PCR)) to produce an amplicon, where the amplicon produced from such reaction would have a DNA sequence corresponding to sequence of the template DNA located between the two sites where the primers hybridized to the template. As understood in the art, an “amplification product” or “amplicon” is a DNA molecule or segment produced by an amplification reaction. Amplification or amplifying refers to making multiple copies of a target DNA molecule or segment from a template DNA. A single “primer” may also be used to initiate a sequencing reaction to determine a DNA sequence of a template DNA according to sequencing methods known in the art. Such a sequencing reaction may be used to determine the presence or absence of a DNA molecule or nucleotide sequence, or a portion or fragment thereof, from soybeanevent MON87751 or a modified soybean event MON87751 . Such a template DNA may comprise all or part of a DNA or nucleotide sequence of soybean event MON87751 or a modified soybean event MON87751, or a portion or fragment thereof, such as a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, or a complement thereof.

[0134] DNA amplification reactions, methods and techniques are known to those skilled in art. DNA amplification can be accomplished by any of the various nucleic acid amplification methods known in the art, including thermal and isothermal amplification methods including the polymerase chain reaction or PCR. Amplification methods are known in the art and are described, inter alia, in U.S. PatentNos. 4,683,195 and 4,683,202 and in PCR Protocols: A Guide toMethods and Applications, ed. Innis et al., Academic Press, San Diego, 1990. PCR amplification methods have been developed to amplify up to 22 kb (kilobase) of genomic DNA and up to 42 kb of bacteriophage DNA (Cheng et al., Proc. Natl. Acad. Sci. USA 91 :5695-5699, 1994). These methods as well as other methods known in the art of DNA amplification may be used in the practice of the present invention. Examples of DNA amplification methods include PCR, Recombinase Polymerase Amplification (RPA) (see for example U.S. Pat No. 7,485,428), Strand Displacement Amplification (SDA) (see for example, U.S. Pat. Nos. 5,455,166 and 5,470,723), Transcription-Mediated Amplification (TMA) (see for example, Guatelli et al., Proc. Natl. Acad. Sci. USA 87: 1874-1878, 1990), Rolling Circle Amplification (RCA) (see for example, Fire and Xu, Proc. Natl. Acad Sci. USA 92:4641-4645, 1995; Lui, etal., J. Am. Chem. Soc. 118: 1587-1594, 1996; Lizardi, etal., Nature Genetics 19:225-232, 1998; U.S. Pat. Nos. 5,714,320 and 6,235,502), Helicase Dependent Amplification (HDA) (see for example Vincent et al., EMBO Reports 5(8): 795-800, 2004; U.S. Pat. No. 7,282,328), and Multiple Displacement Amplification (MDA) (see for example Dean et al., Proc. Natl. Acad Sci. USA 99:5261-5266, 2002). A sequence of the heterologous DNA insert and / or flanking genomic DNA sequence from soybean event MON87751 can be verified or tested by amplifying such DNA molecules from soybean seed containing event MON87751 DNA or soybean plants grown from the soybean seed containing event MON87751 DNA, using primers derived from the sequences provided herein, followed by standard DNA sequencing of the PCR amplicon or a cloned DNA fragment thereof.

[0135] According to present embodiments, the sequence of an amplicon of an amplification reaction may comprise one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, or a fragment thereof. According to present embodiments, the sequence of an amplicon comprises at least one junction sequence or two junction sequences, such as a 5 ' junction sequence and / or a 3' junction sequence for soybean event MON87751 or a modified soybean event MON87751.

[0136] A primer is typically designed to hybridize in a sequence-specific manner to a complementary target DNA strand to form a hybrid between the primer and target DNA strand, and the primer hybridized or bound to the complementary target DNA strand is a point of recognition for a polymerase to begin extension of the primer ( / .< ., polymerization of additional nucleotides into a lengthening nucleotide molecule) using as a template the target DNA strand. Primer pairs refer to use of two primers binding opposite strands of a double stranded DNA or polynucleotide segment for the purpose of amplifying the polynucleotide or DNA segment between the positions targeted for binding by the individual primers of the primer pair to the original template DNA or an amplicon of the amplification reaction, typically in a thermal cycling amplification reaction or other conventional DNA amplification method. Primer pairs are typically designed to hybridize to different nearby target positions of a template DNA molecule on opposing strands of the template DNA molecule such that the intervening region or sequence between the two primers can be specifically amplified for use or detection through multiple rounds of amplification. Exemplary DNA molecules useful as primers are provided as SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 15.

[0137] The primer pair SEQ ID NO: 15 and SEQ ID NO: 16 are useful as a first DNA molecule and a second DNA molecule that is different from the first DNA molecule, and both are each of sufficient length of contiguous nucleotides of SEQ ID NO: 10 to function as DNA primers that, when used together in a thermal amplification reaction with template DNA derived from soybean event MON87751, to produce an amplicon diagnostic for soybean event MON87751 DNA in a sample. The primer pair SEQ ID NO: 14 and SEQ ID NO: 15 are useful as a first DNA molecule and a second DNA molecule that is different from the first DNA molecule, and both are each of sufficient length of contiguous nucleotides of soybean genomic DNA to function as DNA primers that, when used together in a thermal amplification reaction with template DNA derived fromsoybean event MON87751 , to produce an amplicon of the wild-type allele (absence of the transgene insert) diagnostic for the zygosity of soybean event MON87751 DNA in a sample.

[0138] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises at least one of the nucleotide sequences provided as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, or at least 90 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that (i) contains or comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of any one of SEQ ID NOs: 1-10, (ii) is at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 nucleotides in length, and (iii) comprises nucleotides 1,000-1,001 and / or 3,733-3,734 of SEQ ID NO: 10.

[0139] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) two expression cassettes that encode the insect pesticidal insect toxins Cry2Ab and Cry 1 A. 105, and (ii) a junction sequence. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A. 105, and (ii) a 5' flank and / or a 3 ' flank sequence. The expression cassette may comprise in operable linkage: (a) a promoter sequence (b) a transcribableDNA sequence encoding a pesticidal insect toxins Cry2Ab and Cryl A.105 sequence that is toxic to Lepidopteran insect pest species, and (c) a transcription termination or 3' UTR sequence. The expression cassette may further comprise any of the elements described in Table 1, which may be operably linked.

[0140] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) an expression cassette that encodes the pesticidal insect toxins Cry2Ab and Cryl A.105, and (ii) a polynucleotide sequence comprising one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cryl A.105, and (ii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.

[0141] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cryl A.105, and (ii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47 or SEQ ID NO: 28 or SEQ ID NO: 48. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cryl A.105, and (ii) a sequence or flanking sequence, or a 5' flank or 3' flank, that is at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 27 or 47 or SEQ ID NO: 28 or 48, or a fragment of either thereof. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that an pesticidal insect toxins Cry2Ab and Cry 1 A. 105, and (ii) a sequence or flanking sequence, or a 5' flank or 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47 or SEQ ID NO: 28 or 48. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A. 105, and (ii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 49-148. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A. 105, and (ii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 149-248.

[0142] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1A. 105, (ii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47, and (iii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13,at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21 , at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or SEQ ID NO: 48. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A. 105, (ii) a sequence or flanking sequence, or a 5 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 27 or 47, or a fragment of either thereof, and (iii) a sequence or flanking sequence, or a 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 28 or 48, or a fragment of either thereof. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A. 105, and (ii) a sequence or flanking sequence, or a 5' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47, and (iii) a sequence or flanking sequence, or a 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) expression cassettes that encodes the pesticidal insect toxins Cry2Ab and CrylA.105, (ii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 49-148, and (iii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 149-248.

[0143] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A.105, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A.105, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3' end at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A.105, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end a polynucleotide sequence selected from SEQ ID NOs: 49- 148. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1A.105, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3 ' end a polynucleotide sequence selected from SEQ ID NOs: 149-248.

[0144] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A.105, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end at least 50consecutive nucleotides of SEQ ID NO: 27 or 47, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3 ' end at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end a polynucleotide sequence selected from SEQ ID NOs: 49- 148, and / or wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3' end a polynucleotide sequence selected from SEQ ID NOs: 149-248.

[0145] According to present embodiments, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47 at the 5' end of a DNA molecule, construct, segment, amplicon, fragment or polynucleotide may be immediately adjacent to and upstream (on the 5' end) of the transgenic insertion, or may not be immediately adjacent to, but further upstream (on the 5' end) and within about 5000 nucleotides, within about 4000 nucleotides, within about 3000 nucleotides, within about 2000 nucleotides, or within about 1000 nucleotides of the transgenic insertion. According to present embodiments, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or SEQ ID NO: 48 at the 3 ' end of a DNA molecule, construct, segment, amplicon, fragment or polynucleotide may be immediately adjacent to and downstream (on the 3' end) of the transgenic insertion, or may not be immediately adjacent to but further downstream (on the 3' end) and within about 5000 nucleotides, within about 4000 nucleotides, within about 3000 nucleotides, within about 2000 nucleotides, or within about 1000 nucleotides of the transgenic insertion. Any sequence comprising at least 50 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or SEQ ID NO: 48 is within the scope of the present disclosure. A DNA molecule, construct, segment, amplicon, fragment or polynucleotide can comprise at the 5' and / or 3' end of the construct (i) atleast 50 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47; and / or (ii) at least 50 consecutive nucleotides of SEQ ID NO: 28 or SEQ ID NO: 48, respectively.

[0146] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a junction sequence. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a 5' flank and / or a 3 ' flank sequence.

[0147] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47 or SEQ ID NO: 28 or SEQ ID NO: 48. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragmentor polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a sequence or flanking sequence, or a 5' flank or 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 27 or 47 or SEQ ID NO: 28 or 48, or a fragment of either thereof.

[0148] According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a sequence or flanking sequence, or a 5' flank or 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47 or SEQ ID NO: 28 or 48. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, atleast 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 49-148.

[0149] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 149-248.

[0150] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, (ii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or SEQ ID NO: 47, and (iii) a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least1 ,000, at least 1 ,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or SEQ ID NO: 48. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, (ii) a sequence or flanking sequence, or a 5' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 27 or 47, or a fragment of either thereof, and (iii) a sequence or flanking sequence, or a 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 28 or 48, or a fragment of either thereof. According to some embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, and (ii) a sequence or flanking sequence, or a 5' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000consecutive nucleotides of SEQ ID NO: 27 or 47, and (iii) a sequence or flanking sequence, or a 3 ' flank, that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48.

[0151] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises (i) SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, (ii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 49-148, and (iii) a polynucleotide sequence comprising one or more polynucleotide sequences selected from SEQ ID NOs: 149-248.

[0152] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3' end at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises expression cassettes that encodes the pesticidal insect toxins Cry2Ab and Cry 1 A.105, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end a polynucleotide sequence selected from SEQ ID NOs: 49- 148. According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3 ' end a polynucleotide sequence selected from SEQ ID NOs: 149- 248.

[0153] According to present embodiments, a DNA molecule, construct, segment, amplicon, fragment or polynucleotide is provided that contains or comprises SEQ ID NO: 9 or a polynucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 9, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3 ' end at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, wherein theDNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 5' end a polynucleotide sequence selected from SEQ ID NOs: 49-148, and / or wherein the DNA molecule, construct, segment, amplicon, fragment or polynucleotide comprises at its 3' end a polynucleotide sequence selected from SEQ ID NOs: 149-248.

[0154] According to present embodiments, a soybean plant, plant part, plant seed, plant tissue, plant cell or commodity product is provided comprising any DNA molecule, construct, segment, fragment or polynucleotide described herein. A soybean plant comprising a construct as described herein may be further characterized as providing resistance to Lepidopteran insect pest species.

[0155] To detect the presence or absence of soybean event MON87751 or a modified soybean event MON87751, the target positions and / or the intervening region or sequence of a template DNA molecule may comprise at least one junction sequence and / or at least a portion of the insert of soybean event MON87751 or a modified soybean event MON87751. To detect the absence of soybean event MON87751 or a modified soybean event MON87751, the target positions and / or the intervening region or sequence of a template DNA molecule may comprise soybean genomic DNA that does not include a junction sequence or any portion of the insert of soybean event MON87751 or a modified soybean event MON87751. Thus, the presence or absence of an amplicon with a primer pair may be diagnostic of the presence or absence, respectively, of soybean event MON87751 or a modified soybean event MON87751 in a DNA molecule or sample, or vice versa. This may also be possible with more than one primer pair. For example, a first primer pair may produce a first amplicon if soybean event MON87751 or a modified soybean event MON87751 is present, and a second primer pair may produce a second amplicon if soybean event MON87751 or a modified soybean event MON87751 is absent or not present. Alternatively, the size of an amplicon produced in an amplification reaction may also be diagnostic of the presence or absence of soybean event MON87751 or a modified soybean event MON87751 in a DNA molecule or sample - e.g., a primer pair may produce a first amplicon of a first size if soybean event MON87751 or a modified soybean event MON87751 is present or a second amplicon of a second size if soybean event MON87751 or a modified soybean event MON87751 is absent and not present; or a first primer pair may produce a first amplicon of a first size if soybean event MON87751 or a modified soybean event MON87751 is present, and a second primer pair may produce a second amplicon of a second size if soybean event MON87751 or a modified soybean event MON87751 is absent or not present. According to some of these embodiments, at least twoprimer pairs may be used wherein at least one of the primer pairs is used as an internal control and is not associated with soybean event MON87751 or a modified soybean event MON87751.

[0156] According to present embodiments, a primer pair to detect the presence of all or part of soybean event MON87751 or a modified soybean event MON87751 in a DNA molecule or sample comprises a first primer and a second primer, wherein the first primer is complementary to a 5' flanking genomic DNA sequence and the second primer is complementary to a sequence within the transgenic insert; or wherein the first primer is complementary to a 5' flanking genomic DNA sequence and the second primer is complementary to a 3' flanking genomic DNA sequence; or wherein the first primer is complementary to a 3 ' flanking genomic DNA sequence and the second primer is complementary to a 5' flanking genomic DNA sequence; or wherein the first primer is complementary to a sequence within the transgenic insert and the second primer is complementary to a 3 ' flanking genomic DNA sequence; or wherein the first primer is complementary to a sequence within the transgenic insert and the second primer is complementary to a 5' flanking genomic DNA sequence; or wherein the first primer is complementary to a 3 ' flanking genomic DNA sequence and the second primer is complementary to a sequence within the transgenic insert. Each reference in this paragraph to a primer complementary to a 5' flanking genomic DNA sequence, a 3' flanking genomic DNA sequence, or a sequence within the transgenic insert of soybean event MON87751 or a modified soybean event MON87751 is also intended to potentially include a primer complementary to the reverse complement or opposing strand of the respective 5 ' flanking genomic DNA sequence, 3 ' flanking genomic DNA sequence, or sequence within the transgenic insert of soybean event MON87751 or a modified soybean event MON87751.

[0157] Examples of DNA molecules that may be useful as primers are provided as SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 15. The primer pair SEQ ID NO: 11 and SEQ ID NO: 12 can be useful as a first DNA molecule or primer and a second DNA molecule or primer, wherein each primer has sufficient length of consecutive nucleotides of SEQ ID NO: 10 or a sequence complementary to SEQ ID NO: 10 to function as DNA primers that, when used together in an amplification reaction with template DNA derived from soybean event MON87751 or a modified soybean event MON87751, hybridize to opposite strands of the template DNA and produce an amplicon diagnostic for soybean event MON87751 DNA or DNA from a modified soybean event MON87751 in a sample. The primer pair SEQ ID NO: 14 and SEQ ID NO: 15 are useful as a first DNA molecule or primer and a second DNA molecule or primer, wherein eachprimer has sufficient length of consecutive nucleotides of a locus within the soybean genome to function as DNA primers that, when used together in a thermal amplification reaction with template DNA derived from soybean event MON87751 or a modified soybean event MON87751, to produce an amplicon that serves as an internal control for both the diagnosis or detection of soybean event MON87751 or a modified soybean event MON87751, as well as characterizing the zygosity of soybean event MON87751 DNA or DNA from a modified soybean event MON87751 in a sample.

[0158] DNA probes and DNA primers are generally eleven (11) polynucleotides or more in length, often eighteen (18) polynucleotides or more, twenty -four (24) polynucleotides or more, or thirty (30) polynucleotides or more. Such probes and primers are selected to be of sufficient length to hybridize specifically to a target sequence under high stringency hybridization conditions. Preferably, probes and primers according to the present invention have complete sequence similarity with the target sequence, although probes differing from the target sequence that retain the ability to hybridize to target sequences may be designed by conventional methods.

[0159] The nucleic acid probes and primers of the present invention hybridize under stringent conditions to a target DNA molecule. Any conventional nucleic acid hybridization or amplification method can be used to identify the presence of DNA from a transgenic plant in a sample. Polynucleic acid molecules also referred to as nucleic acid segments or fragments thereof are capable of specifically hybridizing to other nucleic acid molecules under certain circumstances.

[0160] As used herein, two polynucleic acid molecules are said to be capable of specifically hybridizing to one another if the two molecules are capable of forming an anti-parallel, doublestranded nucleic acid structure. A nucleic acid molecule is said to be the “complement” of another nucleic acid molecule if they exhibit complete complementarity. As used herein, molecules are said to exhibit “complete complementarity” when every nucleotide of one of the molecules is complementary to a nucleotide of the other. Two molecules are said to be “minimally complementary” if they can hybridize to one another with sufficient stability to permit them to remain annealed to one another under at least conventional "low-stringency" conditions. Similarly, the molecules are said to be “complementary” if they can hybridize to one another with sufficient stability to permit them to remain annealed to one another under conventional "high-stringency" conditions. Conventional stringency conditions are described by Sambrook et al., 1989, and byHaymes etal., In: Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, DC (1985). Departures from complete complementarity are therefore permissible, as long as such departures do not completely preclude the capacity of the molecules to form a double-stranded structure. In order for a nucleic acid molecule to serve as a primer or probe it need only be sufficiently complementary in sequence to be able to form a stable double-stranded structure under the particular solvent and salt concentrations employed.

[0161] As used herein, a substantially homologous sequence is a nucleic acid sequence that will specifically hybridize to the complement of the nucleic acid sequence to which it is being compared under high stringency conditions. Appropriate stringency conditions that promote DNA hybridization, for example, 6.0 x sodium chloride / sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C, are known to those skilled in the art or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50°C to a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C. Both temperature and salt may be varied, or either the temperature or the salt concentration may be held constant while the other variable is changed. In a preferred embodiment, a polynucleic acid of the present invention will specifically hybridize to one or more of the nucleic acid molecules set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, or complements thereof or fragments thereof under moderately stringent conditions, for example at about 2.0 x SSC and about 65°C. In a particularly preferred embodiment, a nucleic acid of the present invention will specifically hybridize to one or more of the nucleic acid molecules set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, or complements or fragments thereof under high stringency conditions. In one aspect of the present invention, a preferred marker nucleic acid molecule of the present invention has the nucleic acid sequence set forth in SEQ ID NO: 1, or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4, or SEQ ID NO: 5, or SEQ ID NO: 6, or SEQ ID NO: 7, or SEQ ID NO: 8, or SEQ ID NO: 9, or SEQ ID NO: 10, or complements thereof, or fragments thereof. The hybridization of the probe to the target DNA molecule can be detected by any number of methods known to those skilled inthe art, these can include, but are not limited to, fluorescent tags, radioactive tags, antibody based tags, and chemiluminescent tags.

[0162] Regarding the amplification of a target nucleic acid sequence (e.g., by PCR) using a particular amplification primer pair, "stringent conditions" are conditions that permit the primer pair to hybridize only to the target nucleic acid sequence to which a primer having the corresponding wild-type sequence (or its complement) would bind and preferably to produce a unique amplification product, the amplicon, in a DNA thermal amplification reaction.

[0163] The term "specific for (a target sequence)" indicates that a probe or primer hybridizes under stringent hybridization conditions only to the target sequence in a sample comprising the target sequence.

[0164] As used herein, “amplified DNA” or “amplicon” refers to the product of polynucleic acid amplification method directed to a target polynucleic acid molecule that is part of a polynucleic acid template. For example, to determine whether a soybean plant resulting from a sexual cross contains transgenic plant genomic DNA from a soybean plant comprising event MON87751 of the present invention, DNA that is extracted from a soybean plant tissue sample may be subjected to a polynucleic acid amplification method using a primer pair that includes a first primer derived from a genomic DNA sequence in the region flanking the heterologous inserted DNA of event MON87751 and is elongated by polymerase 5' to 3' in the direction of the inserted DNA. The second primer is derived from the heterologous inserted DNA molecule is elongated by the polymerase 5' to 3' in the direction of the flanking genomic DNA from which the first primer is derived. The amplicon may range in length from the combined length of the primer pair plus one nucleotide base pair, or plus about fifty nucleotide base pairs, or plus about two hundred-fifty nucleotide base pairs, or plus about four hundred-fifty nucleotide base pairs or more. Alternatively, a primer pair can be derived from genomic sequence on both sides of the inserted heterologous DNA so as to produce an amplicon that includes the entire insert polynucleotide sequence e.g., a forward primer isolated from the genomic portion on the 5' end of SEQ ID NO: 10 and a reverse primer isolated from the genomic portion on the 3' end of SEQ ID NO: 10 that amplifies a DNA molecule comprising the inserted DNA sequence (SEQ ID NO: 9) identified herein in the event MON87751 genome). A member of a primer pair derived from the plant genomic sequence adjacent to the inserted transgenic DNA is located a distance from the inserted DNA sequence,this distance can range from one nucleotide base pair up to about twenty thousand nucleotide base pairs. The use of the term “amplicon” specifically excludes primer dimers that may be formed in the DNA thermal amplification reaction.

[0165] For practical purposes, one should design primers which produce amplicons of a limited size range, for example, between 100 to 1000 bases. Smaller (shorter polynucleotide length) sized amplicons in general are more reliably produced in thermal amplification reactions, allow for shorter cycle times, and can be easily separated and visualized on agarose gels or adapted for use in endpoint TaqMan®-like assays. Smaller amplicons can be produced and detected by methods known in the art of DNA amplicon detection. In addition, amplicons produced using the primer pairs can be cloned into vectors, propagated, isolated, and sequenced or can be sequenced directly with methods well established in the art. Any primer pair derived from the combination of SEQ ID NO: 27 and SEQ ID NO: 9 or the combination of SEQ ID NO: 28 and SEQ ID NO: 9 that are useful in a DNA amplification method to produce an amplicon diagnostic for event MON87751 or a modified soybean event MON87751, or progeny thereof is an aspect of the present disclosure. Any single isolated DNA polynucleotide primer molecule comprising at least 15 contiguous nucleotides of SEQ ID NO: 27, or its complement that is useful in a DNA amplification method to produce an amplicon diagnostic for event MON87751 or a modified soybean event MON87751, or progeny thereof is an aspect of the present disclosure. Any single isolated DNA polynucleotide primer molecule comprising at least 15 contiguous nucleotides of SEQ ID NO: 28, or its complement that is useful in a DNA amplification method to produce an amplicon diagnostic for plants comprising event MON87751 or a modified soybean event MON87751, or progeny thereof is an aspect of the present disclosure. Any single isolated DNA polynucleotide primer molecule comprising at least 15 contiguous nucleotides of SEQ ID NO: 9, or its complement that is useful in a DNA amplification method to produce an amplicon diagnostic for event MON87751 or a modified soybean event MON87751 or progeny thereof is an aspect of the present disclosure.

[0166] Polynucleic acid amplification can be accomplished by any of the various polynucleic acid amplification methods known in the art, including the polymerase chain reaction (PCR). Amplification methods are known in the art and are described, inter alia, in U.S. Patent Nos. 4,683,195 and 4,683,202 and in PCR Protocols: A Guide to Methods and Applications, ed. Innis et al., Academic Press, San Diego, 1990. PCR amplification methods have been developed to amplify up to 22 kb (kilobase) of genomic DNA and up to 42 kb of bacteriophage DNA (Cheng etal., Proc. Natl. Acad. Sci. USA 91:5695-5699, 1994}. These methods as well as other methods known in the art of DNA amplification may be used in the practice of the present invention. The sequence of the heterologous DNA insert or flanking genomic DNA sequence from soybean event MON87751 can be verified (and corrected if necessary) by amplifying such DNA molecules from soybean seed containing event MON87751 DNA or soybean plants grown from the soybean seed containing event MON87751 DNA deposited with the ATCC having accession No. PTA-120166, using primers derived from the sequences provided herein, followed by standard DNA sequencing of the PCR amplicon or cloned DNA fragments thereof.

[0167] A diagnostic amplicon produced by the methods described herein may be detected by a plurality of techniques known in the art, such as sequencing, restriction mapping, Northern analysis, Southern analysis, or any other suitable polynucleotide or DNA hybridization, blotting, polymerization and / or amplification based approach or technique. One method is Genetic Bit Analysis (Nikiforov et al., Nucleic Acid Res. 22:4167-4175, 1994) where a DNA oligonucleotide is designed that overlaps both the adjacent flanking genomic DNA sequence and the inserted DNA sequence - i.e., a junction sequence. The oligonucleotide is immobilized in wells of a microtiter plate. Following PCR of the region of interest (using, for example, one primer in the inserted sequence and one in the adjacent flanking genomic sequence), a single-stranded PCR product can be hybridized to the immobilized oligonucleotide and serve as a template for a single base extension reaction using a DNA polymerase and labeled dideoxynucleotide triphosphates (ddNTPs) specific for the expected next base. Readout may be fluorescent or ELISA-based. A signal indicates presence of the transgene / genomic junction sequence due to successful amplification, hybridization, and single base extension.

[0168] Another method is the Pyrosequencing technique as described by Winge (Innov. Pharma. Tech. 00:18-24, 2000). In this method, an oligonucleotide is designed that overlaps the adjacent genomic DNA and insert DNA junction. The oligonucleotide is hybridized to single- stranded PCR product from the region of interest (one primer in the inserted sequence and one in the flanking genomic sequence) and incubated in the presence of a DNA polymerase, ATP, sulfurylase, luciferase, apyrase, adenosine 5' phosphosulfate and luciferin. DNTPs are added individually and the incorporation results in a light signal that is measured. A light signal indicates the presence of the transgene / genomic sequence due to successful amplification, hybridization, and single or multi-base extension.

[0169] Fluorescence Polarization as described by Chen, et al., (Genome Res. 9:492-498, 1999) is a method that can be used to detect the amplicon of the present invention. Using this method an oligonucleotide is designed that overlaps the genomic flanking and inserted DNA junction. The oligonucleotide is hybridized to single-stranded PCR product from the region of interest (one primer in the inserted DNA and one in the flanking genomic DNA sequence) and incubated in the presence of a DNA polymerase and a fluorescent-labeled ddNTP. Single base extension results in incorporation of the ddNTP. Incorporation can be measured as a change in polarization using a fluorometer. A change in polarization indicates the presence of the transgene / genomic sequence due to successful amplification, hybridization, and single base extension.

[0170] Real-time Polymerase Chain Reaction (PCR) is the ability to monitor the progress of the PCR as it occurs (i.e., in real time). Data is collected throughout the PCR process, rather than at the end of the PCR. In real-time PCR, reactions are characterized by the point in time during cycling when amplification of a target is first detected rather than the amount of target accumulated after a fixed number of cycles. In a real-time PCR assay, a positive reaction is detected by accumulation of a fluorescent signal. The higher the starting copy number of the nucleic acid target, the sooner a significant increase in fluorescence is observed. The cycle threshold (Ct value) is defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e., exceeds background level). Ct levels are inversely proportional to the amount of target nucleic acid in the sample (i.e., the lower the Ct value, the greater the amount of target nucleic acid in the sample).

[0171] TaqMan® (PE Applied Biosystems, Foster City, CA) is described as a method of detecting and quantifying the presence of a DNA sequence using real-time PCR and is fully understood in the instructions provided by the manufacturer. Briefly, a FRET oligonucleotide probe is designed that overlaps the genomic flanking and insert DNA junction. The FRET probe and PCR primers (one primer in the insert DNA sequence and one in the flanking genomic sequence) are cycled in the presence of a thermalstable polymerase and dNTPs. Hybridization of the FRET probe results in cleavage and release of the fluorescent moiety away from the quenching moiety on the FRET probe. A fluorescent signal indicates the presence of the transgene / genomic sequence due to successful amplification and hybridization.

[0172] Other detection methods known in the art may be used. For example, microfluidics (see, e.g., U.S. Patent Publication No. 2006 / 068398; U.S. Patent No. 6,544,734) provide methods and devices that can be used to separate and amplify DNA samples or molecules. Optical dyes can be used to detect and measure specific DNA molecules (see, e.g., WO / 05017181). Nanotube devices (see, e.g., W 0 / 06024023) that comprise an electronic sensor for the detection of DNA molecules or nanobeads that bind specific DNA molecules can then be detected.

[0173] DNA detection kits that are based on DNA amplification methods contain DNA primer molecules that hybridize specifically to a target DNA and amplify a diagnostic amplicon under the appropriate reaction conditions. The kit may provide an agarose gel based detection method or any number of methods of detecting the diagnostic amplicon that are known in the art. DNA detection kits can be developed using the compositions disclosed herein and are useful for identification of soybean event MON87751 DNA or DNA from a modified soybean event MON87751 in a sample and can be applied to methods for breeding soybean plants containing event MON87751 DNA or DNA from a modified soybean event MON87751. A kit that contains DNA primers that are homologous or complementary to any portion of the soybean genomic region as set forth in SEQ ID NO: 10 and to any portion of the inserted transgenic DNA as set forth in SEQ ID NO: 10 is an object of the invention. The DNA molecules can be used in DNA amplification methods (PCR) or as probes in polynucleic acid hybridization methods, i.e., southern analysis, northern analysis. Kits of the invention may optionally also comprise reagents or instructions for performing the detection or diagnostic reactions described herein.

[0174] Probes and primers as provided herein may have complete sequence identity with the target sequence, although primers and probes differing from the target sequence that retain the ability to hybridize preferentially to target sequences may be designed by conventional methods. In order for a nucleic acid molecule to serve as a primer or probe it need only be sufficiently complementary in sequence to be able to form a stable double-stranded structure under the particular solvent and salt concentrations employed. Any conventional nucleic acid hybridization or amplification method can be used to identify the presence of transgenic DNA from soybean event MON87751 or a modified soybean event MON87751 in a sample.

[0175] Any number of methods well known to those skilled in the art can be used to isolate and manipulate a DNA molecule, or fragment thereof, disclosed herein, including DNA isolation or'llthermal amplification or PCR methods. Such DNA molecule or fragment may be inserted or placed into any suitable vector or plasmid or combined with other elements, sequences or fragments using molecular or recombinant techniques.

[0176] The DNA molecules and corresponding nucleotide sequences provided herein are therefore useful for, among other things, identifying soybean event MON87751 or a modified soybean event MON87751, detecting the presence of DNA derived from the transgenic soybean event MON87751 or a modified soybean event MON87751 in a sample, and monitoring samples for the presence and / or absence of soybean event MON87751 or a modified soybean event MON87751 or plant parts derived from soybean plants comprising event MON87751 or a modified soybean event MON87751.

[0177] Reference herein to “soybean” generally is intended to include soybean plants, soybean plant cells, soybean plant tissues, soybean seeds, soybean plant parts, soybean progeny plants, and / or soybean commodity products, depending on the context of its use herein, unless otherwise provided. The present disclosure provides soybean plants, soybean plant cells, soybean plant tissues, soybean seeds, soybean plant parts (such as pollen, ovule, silk, spike, anther, cob, root tissue, stalk tissue, leaf tissue), soybean progeny plants, and soybean commodity products. These soybean plants, soybean plant cells, soybean plant tissues, soybean seeds, soybean plant parts, soybean progeny plants, and soybean commodity products contain a detectable amount of a polynucleotide or DNA molecule or sequence comprising at least one junction sequence and / or heterologous insert sequence of soybean event MON87751 or a modified soybean event MON87751, such as a polynucleotide or DNA molecule or sequence having or comprising at least one of the sequences provided as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

[0178] The present disclosure provides soybean plants, soybean plant cells, soybean seeds, soybean plant parts (such as pollen, ovule, silk, spike, anther, cob, root tissue, stalk tissue, leaf tissue), soybean progeny plants derived from a transgenic soybean plant containing event MON87751 DNA. A representative sample of soybean seed containing event MON87751 DNA has been deposited according to the Budapest Treaty with the American Type Culture Collection(ATCC®). The ATCC repository has assigned the Patent Deposit Designation PTA-120166 to the seed containing event MON87751 DNA.

[0179] The present disclosure provides a microorganism comprising a DNA molecule having at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 present in its genome. A microorganism is intended to include any microscopic cell or organism, whether prokaryote or eukaryote or otherwise, that contains DNA within a genome or chromosome or an extra-chromosomal DNA structure, such as a plasmid or vector, in such microscopic cell. Microscopic cells or organisms include bacteria (prokaryotes) and cells corresponding to higher life forms (eukaryotes) which are beneath the visual range of the average human. An example of such a microorganism is a transgenic plant cell. Microorganisms, such as a plant cell of the invention, are useful in many industrial applications, including but not limited to: (i) use as research tool for scientific inquiry or industrial research; (ii) use in culture for producing endogenous or recombinant carbohydrate, lipid, nucleic acid, or protein products or small molecules that may be used for subsequent scientific research or as industrial products; and (iii) use with modern plant tissue culture techniques to produce transgenic plants or plant tissue cultures that may then be used for agricultural research or production. The production and use of microorganisms such as transgenic plant cells utilizes modem microbiological techniques and human intervention to produce a man-made, unique microorganism. In this process, recombinant DNA is inserted into a plant cell’s genome to create a transgenic plant cell that is separate and unique from naturally occurring plant cells. This transgenic plant cell can then be cultured much like bacteria and yeast cells using modem microbiology techniques and may exist in an undifferentiated, unicellular state. The transgenic plant cell’s new genetic composition and phenotype is a technical effect created by the integration of the heterologous DNA into the genome of the cell. Another aspect of the invention is a method of using a microorganism of the invention. Methods of using microorganisms of the invention, such as transgenic plant cells, include (i) methods of producing transgenic cells by integrating recombinant DNA into the genome of the cell and then using this cell to derive additional cells possessing the same heterologous DNA; (ii) methods of culturing cells that contain recombinant DNA using modern microbiology techniques; (iii) methods of producing and purifying endogenous or recombinant carbohydrate, lipid, nucleic acid, or protein products from cultured cells; and (iv) methods of using modern plant tissue culturetechniques with transgenic plant cells to produce transgenic plants or transgenic plant tissue cultures.

[0180] Soybean plants of the present disclosure may pass along the event MON87751 DNA or DNA from a modified soybean event MON87751, including transgene(s) or cassette(s) inserted in or part of soybean event MON87751 or a modified soybean event MON87751, to progeny or offspring. As used herein, “progeny” includes any plant, plant cell, seed, and / or regenerable plant part containing the event MON87751 DNA or DNA from a modified soybean event MON87751 derived from an ancestor plant and / or comprising a DNA molecule having at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. Soybean plants, progeny, and seeds may be homozygous or heterozygous for the soybean event MON87751 or a modified soybean event MON87751 and / or the transgene(s) or cassette(s) of soybean event MON87751 or a modified soybean event MON87751. Progeny may be grown from seeds produced by a soybean plant comprising or containing soybean event MON87751 or a modified soybean event MON87751 and / or from seeds produced by a plant fertilized with pollen from a soybean plant comprising or containing soybean event MON87751 or a modified soybean event MON87751 (i.e., fertilized with pollen comprising or containing soybean event MON87751 or a modified soybean event MON87751).

[0181] Methods for producing soybean plants and seeds containing or comprising soybean event MON87751 or a modified soybean event MON87751 are provided. Soybean plants may be bred using any method known in the art, for example, descriptions of breeding methods that are commonly used can be found in WR Fehr, in Breeding Methods for Cultivar Development, Wilcox J. ed., American Society of Agronomy, Madison WI (1987). Soybean plants or progeny plants containing or comprising soybean event MON87751 or a modified soybean event MON87751 may be self-pollinated (also known as “selfing”) to generate a true breeding line of soybean plants, i.e., soybean plants homozygous for the transgene and event MON87751 or a modified soybean event MON87751. Selfing can result in progeny known as an “inbred” that can be used to produce soybean inbred lines that are genetically uniform.

[0182] Alternatively, soybean plants or progeny plants containing or comprising soybean event MON87751 or a modified soybean event MON87751 may be out-crossed or cross-pollinated (alsoknown as “crossing”), e.g., bred with another plant having a different germplasm or genotype, to produce a varietal or hybrid seed or plant that may be homozygous or heterozygous for the transgene(s) or cassette(s) and / or event MON87751 or a modified soybean event MON87751 depending on whether the other parental plant also comprises or contains the transgene(s) or cassette(s) and / or event MON87751 or a modified soybean event MON87751. The other parental plant may be transgenic or non-transgenic for the same and / or different trait, transgene or event. A varietal or hybrid seed or plant of the invention may thus be derived by sexually crossing a first parent that lacks the specific and unique soybean event MON87751 or a modified soybean event MON87751 with a second parent comprising soybean event MON87751 or a modified soybean event MON87751, resulting in a hybrid plant or progeny plant containing or comprising the specific and unique soybean event MON87751 or a modified soybean event MON87751. Each parent can be a hybrid or an inbred / varietal plant, so long as a parent or progeny plant or seed of the cross has or comprises at least one copy of the soybean event MON87751 or a modified soybean event MON87751 and / or a DNA molecule having or comprising at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

[0183] Sexually crossing one plant with another plant, i.e., cross-pollinating, may be accomplished or facilitated by human intervention, for example: by human hands or other mechanical means under human, computer or automated control collecting the pollen of one plant and contacting this pollen with the style or stigma of a second plant; by human hands and / or human actions or other mechanical means under human, computer or automated control removing, destroying, devitalizing or covering the stamen or anthers of a plant (e.g., by manual intervention or by application of a chemical gametocide) so that natural self-pollination is prevented and crosspollination would have to take place in order for fertilization to occur; by human placement of pollinating insects in a position for “directed pollination” (e.g., by placing beehives in orchards or fields or by caging plants with pollinating insects); by human opening or removing of parts of the flower to allow for placement or contact of foreign pollen on the style or stigma; by selective placement of plants (e.g., intentionally planting plants in pollinating proximity); and / or by application of chemicals to precipitate flowering or to foster receptivity (of the stigma for pollen).

[0184] Two different transgenic plants may thus be crossed to produce hybrid offspring plants, plant parts and / or seeds that contain two independently segregating transgenes or events whereinat least one of those transgenes or events comprises or is contained within soybean event MON87751 or a modified soybean event MON87751. For example, transgenic plants comprising soybean event MON87751 or a modified soybean event MON87751 can be crossed with other transgenic soybean plants to produce a plant having the characteristics of both transgenic parents. Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated, as is vegetative propagation. Descriptions of other breeding methods that are commonly used for different traits and crops are known in the art and can be found in one of several references, e.g., Fehr, in Breeding Methods for Cultivar Development, Wilcox J. ed., American Society of Agronomy, Madison WI (1987).

[0185] According to some embodiments, a reduced plant height trait or phenotype may be used to select one or more progeny soybean plants, plant parts or seeds that contain soybean or soybean event MON87751. Alternatively, progeny plants, plant parts or seeds may be analyzed using diagnostic methods as described herein to select for plants, plant parts or seeds containing or comprising soybean or soybean event MON87751 or a modified soybean event MON87751. Alternatively, progeny plants, plant parts or seeds may be analyzed using diagnostic methods as described herein to select for plants, plant parts or seeds containing or comprising soybean event MON87751 or a modified soybean event MON87751.

[0186] Soybean plants, progeny, seeds, cells and plant parts comprising soybean event MON87751 or a modified soybean event MON87751, and / or one or transgene(s) or cassette(s) of soybean event MON87751 or a modified soybean event MON87751 , may also contain one or more additional soybean trait(s) or transgenic event(s), particularly those introduced by crossing a soybean plant containing such transgene(s) or cassette(s) and / or soybean event MON87751 or a modified soybean event MON87751 with another soybean plant containing the additional trait(s) or transgenic event(s). Such trait(s) or transgenic events include, but are not limited to, increased insect resistance, herbicide tolerance, increased water use efficiency, increased yield performance, increased drought resistance, increased seed quality, improved nutritional quality, hybrid seed production, or disease or fungal resistance. A soybean trait may include any transgenic traits or mutant or edited traits or alleles. Mutant traits or alleles of a gene may be created by any mutagenesis technique known in the art, whereas edited traits may be generated by any genome editing technique or method known in the art. Many transgenic events in soybean are known to those of skill in the art. For example, a list of such traits is provided by the United StatesDepartment of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) and can be found on their website: www.aphis.usda.gov. Two or more trait(s) and / or transgenic event(s) comprising or including at least one copy of soybean event MON87751 or a modified soybean event MON87751 may thus be combined in a progeny seed or plant by crossing two parent plants, each comprising one or more trait(s) and / or transgenic event(s), collecting the progeny seed, and selecting for progeny seed or plants that contain the two or more trait(s) and / or transgenic event(s). These steps may be repeated until the desired combination of trait(s) and / or transgenic event(s) in a progeny plant is achieved. For the present application, the progeny plant will generally comprise soybean event MON87751 or a modified soybean event MON87751. Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated and is vegetative propagation.

[0187] A plant part is provided that comprises event MON87751 or a modified soybean event MON87751 and / or is derived from soybean plants comprising event MON87751 or a modified soybean event MON87751. As used herein, a “plant part” refers to any part of a plant which may comprise event MON87751 or a modified soybean event MON87751 and / or material derived from a soybean plant comprising event MON87751 or a modified soybean event MON87751. Plant parts include, but are not limited to, plant tissue, pollen, ovule, silk, spike, anther, cob, root tissue, stalk tissue, and leaf tissue. Plant parts may be viable, nonviable, regenerable, and / or non- regenerable.

[0188] A commodity product is provided that is derived from one or more soybean plants, plant parts, seeds and / or plant tissues comprising event MON87751 or a modified soybean event MON87751 and that contains a detectable amount of a nucleic acid or DNA molecule, segment or sequence specific for event MON87751 or a modified soybean event MON87751. As used herein, a “commodity product” refers to any composition or product comprising material derived from one or more soybean plants, whole or processed soybean seed, one or more plant cells, and / or one or more plant parts containing or comprising the soybean event MON87751 DNA or DNA from a modified soybean event MON87751. Nonviable commodity products include, but are not limited to, nonviable seeds, whole or processed seeds, seed parts, and plant parts; animal feed comprising soybean, soybean oil, soybean meal, soybean flour, soybean flakes, soybean bran, pasta made with soybean, soybean biomass, and fuel products produced using soybean and soybean parts. Viable commodity products include, but are not limited to, seeds, plants, and plant cells. The soybeanplants comprising event MON87751 or a modified soybean event MON87751 can thus be used to manufacture any commodity product typically acquired from soybean. Any such commodity product that is derived from soybean plants comprising event MON87751 or a modified soybean event MON87751 may contain at least a detectable amount of the specific and unique DNA corresponding to soybean event MON87751 or a modified soybean event MON87751, and specifically may contain a detectable amount of a polynucleotide or DNA molecule having or comprising at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. Detection of one or more of these polynucleotide or DNA sequences in a sample may be used to determine or diagnose that the sample is taken from a soybean plant, soybean plant part, soybean plant tissue, soybean plant cell, and / or soybean plant product, such as a soybean commodity product, comprising event MON87751 or a modified soybean event MON87751, or to determine the content or source of a soybean plant, soybean plant part, soybean plant tissue, soybean plant cell, and / or soybean plant product, such as a soybean commodity product. Any standard method of detection for nucleotide molecules may be used, including methods of detection disclosed herein. A commodity product is within the scope of the present disclosure if there is any detectable amount of a DNA molecule having at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 contained or comprised in the commodity product.

[0189] The soybean plants, soybean plant cells, soybean seeds, soybean plant parts (such as pollen, ovule, silk, spike, anther, cob, root tissue, stalk tissue, leaf tissue), soybean progeny plants, and commodity products of the invention are therefore, useful for, among other things, growing plants for the purpose of producing seed and / or plant parts comprising soybean event MON87751 or a modified soybean event MON87751 for agricultural purposes, producing progeny comprising soybean event MON87751 or a modified soybean event MON87751 for plant breeding and research purposes, use with microbiological techniques for industrial and research applications, and sale to consumers.

[0190] Methods for producing an insect resistant soybean plant comprising the DNA sequences specific and unique to event MON87751 or a modified soybean event MON87751 of the present disclosure are provided. A progeny soybean plant comprising the event MON87751 or a modifiedsoybean event MON87751 may be produced, for example, by selfing a parent plant or line comprising the event MON87751 or a modified soybean event MON87751, wherein such parent plant or line is homozygous or hemizygous for the event MON87751 or a modified soybean event MON87751, or by crossing a first parent plant or line comprising the event MON87751 or a modified soybean event MON87751, wherein such parent plant or line is homozygous or hemizygous for the event MON87751 or a modified soybean event MON87751, with a second parent plant or line having a different genotype or germplasm than the first parent line, wherein the second parent plant or line may or may not contain or comprise the event MON87751 or a modified soybean event MON87751. As described further herein, a modified soybean event MON87751 may contain one or more of the expression cassette(s) or transgene(s) as provided herein, such as one or more of Cry2Ab and / or Cry 1 A.105 expressing transgene cassette(s). According to some embodiments, the transgenic soybean plant(s) comprising the event MON87751 or a modified soybean event MON87751 of the present disclosure may exhibit resistance to one or more Lepidopteran insect pest species, such as Spodoptera frngiperda (fall armyworm, FAW), Spodoptera eridania (southern armyworm, SAW), Spodoptera exigua (beet army worm, BAW), Spodoptera ornithogalli (yellowstriped army worm, YSAW), Crocidosema aporema (bean shoot moth, BSM), Rachiplusia nu (sunflower looper, SFL), Anticar sia gemmatalis (velvetbean caterpillar, VBC), Chrysodeixis includens (soybean looper, SBL), Helicoverpa zea (soybean podworm, SPW), Helicoverpa gelotopeon (South American bollworm ), Elasmopalpus lignosellus, (lesser cornstalk borer), Estigmene acrea (saltmarsh caterpillar), and Plathypena scabra (green cloverworm), relative to a non-transgenic control plant. Transgenic plants used in these methods may be homozygous or heterozygous for the transgene or event. Progeny plants produced by these methods may be varietal or hybrid plants; may be grown from seeds produced by plants containing soybean event MON87751 or a modified soybean event MON87751 and / or from seeds produced by a plant fertilized with pollen from a plant containing soybean event MON87751 or a modified soybean event MON87751; and may be homozygous or heterozygous for one or more transgene(s) described herein and / or soybean event MON87751 or a modified soybean event MON87751. Progeny plants may be subsequently self-pollinated to generate a true breeding line of plants, i.e., plants homozygous for the transgene, or alternatively may be out-crossed, e.g., bred with another unrelated plant, to produce a varietal or a hybrid seed or plant.

[0191] Methods of detecting the presence of DNA derived from a soybean cell, soybean tissue, soybean seed, or soybean plant comprising soybean event MON87751 or a modified soybean event MON87751 in a sample are provided. One method consists of (i) extracting a DNA sample from at least one soybean cell, soybean tissue, soybean seed, or soybean plant; (ii) contacting the DNA sample with at least one primer that is capable of producing DNA sequence specific to event MON87751 DNA or DNA from a modified soybean event MON87751 under conditions appropriate for DNA sequencing; (iii) performing a DNA sequencing reaction; and then (iv) confirming that the nucleotide sequence comprises a nucleotide sequence specific for event MON87751 or a modified soybean event MON87751, of the construct comprised therein, such as one selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

[0192] Another method consists of (i) extracting a DNA sample from at least one soybean cell, soybean tissue, soybean seed, or soybean plant; (ii) contacting the DNA sample with a primer pair that is capable of producing an amplicon from event MON87751 DNA or DNA from a modified soybean event MON87751 under conditions appropriate for DNA amplification; (iii) performing a DNA amplification reaction; and then (iv) detecting the amplicon molecule and / or confirming that the nucleotide sequence of the amplicon comprises a nucleotide sequence specific for event MON87751 or a modified soybean event MON87751, such as one selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. The amplicon should be one that is specific for event MON87751, such as an amplicon that comprises SEQ ID NO: 1, or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4, or SEQ ID NO: 5, or SEQ ID NO: 6, or SEQ ID NO: 7, or SEQ ID NO: 8, or SEQ ID NO: 9, or SEQ ID NO: 10. The detection of a nucleotide sequence specific for event MON87751 or a modified soybean event MON87751 in the amplicon is determinative and / or diagnostic for the presence of the soybean event MON87751 specific DNA or DNA specific for a modified soybean event MON87751 in the sample. An example of a primer pair that is capable of producing an amplicon from event MON87751 DNA or DNA from a modified soybean event MON87751 under conditions appropriate for DNA amplification is provided as SEQ ID NO: 15 and SEQ ID NO: 16. Other primer pairs may be readily designed by one of skill in the art and would produce an amplicon comprising SEQ ID NO:1 , or SEQ ID NO: 2, or SEQ ID NO: 3, or SEQ ID NO: 4, or SEQ ID NO: 5, or SEQ ID NO: 6, or SEQ ID NO: 7, or SEQ ID NO: 8 wherein such a primer pair comprises at least one primer within the genomic region flanking the insert and a second primer within the insert.

[0193] Another method of detecting the presence of DNA derived from a soybean cell, soybean tissue, soybean seed, or soybean plant comprising soybean event MON87751 or a modified soybean event MON87751 in a sample consists of (i) extracting a DNA sample from at least one soybean cell, soybean tissue, soybean seed, or soybean plant; (ii) contacting the DNA sample with a DNA probe specific for event MON87751 or a modified soybean event MON87751; (iii) allowing the probe and the DNA sample to hybridize under stringent hybridization conditions; and then (iv) detecting hybridization between the probe and the target DNA sample. An example of the sequence of a DNA probe that may be specific for event MON87751 or a modified soybean event MON87751 is provided as SEQ ID NO: 17. Other probes may be readily designed by one of skill in the art and would comprise at least one fragment of genomic DNA flanking the insert and at least one fragment of insert DNA such as the sequence provided in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 10. Detection of probe hybridization to the DNA sample is diagnostic for the presence of soybean event MON87751 specific DNA or DNA specific for a modified soybean event MON87751 in the sample. Absence of hybridization is alternatively diagnostic of the absence of soybean event MON87751 specific DNA or DNA specific for a modified soybean event MON87751 in the sample.

[0194] DNA detection kits are provided that are useful for the identification of soybean event MON87751 DNA or DNA from a modified soybean event MON87751 in a sample and can also be applied to methods for breeding soybean plants containing the appropriate event DNA. Such kits may contain DNA primers and / or probe(s) which are specific for soybean event MON87751 or a modified soybean event MON87751. Such DNA primers and / or probe(s) may comprise one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. One example of such a kit comprises at least one DNA molecule of sufficient length of continuous nucleotides of SEQ ID NO: 10 to function as a DNA probe useful for detecting the presence and / or absence of DNA derived from transgenic soybean plants comprising event MON87751 or a modified soybean event MON87751 in a sample. The DNA derived from transgenic soybean plants comprisingevent MON87751 or a modified soybean event MON87751 would comprise a DNA molecule having at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. The primers may comprise a primer pair including a first primer and a second primer, wherein at least one of the primers hybridizes to a flanking sequence and the other primer hybridizes to either an insert sequence of event MON87751 or a modified soybean event MON87751 in the plant genome or the flanking sequence on the opposite side of the insert. The first and second primers hybridize to opposing strands of the soybean plant genomic DNA at different spaced apart positions such that an amplification reaction involving the two primers produces an amplicon comprising the primer sequences and the intervening sequence between the two primers. A probe may be chosen to correspond or hybridize to the amplicon produced with a primer pair or set of primers and may comprise all or part of the primer sequence(s) and / or the intervening sequence of the amplicon between the two primers. A DNA molecule that may be used as a DNA probe for determining, detecting, or diagnosing the presence and / or absence of soybean event MON87751 or a modified soybean event MON87751 in a sample is provided as SEQ ID NO: 17. Suitable probes may be readily designed by one of skill in the art and should comprise at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, or at least 40 contiguous nucleotides of SEQ ID NO: 10 and be sufficiently unique to soybean event MON87751 or a modified soybean event MON87751 in order to identify DNA derived from the event.

[0195] Another type of kit comprises a primer pair useful for producing an amplicon useful for detecting the presence and / or absence of DNA derived from transgenic soybean event MON87751 or a modified soybean event MON87751 in a sample. Such a kit would employ a method comprising contacting a target DNA sample with a primer pair as described herein, then performing a nucleic acid amplification reaction sufficient to produce an amplicon comprising a DNA molecule having at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 and then detecting the presence and / or absence of the amplicon. Such a method may also include sequencing the amplicon or a fragment thereof, which would bedeterminative of, z.e., diagnostic for, the presence of the soybean event MON87751 specific DNA or DNA specific for a modified soybean event MON87751 in the target DNA sample. Other primer pairs may be readily designed by one of skill in the art and should comprise at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or at least 30 contiguous nucleotides of sequences provided in, but not limited to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, and be sufficiently unique to soybean event MON87751 DNA or DNA from a modified soybean event MON87751 in order to identify DNA derived from the event.

[0196] The kits and detection methods of the invention are useful for, among other things, identifying soybean event MON87751 or a modified soybean event MON87751, selecting plant varieties or hybrids comprising soybean event MON87751 or a modified soybean event MON87751, detecting the presence of DNA derived from the transgenic soybean plant comprising event MON87751 or a modified soybean event MON87751 in a sample, and monitoring samples for the presence and / or absence of soybean plants comprising event MON87751 or a modified soybean event MON87751, or plant parts derived from soybean plants comprising event MON87751 or a modified soybean event MON87751.

[0197] The sequences of the heterologous DNA insert, junction sequences, or flanking sequence from soybean event MON87751 or a modified soybean event MON87751 can be verified (and corrected if necessary) by amplifying such sequences from the event using primers derived from the sequences provided herein followed by standard DNA sequencing of the amplicon or of the cloned DNA.

[0198] Methods of detecting the zygosity of the transgene allele of DNA derived from a soybean cell, soybean tissue, soybean seed, or soybean plant comprising soybean event MON87751 or a modified soybean event MON87751 in a sample are provided. One method consists of (i) extracting a DNA sample from at least one soybean cell, soybean tissue, soybean seed, or soybean plant; (ii) contacting the DNA sample with a primer pair that is capable of producing a first amplicon diagnostic for event MON87751 or a modified soybean event MON87751; (iii) contacting the DNA sample with a primer pair that is capable of producing a second amplicon diagnostic for native soybean genomic DNA not comprising event MON87751 or a modifiedsoybean event MON87751 ; (iv) performing a DNA amplification reaction; and then (v) detecting the amplicons, wherein the presence of only the first amplicon is diagnostic of a homozygous event MON87751 DNA or DNA from a modified soybean event MON87751 in the sample, and the presence of both the first amplicon and the second amplicon is diagnostic of a soybean plant heterozygous for event MON87751 or a modified soybean event MON87751. An example of a set of primers pairs are presented as SEQ ID NO: 11 and SEQ ID NO: 12 which produce an amplicon diagnostic for event MON87751; and SEQ ID NO: 14 and SEQ ID NO: 15 which produces an amplicon diagnostic for non-inserted wild-type soybean genomic DNA not comprising event MON87751 or a modified soybean event MON87751. A set of probes can also be incorporated into such an amplification method to be used in a real-time PCR format using the primer pair sets described above. An example set of probes are presented as SEQ ID NO: 13 (diagnostic for the amplicon for the event MON87751 or a modified soybean event MON87751) and SEQ ID NO: 16 (diagnostic for the amplicon for wild-type soybean genomic DNA not comprising event MON87751 or a modified soybean event MON87751).

[0199] Another method for determining zygosity consists of (i) extracting a DNA sample from at least one soybean cell, soybean tissue, soybean seed, or soybean plant; (ii) contacting the DNA sample with a probe set which contains at least a first probe that specifically hybridizes to event MON87751 DNA or DNA from a modified soybean event MON87751 and at least a second probe that specifically hybridizes to soybean genomic DNA that was disrupted by insertion of the heterologous DNA of event MON87751 or a modified soybean event MON87751 and does not hybridize to event MON877 1 DNA or DNA from a modified soybean event MON87751; (iii) hybridizing the probe set with the sample under stringent hybridization conditions, wherein detecting hybridization of only the first probe under the hybridization conditions is diagnostic for a homozygous allele of event MON87751 DNA or DNA from a modified soybean event MON87751 in the sample; and wherein detecting hybridization of both the first probe and the second probe under the hybridization conditions is diagnostic for a heterozygous allele of event MON87751 or a modified soybean event MON87751 in a DNA sample; and wherein detecting hybridization of only the second probe under the hybridization conditions is diagnostic for the absence of soybean event MON87751 DNA or DNA from a modified soybean event MON87751 in the sample.

[0200] Yet another method for determining zygosity consists of (i) extracting a DNA sample from at least one soybean cell, soybean tissue, soybean seed, or soybean plant; (ii) contacting the DNA sample with a primer pair that is capable of producing an amplicon from one or more of the toxin coding sequences encoding Cry2Ab and / or Cry 1 A.105 and / or DNA from soybean event MON87751 or a modified soybean event MON87751; (iii) contacting the DNA sample with a primer pair that is capable of producing an amplicon of an internal standard known to be singlecopy and homozygous in the soybean plant; (iv) contacting the DNA sample with a probe set which contains at least a first probe that specifically hybridizes to one or more of the toxin coding sequences encoding Cry2Ab and / or Cry 1 A.105 and / or DNA from soybean event MON87751 or a modified soybean event MON87751, and at least a second probe that specifically hybridizes to the internal standard genomic DNA known to be single-copy and homozygous in the soybean plant; (v) performing a DNA amplification reaction using real-time PCR and determining the cycle thresholds (Ct values) of the amplicon corresponding to the toxin coding sequence and the singlecopy, homozygous internal standard; (vi) calculating the difference (ACt) between the Ct value of the single-copy, homozygous internal standard amplicon and the Ct value of the toxin coding sequence amplicon; and (vii) determining zygosity, wherein a ACt of around zero (0) indicates homozygosity of the inserted T-DNA and a ACt of around one (1) indicates heterozygosity of the inserted T-DNA. Heterozygous and homozygous events are differentiated by a ACt value unit of approximately one (1). Given the normal variability observed in real-time PCR due to multiple factors such as amplification efficiency and ideal annealing temperatures, the range of “about one (1)” is defined as a ACt of 0.75 to 1.25. Primer pairs and probes for the above method for determining zygosity can amplify and detect amplicons from the Cry2Ab cassette or coding sequence and / or the Cry 1 A.105 cassette or coding sequence and / or a junction sequence, and an internal control. An example of a primer pair for the detection of the amplicon corresponding to the 3' junction sequence are presented as SEQ ID NO: 11 combined with SEQ ID NO: 12 and the internal standard presented as SEQ ID NO: 249 combined with SEQ ID NO: 250. The accompanying exemplary probes are presented as SEQ ID NO: 13 (3' junction sequence) and SEQ ID NO: 251 (internal standard).

[0201] According to embodiments of the present disclosure, a transgenic soybean plant or plant part, one or more transgenic soybean plants or plant parts or a plurality transgenic soybean plants or plant parts as provided herein, or an agricultural field or soil in which a transgenic soybean plantor plant part, one or more transgenic soybean plants or plant parts or a plurality of transgenic soybean plants or plant parts as provided herein are planted or grown, can be treated with an agricultural composition comprising one or more active ingredients or other agents, such as, for example and without limitation, an herbicide or one or more herbicides, a fungicide or one or more fungicides, an insecticide or one or more insecticides, a plant growth regulator or plant stimulant or one or more plant growth regulators and / or plant stimulants, and / or a safener or one or more safeners. Provided below are lists of possible or representative compounds for each of these types of actives or agents, and an agricultural composition may comprise one or any combination or multiplicity of these actives, agents or compounds. Such an agricultural composition may be applied, for example, as a foliar, soil or in-furrow treatment, as a pre-emergent, pre-sowing and / or post-emergent treatment, and / or in some cases, may be applied to a transgenic plant part or seed provided herein.

[0202] An agricultural composition may be formulated according to its intended use and application. The appropriate formulation of the agricultural composition may be chosen to have different physicochemical parameters, components and stabilities of the respective compound(s). Possible types of formulations for an agricultural composition can include, for example: wettable powders (WP), water-soluble powders (SP), water-soluble concentrates, emulsifiable concentrates (EC), emulsions (EW), such as oil-in-water and water-in-oil emulsions, sprayable solutions, suspension concentrates (SC), dispersions based on oil or water, oil-miscible solutions, capsule suspensions (CS), dusting products (DP), dressings, granules for scattering and soil application, granules (GR) in the form of microgranules, spray granules, absorption and adsorption granules, water-dispersible granules (WG), water-soluble granules (SG), ULV formulations, microcapsules and waxes. If appropriate, some agricultural compositions of a pesticidal compound or one or more pesticidal compounds might be formulated and used as a seed coating applied to a plant part or seed as provided herein.

[0203] Plants, progeny, plant parts, plant seeds, plant tissues, and plant cells may contain or comprise one or more additional desirable trait(s). Such desirable traits may be transgenic traits, native traits, or traits produced by other methods, such as genome editing, base editing, prime editing or other conventional mutagenesis methods. Such desirable trait(s) may provide an agronomic, agricultural or commodity benefit to a plant, plant part, plant seed or plant product. Desirable traits may be combined with soybean event MON87751 or a modified soybean eventMON87751 by, for example, crossing a soybean plant comprising soybean event MON87751 or a modified soybean event MON87751 with another soybean plant containing the additional trait(s). Alternatively, a trait may be created by mutagenesis, editing or site-directed integration of or into a plant, plant part or plant cell comprising soybean event MON87751 or a modified soybean event MON87751. Such traits may include, but are not limited to, increased insect resistance, increased water use efficiency, increased nitrogen use efficiency, increased yield performance, increased drought resistance, increased disease resistance, increased seed quality, improved nutritional quality, hybrid seed production, and / or increase herbicide tolerance, in which the trait is measured with respect to a soybean plant lacking such transgenic trait. For example, the MON87751 event or a modified soybean event MON87751 could be stacked by breeding or introgression with another event(s), or a combination of events, known in the art including, but not limited to:• A2704-12 (Liberty Link® for glufosinate herbicide tolerance; described in US Patent Application Publication No. 2008 / 0320616).• A2704-21 (Liberty Link® for glufosinate herbicide tolerance).• A5547-127 (Liberty Link® for glufosinate herbicide tolerance; described in US Patent Application Publication No. 2008 / 0196127).• A5547-35 (Liberty Link® for glufosinate herbicide tolerance).• CV127 (Cultivance for sulfonylurea herbicide tolerance; described in US Patent Application Publication No. 2012 / 0117676).• DAS44406-6 (for glufosinate, glyphosate and 2,4-D herbicide tolerance; deposited as ATCC PTA-11335 and described in US Patent Application Publication No. 2013 / 0338006).• DAS81419 (for glufosinate tolerance and Lepidopteran resistance; deposited as ATCC PTA-12006 and described in US Patent Application Publication No. 2013 / 0065230).• DP356043 (Optimum GAT™ for glyphosate and sulfonylurea herbicide tolerance; deposited as ATCC PTA-8287 and described in International Patent Application Publication No. 2008 / 002872).• FG72 (for glyphosate and isoxaflutole herbicide tolerance; deposited as ATCC PTA- 11402 and described in US Patent Application Publication No. 2011 / 0239321).• FG72*A5547-127 (Liberty Link® GT27™ for glufosinate, glyphosate and isoxaflutole herbicide tolerance).• GMB151 (for isoxaflutole herbicide tolerance; deposited as ATCC PTA-123625 and described in US Patent Application Publication No. 2020 / 0123561).• GTS 40-3-2 (Roundup Ready™ for glyphosate herbicide tolerance).• GU262 (Liberty Link™ for glufosinate herbicide tolerance, and antibiotic resistance).• MON87708 (Genuity® Roundup Ready™ 2 Xtend™ for glyphosate and dicamba herbicide tolerance, deposited as ATCC PTA-9670 and described in US Patent Application Publication No. 2011 / 0067134).• MON89788 (Genuity® Roundup Ready 2 Yield™ for glyphosate herbicide tolerance, deposited as ATCC PTA-6708 and described in US Patent Application Publication No. 2012 / 0070839).• SYHT0H2 (Herbicide-Tolerant Soybean Line for glufosinate and mesotrione herbicide tolerance, deposited as ATCC PTA-11226 and described in US Patent Application Publication No. 2014 / 0201860).• W62 (Liberty Link™ for glufosinate herbicide tolerance), and W98 (Liberty Link™ for glufosinate herbicide tolerance).• MON87701 (for Lepidopteran insect resistance; deposited as ATCC PTA-8194 and described in US Patent Application Publication No. 2009 / 0130071).• DAS81419*DAS44406 (Conkesta Enlist E3™ for glufosinate, glyphosate and 2,4-D herbicide tolerance, and Lepidopteran insect resistance).• MON87701 xMON89788 (Intacta™ Roundup Ready™ 2 Pro for glyphosate herbicide tolerance and Lepidopteran insect resistance).• MON87751xMON87701 xMON87708xMON89788 (for glyphosate and dicamba herbicide tolerance, and Lepidopteran insect resistance) to provide herbicide tolerance and / or to control Lepidopteran pests.• DP305423 (Treus™, Plenish™ for sulfonylurea herbicide tolerance, and modified oil / fatty acid)• MON87705 (Vistive Gold™ for glyphosate herbicide tolerance and modified oil / fatty acid, deposited as ATCC PTA-9241 and described in US Patent Application Publication No. 2010 / 0080887).• MON87712 (for glyphosate herbicide tolerance and enhanced photosynthesis / yield; deposited as ATCC PTA-10296 and described in US Patent Application Publication No. 2014 / 0007267).• MON87769 (for glyphosate herbicide tolerance and modified oil / fatty acid; deposited as ATCC PTA-8911 and described in US Patent Application Publication No. 2011 / 0067141).• MON94313 (for tolerance to glufosinate, dicamba, 2,4-D, and mesotrione herbicides; deposited as ATCC PTA -127099 and described in US Patent Application Publication No. 2023 / 034927.• MON94637 (for Lepidopteran resistance; deposited as ATCC PTA-126048 and described in International Patent Application Publication No. 2024 / 006698).• HB4 (Verdeca HB4 Soybean for drought stress tolerance) to provide tolerance to herbicides and / or modified oils, enhanced photosynthesis / yield, or drought tolerance.• The MON87751 event could also be stacked by breeding or by site directed introgression with genome edited events known in the art including, but not limited to, high-oleic soybean trait, and high oleic low linolenic (HOLL) soybean trait.DEPOSIT INFORMATION

[0204] A deposit of a representative sample of Glycine max seed containing event MON87751 DNA has been made on February 28, 2013, according to the Budapest Treaty with the American Type Culture Collection (ATCC) having an address at 10801 University Boulevard, Manassas, Virginia USA, Zip Code 20110, and assigned ATCC Accession No. PTA-120166.EXAMPLE 1

[0205] This example describes the transformation and selection of soybean event MON87751. The expression of foreign genes in plants is known to be influenced by their chromosomal position, perhaps due to chromatin structure ( .g., heterochromatin) or the proximity of transcriptional regulation elements (e.g., enhancers) close to the integration site (Weising, 1988). For this reason, it is often necessary to screen a large number of events in order to identify an event characterized by optimal expression of an introduced gene of interest. For example, it has been observed in plantsand in other organisms that there may be wide variation in the levels of expression of an introduced gene among events. There may also be differences in spatial or temporal patterns of expression, for example, differences in the relative expression of a transgene in various plant tissues, that may not correspond to the patterns expected from transcriptional regulatory elements present in the introduced gene construct. For these reasons, eleven different expression vectors were generated and tested in transformed soybean during the selection of event MON87751.

[0206] Eleven different expression constructs were transformed and tested in plants. The individual expression constructs varied in the combination of the use of expression elements, i.e., enhancer (E), promoter (P), leader (L), introns (I), chloroplast targeting peptide (CTP), and 3 ' transcription termination and polyadenylation signal (T). Also, T-DNA segments contained two expression cassettes encoding both Cry proteins (Cry2Ab and Cry 1 A.105), or contained one expression cassette encoding a single Cry protein, i.e., Cry2Ab or Cry 1 A. 105. A further variation in the expression constructs with the T-DNA segments containing both Cry2Ab and CrylA.105 expression cassettes was the relative orientation of the two cassettes encoding the Cry proteins. Specifically, the two Cry protein expression cassettes were either positioned in a relative tandem orientation of transcription so that expression from each promoter of the respective Cry proteins proceeds in the same direction, but each from their separate respective promoters (see Figure 2), or the two Cry protein expression cassettes were in a reversed orientation so that expression from each promoter of the two Cry proteins is away from a point centered between the two promoters, i.e., transcription of each Cry protein expression cassette proceeds in opposite directions and does not converge (see Figure 2). The DNA sequence encoding Cry 1 A.105 was sequence diversified in constructs 4, 6, 7, 8, and 9, compared to constructs 1 and 3. In yet a further variation, in two of the constructs with the two Cry expression cassettes oriented in reverse orientation of transcription, transcription enhancers were positioned between the diverging promoters (see Figure 2).

[0207] The eleven expression constructs were transformed at three separate times, by Agrobaclerium-mediated transformation of soybean meristem tissue. The method was described in U.S. Patent No. 8,030,544, which allows for the generation of transformed plants without utilization of callus. Briefly, meristem tissues were excised from the embryos of germinated A3555 soybean seed (Asgrow, St Louis, MO). Construct 1 comprised two separate T-DNA segments, each bounded by Agrobacterium border sequences (T-DNA segment). The first T-DNA segment of the transformation construct contained two expression cassettes with the first expressioncassette encoding a region of the Tn7 adenylyltransferase gene from Escherichia coli (which confers spectinomycin and streptomycin resistance; aadA-SPR) and is used for selection; and the second expression cassette encoding a region of the sucrose phosphorylase gene from Agrobacterhim tumefaciens strain C58 (which catalyzes the conversion of sucrose to fructose and glucose- 1 -phosphate; STR+OriRi) and is used as a scorable marker. The second T-DNA segment of the different transformation constructs contained either one expression cassette encoding only Cry2Ab (constructs 2, 5, 10 or 11) or an expression cassette encoding only Cry 1 A.105 (constructs 3 or 6); or the second T-DNA segment of the different transformation constructs contained one expression cassette encoding Cry2Ab and one expression cassette encoding Cry 1 A.105 (constructs 1, 4, 7, 8, or 9) (illustrated in Figure 2). Because each T-DNA segment of the transformation construct is bounded by separate Agrobacterium border sequences, the T-DNA segment comprising the selection and scorable marker cassettes may integrate into the soybean cell genome at a site that is different from the site of integration of the T-DNA segment encoding the Cry2Ab and / or Cry 1 A.105 expression cassettes. Thus, events can be screened for segregation and loss of the selection and scorable marker sequences. All events were selected for absence of the backbone and absence of the selection / scorable marker cassette sequences. After co-culturing with Agrobacterium carrying the transformation construct, the meristems were placed on selection medium containing spectinomycin, carbenicillin disodium salt, cefotaxime sodium salt, and ticarcillin disodium salt / potassium clavulanate mixture to inhibit the growth of untransformed plant cells and excess Agrobacterium . The meristems were then placed in media conducive to shoot and root development. Rooted plants (RO) with normal phenotypic characteristics were selected and transferred to soil for growth and further assessment.

[0208] The expression construct 1, used to generate event MON87751, contained a T-DNA segment encoding two different Cry proteins, in a 5' to 3' relative order of plant expression elements (with or without intervening sequences): a promoter, leader and first intron derived from the Arabidopsis thaliana Actin 2 gene(P-At.Act2), a chimeric coding sequence comprised of the N-terminal chloroplast transit peptide coding sequence derived from the Arabidopsis 5- enolpyruvylshikimate-3-phosphate synthase (EPSPS) gene fused in frame to a gene encoding Cry2Ab (which encodes a protein that confers insect resistance) from Bacillus thuringiensis (Bt) with nucleotides modified for plant expression (CTP2-Cry2Ab), a 3 ' transcription termination and polyadenylation element (3 ' UTR) derived from an Oryza sativa metallothionein-like protein gene(T.OsMth), an intervening sequence between the first Cry protein expression cassette and the second Cry protein expression cassette; a promoter and leader derived from the Arabidopsis ribulose 1,5-bisphosphate carboxylase small subunit 1A gene (P-At.RbcS4), this promoter-leader is linked to a chimeric coding sequence comprised of chloroplast transit peptide coding sequence derived from the Arabidopsis ribulose 1,5-bisphosphate carboxylase small subunit 1 A protein gene (CTP1) which also contained coding sequence encoding a repeat of the transit peptide cleavage site and 3 amino acids from the mature protein fused in frame with a gene encoding Cry 1 A.105 (which encodes a protein that confers insect resistance), composed of segments of genes encoding CrylAbl (domains I & II), Cry IFal (domain III), and CrylAcl (protoxin domain) from Bacillus thuringiensis (Bt) with nucleotides modified for plant expression, a 3' UTR (T-Mt.Ptl) derived from the Medicago truncatula phosphate transporter 1 gene. In the construct 1 expression cassette, the T-DNA cassette containing the two separate Cry2Ab and CrylA.105 expression cassettes has an Agrobacterium right border on the arbitrarily designated 5' end, which is 5' to the Cry2Ab cassette; and an Agrobacterium left border on the arbitrarily designated 3' end, which is 3 ' to the Cry 1 A.105 cassette. The Cry2Ab cassette (promoter through terminator) is at positions 123-3785 in SEQ ID NO: 9, and the Cry 1 A.105 cassette (promoter through terminator) is at positions 3831- 9754 in SEQ ID NO: 9.

[0209] The T-DNA cassette for construct 2 (Cry2Ab) and for construct 3 (Cry 1 A.105) contained single Cry-protein encoding cassettes with the same elements for the respective Cry-protein encoding genes used in construct 1, see Figure 2.

[0210] Constructs 4, 5, and 6 were similar in element orientation to constructs 1, 2, and 3, respectively, but with differing promoter-leader-intron and chloroplast transit peptide for both the Cry2Ab and Cry 1 A.105 cassettes. The terminators for the corresponding Cry protein cassettes (Cry2Ab with T-Os.Mth, or Cry 1 A.105 with T-Mt.Ptl) were identical in all expression constructs 1 through 11 (see Figure 2).

[0211] The promoter-leader-intron and chloroplast transit peptide, Cry-protein encoding sequence, and terminator used for both the Cry2Ab and Cry 1A.105 cassettes in each of the constructs 7 - 11 were identical to those used in constructs 4, 5, and 6. However, for constructs 7, 8, and 9 the orientation of the Cry2Ab cassette and the Cry 1 A.105 cassette were inverted or reversed relative to one another and the orientation of transcription was in opposite directions,each from their respective promoters, see Figure 2. Constructs 7, 8, and 9 differed in the absence (construct 7) of an enhancer between the two cassettes, or the presence of an enhancer; construct 8 with enhancer 1 (El), or construct 9 with enhancer 2 (E2), see Figure 2. Construct 10 and construct 11 were single Cry2Ab cassettes with either El (construct 10) or E2 (construct 11).

[0212] Following transformation, and transfer of (RO) events to soil, extensive molecular, agronomic, and phenotypic analysis was done to select events for further testing. Additionally, events were self-pollinated and the resulting seed from the selected events was used for field and additional molecular testing.

[0213] The molecular testing included the following: assays to determine copy number, assays to determine integrity of both Cry protein containing expression cassettes (constructs 1, 4, 7, 8, and 9), presence of Cry protein encoding T-DNA cassette (single Cry protein expression cassettes (constructs 2, 3, 6, 10, or 11) or two Cry protein expression cassettes (constructs 1, 4, 7, 8, or 9)); assays to determine protein expression as measured by ELISA, and assays to determine segregation ratio of the T-DNA expression cassette (1 :2: 1 or 1 :3). Agronomic assays included (for R0 events generated from constructs 1, 2, and 3, insect efficacy by leaf disc bioassay for two pest species (Anticarsia gemmatalis (velvetbean caterpillar, VBC) and Chrysodeixis includens (soybean looper, SBL)). R0 plants were grown to maturity, events were self-pollinated, and seed set for each event was determined.

[0214] The number of R0 events generated by transformation with the 11 individual constructs and transferred to soil varied, and ranged from 420 events to greater than 5000 events (see Table 1). For the transformation with the construct 1, from which event MON87751 was generated, there were a total of 1102 R0 plants rooted into soil, of which from these only 281 events passed the initial molecular analysis. The additional molecular, agronomic and phenotypic analysis of these 281 events which were generated by transformation with construct 1 resulted in only 29 R1 events evaluated for additional greenhouse analysis.Table 1 . RO events produced from the eleven transformation constructs showing the number of events transferred to soil and the number of events passing a copy number assay.

[0215] For the 29 R1 events generated from transformation with construct 1 and evaluated for further analysis, the R1 seed was planted in a greenhouse for analysis of the R1 events with assays including: (a) R1 germination (100% germination); (b) identification of homozygous plants; (c) confirmation PCR analysis that the homozygous plants no longer contained the selection / scorable marker sequence (it had segregated independently); (d) insect efficacy as determined by leaf disc bioassay for C. inchidens (SBL); and (e) insect efficacy as determined by leaf disc bioassay for Spodoptera frugiperda (fall armyworm, FAW), (f) protein expression by ELISA analysis on V7 stage leaf tissue, advancing events with Cry2Ab and Cry 1A.105 protein levels over >4 ppm. In addition to the molecular analysis and insect leaf disc bioassay results, agronomic phenotype observations and seed set from four selections / event were collected. Based on the totality of these data, R2 seed from 21 of R1 events generated by transformation with construct 1 were evaluated in agronomic field trials and efficacy screenhouse trials.EXAMPLE 2

[0216] Agronomic field trials were designed to evaluate the phenotypic characteristics and yield of soybean events expressing Cry2Ab and Cry 1 A.105 compared to the control, A3555 (parental background). In these agronomic field trials, the controls and events were of soybean variety A3555, with a relative maturity group 3 (RM3). The trials were planted under a randomizedcomplete block design (RCBD) over four seasons and two geographic locations. In one geographic location the agronomic field trials were conducted at 25 field sites in each season, and in a second geographic location the agronomic field trials were conducted at 14 field sites in each season. Standard agronomic practices were followed in the planting and data collection for all trials. The data collected included emergence rating, seedling vigor, flowering date, flower color observation, phenotype observation, pubescence color, maturity, lodging, plant height, shattering score, harvest date, seed weight / plot, seed moisture / plot, and yield in bushels per acre (bu / ac).

[0217] For data analysis, some locations were dropped due to pre-harvest quality issues (i.e., standing water, inadequate soil moisture, poor emergence, late season pod shattering due to hail storm), or some locations were dropped due to a coefficient of variation (CV) above 15% and / or a high location quality index (LQI).

[0218] Across all locations tested, the phenotype measures taken indicated that the agronomic ratings for the events were within the normal range of the control, A3555. Not all observations were taken at all sites and some data, for example emergence, may have been collected but yield was not determined because the location was dropped for issues which occurred post collection of the early phenotype data.

[0219] For the agronomic field trials, the number of events generated by construct 1, 2, 3, 4, 5, or 6 and tested at each field trial in two geographic locations, and the soybean event generation tested (i.e., R3, R4, R5, R6, or R7) is shown in Table 2.Table 2. Number of events (and soybean event generation) tested per construct during two seasons and two geographic locations of agronomic field trials (n.t. means not tested).

[0220] Meta analysis of agronomic field trials for events tested across each season, each geographic location, and each field trial testing mean yield (bu / acre) demonstrated that there was a statistically significant increase in yield for event MON87751 compared to control A3555 (Table 2). The events expressing only Cry2Ab did not have a statistically significant difference in yieldcompared to the control A3555, see Table 3. The event expressing only Cryl A.105 had a statistically significant decrease in yield compared to the control A3555, see Table 3.Table 3. Meta analysis of agronomic field trials for events tested across each season, each geographic location, and each field trial testing yield when compared to non-transgenic soybean line A3555.EXAMPLE 3

[0221] Efficacy screenhouse trials were conducted to evaluate the efficacy of experimental soybean events expressing both Cry proteins from an insertion of a T-DNA segment from a single construct with two expression cassettes (i.e., both Cry2Ab and Cry 1 A.105), or single Cry proteins (z.e., Cry2Ab only, or Cry 1 A.105 only) against artificial infestations of lepidopteran pest populations contained in screenhouse enclosures. The comparison of single- to double-gene events was used to determine the relative contribution of each single Cry protein towards the efficacy observed in the double-gene expression construct events. The screenhouse trials were conducted during multiple seasons in two geographic locations. In one geographic location, 5 target pest species were tested: Anticarsia gemmatalis (velvetbean caterpillar, VBC), Chrysodeixis includens (soybean looper, SBL), Spodoptera eridania (southern armyworm, SAW), Spodoptera frugiperda (fall armyworm, FAW), and Helicoverpa zea (soybean podworm, SPW). In the second geographic location, 3 target pest species were tested: Crocidosema aporema (bean shoot moth, BSM), Rachiplusia nu (sunflower looper, SFL), and Spodoptera frugiperda (fall armyworm, FAW).

[0222] The events (i.e., entries) which were tested in these screenhouse trials were generated from transformations with each of the separate transformation constructs. Transformation events generated from construct 1, 2, or 3, were evaluated in the R2 generation in screenhouse trials andincluded twenty events expressing both proteins (events generated from transformation with construct 1), six events expressing only Cry2Ab (events generated from transformation with construct 2), and six events expressing only Cry 1A.105 (events generated from transformation with construct 3). Of these, 12 events with both Cry2Ab and Cry 1 A.105 (construct 1), two events with Cry2Ab-only (construct 2), and three events with CrylA.105-only (construct 3) were evaluated in the R3 generation in screenhouse trials. Eleven of the events with both Cry2Ab and Cry 1 A.105 (construct 1) were further evaluated in the R4 generation screenhouse trials. Three events with both Cry2Ab and Cry 1 A.105 (construct 1), one event with Cry2Ab-only (construct 2), and one event with CrylA.105-only (construct 3) were evaluated in the R5, R6, and R7 screenhouse trials. Ten events expressing Cry2Ab and CrylA.105 (events generated from transformation with construct 4), three Cry2Ab-only events (events generated from transformation with construct 5), and three CrylA.105-only events (events generated from transformation with construct 6) were evaluated in the R3 generation to screenhouse trials. Two events with both Cry2Ab and CrylA.105, one event with Cry2Ab-only, and one event with CrylA.105-only were evaluated in the R4 screenhouse trials, and one event each was evaluated in the R5 screenhouse trials. Three events expressing both Cry2Ab and CrylA.105 in opposing 5' to 3 ' orientation with an enhancer (events generated from transformation with construct 8), 3 stacked events expressing both Cry2Ab and CrylA.105 in opposing 5' to 3' orientation without an enhancer (events generated from transformation with construct 7), and 2 Cry2Ab-only events (events generated from transformation with construct 10) were evaluated in the R2 generation were evaluated in screenhouse trials. The positive transgenic soybean controls included MON87701 or event GM Al 9478 (generated at the same time as MON87701), and both expressing Cry 1 Ac. Non- transgenic soybean lines A3555 (parental background for MON87751 events, relative maturity 3 (RM3)) and A5547 (parental background for MON87701 and GM_A19478, RM5) were included in all screenhouse and field trials as negative controls. The non-transgenic soybean line AG3705 was included as a white flower check in some trials.

[0223] Standard practices were followed in establishing and conducting the screenhouse trials. The plots were evaluated once after each infestation at the time of maximal damage to the negative checks (usually 3-4 weeks after pupae were placed within the screenhouse). At each evaluation, the following agronomic observations were recorded: the date and the stage of plant growth. Additionally, for defoliating insects, an estimated percent defoliation in each plot was recorded.For C. aporema, ten plants were randomly selected in each plot and the number of plants with damage was recorded. In some cases, the numbers of live larvae were also recorded.

[0224] Defoliation data were subjected to ANOVA to determine significant sources of variability among line and replicate for each insect at each location at the 0.05 probability level (P). Significant differences among means were determined using the Tukey-Kramer test (Kramer 1956) at P = 0.05.

[0225] Three small-plot screenhouse trials were conducted in the second geographic location during one season using R. nu and C. aporema for infestation. The trial design included Randomized Complete Block Design (RCBD) test blocks with three replicates per event or control, with events tested shown in Table 4. One trial was infested with C. aporema during mid-vegetative stage of soybean growth and again at early reproductive stage of soybean growth. Two trials were infested with R. nu during mid-vegetative stage of soybean growth.

[0226] For the C. aporema trial, very heavy pressure was achieved. Replicate was not a significant source of variability in damage (F = 0.8794; df = 2, 69; P = 0.4196), but event was highly significant (F = 11.9398; df = 23, 48; P < 0.0001). The maximum percent of plants damaged (Table 4) averaged 83-100% in the negative checks but was absent in the Cry 1 Ac positive control. Events generated from transformation construct 1 and expressing Cry2Ab and Cry 1 A.105 exhibited 0- 13% of plants damaged, while those expressing Cry2Ab-only or CrylA.105-only exhibited 10- 17% and 10-13%, respectively. The small, albeit significant, numbers of plants recorded as damaged in this trial may be due to the criteria used by the individuals when recording the damage rating.

[0227] For the R. nu trials, heavy pressure was achieved in one screenhouse trial. Replicate was not a significant source of variability in defoliation (F = 0.203; df = 2, 69; P = 0.8167), but event was highly significant (F = 20.2461; df = 23, 48; P < 0.0001). Maximum defoliation (Table 4) averaged 60-63% in the negative checks but was absent in the Cry 1 Ac positive control and events generated from transformation construct 1 expressing Cry2Ab+CrylA.105 or events generated from transformation construct 2 expressing Cry2Ab-only. Events generated from transformation construct 3 expressing CrylA.105-only exhibited slightly higher defoliation (4-10%). Moderately heavy pressure was achieved in the second screenhouse trial evaluating Rnu. Replicate was not a significant source of variability in defoliation in either trial (F = 0.2542; df = 2, 69; P = 0.7763),but event was highly significant (F = 16.1793; df = 23, 48; P < 0.0001). Maximum defoliation (Table 4) averaged 38-40% in the negative checks but was negligible in the Cry 1 Ac positive control (4%) and absent in events generated with construct 1 and expressing Cry2Ab+Cry 1A.105 or events generated with construct 2 and expressing Cry2Ab-only. Events generated with construct 3 and expressing CrylA.105-only exhibited slightly higher defoliation (2-7%).

[0228] In these screenhouse trials, soybean event MON87751 exhibited no damaged plants due to infestation of the insect pests, C. aporema or A. nu, which was significant compared to the damage and / or defoliation of the controls in the same trial (Table 4).Table 4. Damage by C. aporema and defoliation by R. mi larvae to events generated using constructs 1, 2, or 3 and evaluated in artificially-infested screenhouses.

[0229] In a subsequent season of small-plot screenhouse trials conducted in the second geographic location, local lab populations of R. mi, C. aporema and S. frugiperda were used for infestation.The protocols for conducting the trials were essentially as described above, and with events and controls tested shown in Table 5.

[0230] For the trial infested with C. aporema, heavy pressure was achieved. Replicate was not a significant source of variability in damage (F = 0.2742; df = 2, 33; P = 0.7619), but event was highly significant (F = 8.2313; df = 11, 24; P < 0.0001). Maximum damage averaged 4.2-5.5 damaged points per plant in the negative checks, with 80-100% of plants exhibiting damage, but was negligible in the positive control and all test events (Table 5).

[0231] For the trial infested with R. nu, moderately heavy pressure was achieved. Replicate was not a significant source of variability in damage (F = 0.041; df = 2, 33; P = 0.9599), but event was highly significant (F = 143.5526; df = 11, 24; P < 0.0001). Maximum damage averaged 33.3— 40.0% defoliation in the negative checks (well above economic threshold) but was absent or negligible in the positive control and all test events except the events generated by transformation with construct 6 expressing only TIC 105 (Table 5).

[0232] For the trial infested with S. frugiperda, light pressure was achieved. Replicate was not a significant source of variability in damage (F = 0.1187; df = 2, 33; P = 0.8884), but event was highly significant (F = 12.8602; df = 11, 24; P < 0.0001). Maximum damage averaged 7.5-15.0% defoliation in the negative checks — just reaching the economic threshold. Some damage was also noted in events expression only Cry2Ab generated by transformation with either construct 2 or construct 5, but damage was absent or negligible in the positive control and all other test events (Table 5).

[0233] In these screenhouse trials, soybean event MON87751 exhibited no damaged plants due to infestation of the insect pests, C. aporema R. nu, S. frugiperda, which was significant when compared to damage to the negative controls in the same trial (Table 5). Soybean event MON87751 had significantly less damage from R. nu when compared to transgenic soybean events generated by transformation with construct 6 expressing only Cry 1 A.105 (Table 5), though it is noted that there is lower expression of Cry 1 A.105 protein in the events generated by transformation with construct 6. These results also demonstrate for the first time the expanded spectrum of control of the insect pest 5. frugiperda.Table 5. Maximum damage by C. aporema, and mean percent defoliation by R. nu and S. frugiperda larvae in artificially-infested screenhouses evaluating events generated with constructs 1, 2, 3, 4, 5, or 6 and compared to positive and negative controls.

[0234] One small-plot screenhouse trial was conducted in the first geographic location using infestation of a lab population of H. zea. The trial design included Randomized Complete Block Design (RCBD) test blocks with three replicates per event, with events and controls tested shown in Table 6. There were two infestations of H. zea and defoliation was assessed 19-27 days postinfest (R2-R3 stage of soybean growth) for the first infestation, and 25-28 days post-infest (R5 stage of soybean growth) for the second infestation. The results from the screenhouse trials testing the insect pest, H. zea, are as follows: moderately heavy pressure was achieved. Replicate was not a significant source of variability in defoliation (F = 0.326; df = 2, 105; P = 0.7225), but event was highly significant (F = 13.8864; df = 35, 72; P < 0.0001). Maximum defoliation (Table 6) averaged 32-33% in the negative checks but was negligible in the Cry 1 Ac positive control (1%) and events generated with construct 1 and expressing Cry2Ab+CrylA.105 (2-4%). A somewhat higher defoliation was observed in events generated with construct 4 expressing Cry2Ab+CrylA.105 (5- 12%), events generated with construct 5 expressing only Cry2Ab (13-17%) or events generated with construct 6 expressing only CrylA.105 (8-12%).

[0235] Soybean event MON87751 exhibited significantly less damage by H. zea in this screenhouse trial when compared to damage to the negative controls in the same trial. This level of control by H. zea is within acceptable commercial level of control for this soybean pest species.Additionally, in this screenhouse trial, soybean event MON87751 had significantly less damage when compared to transgenic soybean events generated with construct 5 expressing only Cry2Ab (Table 6), demonstrating expanded level of control. However, expression of Cry2Ab is lower in events generated with construct 5 than in events generated with construct 2, and the significant defoliation of events generated with construct 5 expressing only Cry2Ab may indicate that there may be reduced efficacy against H. zea by Cry2Ab in generated with construct 5.Table 6. Maximum seasonal defoliation to events generated with constructs 1, 4, 5, or 6 by H. zea larvae in artificially-infested screenhouse trial when compared to positive and negative controls.

[0236] In another season of small-plot screenhouse trials conducted in the first geographic location, resistance to infestation from lab populations of the insect pests S. eridania (lst-instar or 3rd-instar), A. gemmatalis (1st-instar), and C. includens (lst-instar) was tested. The results from these trials are as follows: extreme pressure was achieved with lst-instar S. eridania, and moderate pressure was achieved with A. gemmatalis. Maximum percent defoliation (means ± S.E.) by A. gemmatalis (lst-instar) and S. eridania (lst-instar) larvae are reported in Table 7.Table 7. Maximum percent defoliation by A. gemmatalis (Ist-instar) and S. eridania (Ist-instar) larvae in artificially-infested screenhouses evaluating events generated with constructs 1, 2, 3, 4, 5, 6, 7, 8, and 10 and compared to positive and negative controls.

[0237] For the trials testing C. includens (Ist-instar) and 5. eridania (3rd-instar), extreme pressure was achieved for both of the insect pests. Maximum percent defoliation (means ± S.E.) by C. includens (Ist-instar) larvae and S. eridania (3rd-instar) larvae in these artificially-infested screenhouses is reported in Table 8.Table 8. Maximum percent defoliation by C. includens (I st-instar) and S. eridania (3rd-instar) larvae in artificially-infested screenhouses evaluating events generated with constructs 1, 2, 3, 4, 5, 6, 7, 8, and 10 and compared to positive and negative controls.

[0238] The results for these screenhouse trials show that soybean event MON87751 exhibited significantly less damage by S. eridania (lst-instar or 3rd-instar), A. gemmatalis (lst-instar), or C. includens (lst-instar) when compared to damage to the negative controls in the same trial (Table 7 and Table 8). Additionally, in these screenhouse trials, soybean event MON87751 had significantly less damage by S. eridania (lst-instar and 3rd-instar) larvae when compared to transgenic soybean events expressing Cry 1 Ac (Table 7 and Table 8), demonstrating the expanded performance of event MON87751 to transgenic soybean event currently available for lepidopteran pest control. Further, in these screenhouse trials, soybean event MON87751 had significantly less damage by S. eridania larvae when compared to [1] any of the events generated with constructs 4, 5, or 6 (3rd-instar larvae), or events generated with construct 6 expressing only Cry 1 A.105 event (1stinstar larvae), or events generated with construct 3 expressing only Cry 1 A.105 event (1stinstarlarvae and 3rd-instar larvae) and [2] when compared to events generated with construct 7 expressing Cry2Ab and Cry 1 A.105 without an enhancer (1stinstar- and 3rd-instar larvae), demonstrating the superior performance of the event MON87751 to the events generated with constructs 4, 5, 6, or 7 (Table 7 and Table 8).EXAMPLE 4

[0239] Open field efficacy trials were conducted to evaluate the efficacy of experimental soybean event MON87751 and events created using the different transformation constructs 1, 2, 3, 4, 5, and 6, against natural field infestations of lepidopteran pest populations. The comparison of events generated with construct 2 or 5 (expression of Cry2Ab only), and events generated with construct 3 or 6 (expression of Cry 1 A.105 only), to events generated with construct 1 or 4 (expression of both Cry 1 Ab and Cry 1 A.105) was used to determine the relative contribution of each single Cry protein (i.e. Cry 2 Ab only, or Cry 1 A.105 only) towards the efficacy observed in events expressing both Cry proteins (i.e., Cry2Ab and CrylA.105) from a single construct. The efficacy field trials of native populations of endemic soybean pests were conducted over multiple seasons, at multiple field trial sites, and in three geographic locations.

[0240] In the initial efficacy field trials conducted in one geographic location, the events (i.e., entries) evaluated included twelve events generated by construct 1 and expressing both Cry proteins, Cry2Ab and Cry 1 A.105 (and including event MON87751), two events generated by construct 2 and expressing only Cry2Ab, and three events generated by construct 3 expressing only Cry 1 A.105. In the initial efficacy field trials conducted in a second geographic location, the events generated by constructs 1, 2 and 3 were evaluated and included 11 events expressing both Cry proteins, Cry2Ab and Cry 1 A.105 (generated from transformation with construct 1 and including event MON87751), two events expressing only Cry2Ab (events generated from transformation with construct 2), and three events expressing only Cry 1 A.105 (events generated from transformation with construct 3). In a second season of efficacy field trials conducted in 3 geographic locations, the events (i.e., entries) evaluated included three events expressing both Cry proteins, Cry2Ab and Cry 1 A.105 (events generated from transformation with construct 1 and including event MON87751), one event expressing only Cry2Ab (events generated from transformation with construct 2), and one event expressing only Cry 1 A.105 (events generated fromI l ltransformation with construct 3). The events evaluated in the open field efficacy trials included generations R3 through R7.

[0241] For each efficacy field trial site, test blocks were planted and natural infestation by native pest populations of the target lepidopteran insects was allowed to occur. The test block remained untreated with insecticides for the target pests (Lepidoptera). However, the test blocks may have been sprayed to prevent significant damage by non-target insect pests. All experimental events were in the soybean germplasm background A3555, of relative maturity group 3 (RM3). The other entries in the trials included the positive control MON87701 (expressing Cry 1 Ac) or GM_A19459 (RM5); the negative parental check A3555 (purple flower, RM3); and the negative commercial check A5547 (white flower, MG5) or CMA58O5 (white flower, RM5).

[0242] Standard practices were followed in establishing and conducting the open field efficacy trials. Larval incidence of lepidopteran pests, defoliation, and plant growth stage were recorded periodically (z.e., every 5-14 days) commencing with onset of target lepidopteran activity and ending when target lepidopteran activity ceased or plants reached R7 stage of growth. Pest incidence data was collected from rows 1 and 4 only to avoid plant damage in rows 2 and 3, which were harvested for yield data. Monitoring and recording of pest incidence data occurred as follows: defoliating lepidopterans (z.c. , A. gemmatalis, C. includens R. nu, Spodoptera spp.) were monitored using a drop cloth or vertical beating sheet, with at least two drop cloth or four vertical beating sheet samplings per plot. The total number of larvae for each target species encountered and the number of samplings within each plot were recorded as the mean number of larvae per m row (total number larvae number samplings cloth / sheet length in meters) for each target species encountered. Subsequent samplings were done in a manner which avoided repeated sampling in the same area of each plot. In the efficacy field trials conducted at one geographic location, data were also recorded at two trial sites for opportunistically for damage by H. zea by randomly selecting 20 or 33 plants / location, and recording the number with larval feeding damage. At a second geographic location, one trial was rated opportunistically for H. zea by randomly selecting 10 plants per plot and recording total number of pods and number of damaged pods per plant.

[0243] Data for infestation by Elasmopalpus lignosellus were recorded by counting the total number of plants in each plot with damage (wilted, dying, or dead) due to larval feeding. Damage data for this insect was taken at a single time point when maximal damage was noted.

[0244] In addition to target pests, non-targets pests, primarily those with potential for surpassing economic thresholds (e. ., stink bugs), were monitored periodically by sweep net, modified sweep net, or ground cloth at randomly selected locations within the test block, and assessed to determine whether they reached or were approaching economic injury levels.

[0245] At trial maturity, the entire length of rows 2 and 3 of each plot were harvested, and both total weight and percent moisture for each plot was recorded. During harvest, significant gaps (plants not touching each other) in harvested rows were noted and the total length of these gaps was recorded. Yields were calculated after correcting seed weight to 13% moisture. Larval incidence, defoliation, and yield data were subjected to ANOVA to determine significant sources of variability among line and replicate for each location at the 0.05 probability level (P). Significant differences among means were determined using the Tukey -Kramer test (Kramer 1956) at P = 0.05.

[0246] In open field trials conducted at field trial site 1, defoliating caterpillars were first encountered at the R3 stage of growth, and increased to moderately damaging levels by the R6 stage of growth. Species encountered included A. gemmatalis (98%), R. nu (2%) and Spodoptera spp. (1%). Replicate was not a significant source of variability in larval incidence (F = 0.0435; df = 2, 57; P = 0.9575), defoliation (F = 0.0807; df = 2, 57; P = 0.9226) or yield (F = 0.0213; df = 2, 57; P = 0.979), but event was highly significant for all three (larval incidence: F = 69.6956; df = 19, 38; P < 0.0001 ; defoliation: F = 25.9918; df = 19, 40; P < 0.0001 ; yield: F = 3.357; df = 19, 38; P = 0.0007). Cumulative larval incidence (Table 9) reached 139-189 larvae per m row in the negative checks, while virtually no larvae were encountered in any of the transgenic entries. Maximum defoliation (Table 9) averaged 21-27% in the negative checks and was absent in all transgenic entries. Yields (Table 9) were reduced in both negative checks relative to all transgenic entries, although variability in yield reduced the significance of these reductions...

Claims

What is claimed is:1 . A recombinant DNA molecule comprising: a) a first nucleotide sequence (i) comprising an expression cassette that encodes a Cry2Ab or Cry 1 A. 105, and / or (ii) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8; and b) a second nucleotide sequence that i. comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47, or ii. is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 27 or 47, or iii. is selected from the group consisting of SEQ ID NOs: 49-148.

2. The recombinant DNA molecule of claim 1, further comprising: c) a third nucleotide sequence that i. comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or ii. is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or iii. is selected from the group consisting of SEQ ID NOs: 149-248.

3. The recombinant DNA molecule of claim 2, wherein the third nucleotide sequence is selected from the group consisting of SEQ ID NOs: 149-248.

4. The recombinant DNA molecule of claim 3, wherein the recombinant DNA molecule has a deletion of one or more consecutive nucleotides between the second nucleotide sequence and the third nucleotide sequence relative to SEQ ID NO: 10, 28, or 48.

5. The recombinant DNA molecule of any one of claims 1-4, wherein the second nucleotide sequence is selected from the group consisting of SEQ ID NOs: 49-148.

6. The recombinant DNA molecule of any one of claims 1-5, wherein the recombinant DNA molecule has a deletion of one or more consecutive nucleotides between the first nucleotide sequence and the second nucleotide sequence relative to SEQ ID NO: 10, 27, or 47.

7. A recombinant DNA molecule comprising: a) a first nucleotide sequence (i) comprising an expression cassette that encodes a Cry2Ab or Cry 1 A.105, and / or (ii) selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; andb) a second nucleotide sequence that i. comprises at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or ii . is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 28 or 48, or iii. is selected from the group consisting of SEQ ID NOs: 149-248.

8. The recombinant DNA molecule of claim 7, wherein the second nucleotide sequence is selected from the group consisting of SEQ ID NOs: 149-248.

9. The recombinant DNA molecule of claim 7 or 8, wherein the recombinant DNA molecule has a deletion of one or more consecutive nucleotides between the first nucleotide sequence and the second nucleotide sequence relative to SEQ ID NO: 10, 28, or 48.

10. The recombinant DNA molecule of any one of claims 1-9, further comprising nucleotides 1-1,334 or 10,120-12,640 of SEQ ID NO: 10.

11. The recombinant DNA molecule of any one of claims 1-10, wherein said recombinant DNA molecule is comprised in a soybean plant, soybean plant part, soybean plant cell, soybean plant seed, soybean progeny plant, or commodity or fuel product made from soybean and soybean plant parts.

12. The recombinant DNA molecule of any one of claims 1-10, wherein said recombinant DNA molecule comprises an amplicon diagnostic for the presence of DNA comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

13. The recombinant DNA molecule comprising a polynucleotide of claims 1-11, wherein the recombinant DNA molecule is derived from a soybean plant, soybean plant part, soybean seed, processed soybean seed, soybean plant cell or tissue, animal feed comprising soybean, soybean oil, soybean meal, soybean flour, soybean flakes, soybean bran, food made comprising soybean, soybean biomass, or fuel products made from soybean and soybean plant parts.

14. A recombinant DNA molecule comprising a polynucleotide segment of sufficient length to function as a DNA probe that hybridizes specifically under stringent hybridization conditions with a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 47, and SEQ ID NO: 48.

15. A pair of DNA molecules that can function as DNA primers when used together in an amplification reaction comprising a first DNA molecule and a second DNA molecule, wherein the first DNA molecule and the second DNA molecule are different, a) wherein the first DNA molecule is: i. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof, orii. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; and b) wherein the second DNA molecule is: i. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof, or ii. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 1 1, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof, or iii. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%,at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof.

16. The pair of DNA molecules of claim 15, wherein the first DNA molecule and the second DNA molecule can be used together in an amplification reaction with a sample from a plant, plant part, plant seed, plant cell, food or animal feed, or commodity or fuel product made from a plant or plant part to produce an amplicon diagnostic for the presence of a modified soybean event MON87751 DNA in said sample.

17. The pair of DNA molecules of claim 16, wherein the amplicon comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

18. The pair of DNA molecules of claim 16 or 17, wherein the modified soybean event MON87751 DNA is a further modified soybean event MON87751 DNA.

19. A method of detecting the presence of a DNA segment diagnostic for a modified soybean event MON87751 DNA in a sample, said method comprising: a) contacting said sample with the DNA molecule of any one of claims 1-14; b) subjecting said sample and said DNA molecule to stringent hybridization conditions; and c) detecting hybridization of said DNA molecule to said DNA segment in said sample, wherein said detection is diagnostic for the presence of said modified soybean event MON87751 DNA in said sample.

20. A method of detecting the presence of a DNA segment diagnostic for a modified soybean event MON87751 DNA in a sample, said method comprising: a) contacting said sample with the pair of DNA molecules of any one of claims 15- 18; b) performing an amplification reaction sufficient to produce a DNA amplicon; andc) detecting the presence of said DNA amplicon in said reaction, wherein the presence of said DNA amplicon is diagnostic for the presence of said modified soybean event MON87751 DNA in said sample.

21. A method of detecting the presence of a DNA segment diagnostic for a modified soybean event MON87751 DNA in a sample, said method comprising performing a sequencing reaction with the sample, wherein the production in the sequencing reaction of a target nucleotide sequence comprising at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof, is diagnostic for the modified soybean event MON87751 DNA in the sample.

22. The method of claim 19, 20, or 21, wherein the modified soybean event MON87751 is a further modified soybean event MON87751.

23. A modified soybean plant, soybean plant part, soybean seed, or soybean cell comprising a modified soybean event MON87751 or the recombinant DNA molecule of any one of claims 1-14.

24. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of claim 23 comprising: a) the recombinant DNA molecule of any one of claims 1-14; or b) a recombinant DNA molecule or DNA segment comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, or a complement thereof; or c) a recombinant DNA molecule or DNA segment comprising a nucleotide sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19,at least 20, at least 21 , at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, at least 1,000, at least 1,500, or at least 2,000 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 47, or SEQ ID NO: 48, or a complement thereof.

25. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of claim 23 or 24, wherein the soybean plant, soybean plant part, soybean seed, or soybean cell is further defined as a progeny plant of any generation of a soybean plant comprising a modified soybean event MON87751, or a soybean plant part, soybean seed, or soybean cell derived therefrom.

26. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of any of claims 23-25, wherein the soybean plant, soybean plant part, soybean seed, or soybean cell is further designed as a progeny plant of any generation of a soybean plant comprising a modified soybean event MON87751, or a soybean plant part, soybean seed, or soybean cell derived therefrom27. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of any of claims 23-26, wherein the soybean plant, soybean plant part, soybean seed, or soybean cell exhibits resistance to a Lepidopteran insect pest species and / or comprises an expression cassette that encodes a CryA.105 or Cry2Ab protein.

28. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of any of claims 23-27, wherein the recombinant DNA molecule is chromosome 2 of the genome of the modified soybean plant, soybean plant part, soybean seed, or soybean cell, or the DNA segment is present in chromosome 2 of the modified soybean plant, soybean plant part, soybean seed, or soybean cell.

29. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of any one of claims 23-28, wherein the modified soybean event MON87751 is a further modified soybean event MON87751.

30. The modified soybean plant, soybean plant part, soybean seed, or soybean cell of claim 23, wherein the modified soybean event MON87551 of the modified soybean plant, soybean plant part, soybean seed, or soybean cell comprises a genetic modification, mutation, or edit, relative to the soybean event MON87751, introduced via a targeted genome editing technique.

31. A DNA detection kit comprising: a) the recombinant DNA molecule of claim 14; and b) the pair of DNA molecules of any one of claims 15-17.

32. A method of producing a progeny soybean plant comprising a modified soybean event MON87751 comprising: a) sexually crossing a first modified soybean plant that comprises a modified soybean event MON87751 with itself or a second soybean plant; b) collecting one or more seeds produced from said cross; c) growing said seed to produce one or more progeny plants; and d) selecting at least a first progeny plant or seed comprising a modified soybean event MON87751.

33. The method of claim 32, wherein the modified soybean event MON87751 is a further modified soybean event MON87551.

34. The method of claims 32 or 33, further comprising: e) collecting seed from said at least first progeny plant comprising a modified soybean event MON87751.

35. A hybrid modified soybean plant or seed comprising a modified soybean event MON87751 produced by the method of any one of claims 32-34.

36. The hybrid modified soybean plant or seed of claim 35, wherein the modified soybean event MON87751 is further modified soybean event MON87751.

37. A nonliving soybean plant material comprising a detectable amount of the recombinant DNA molecule of any one of claims 1-14.

38. A microorganism comprising the recombinant DNA molecule of any one of claims 1-14.

39. The microorganism of claim 38, wherein the microorganism is a plant cell.

40. A commodity product comprising the recombinant DNA molecule of any one of claims 1- 14.41 . The commodity product of claim 40, wherein said commodity product is produced from a modified soybean plant, soybean plant part, soybean seed, or soybean tissue or cell comprising a modified soybean event MON87751.

42. The commodity product of claims 40 or 41, further selected from the group consisting of whole or processed soybean seed, animal feed comprising soybean, soybean oil, soybean meal, soybean flour, soybean flakes, soybean bran, soybean biomass, and fuel products produced using soybean and soybean plant parts.

43. The commodity product of any one of claims 40-42, wherein the modified soybean event MON87751 is a further modified soybean event MON87551.

44. A method of producing a commodity product, said method comprising: a) obtaining a modified soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751; and b) producing a commodity product from the transgenic soybean plant, soybean plant part, or soybean seed.

45. A soybean plant, soybean plant part, or soybean seed comprising a DNA molecule or segment functional as a template when tested in a DNA amplification method to produce an amplicon diagnostic for the presence of a modified soybean event MON87751 DNA.

46. A method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: a) contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with the pair of DNA molecules of claim 15; b) performing a nucleic acid amplification reaction with the sample and the pair of DNA molecules; and c) detecting in the nucleic acid amplification reaction a first amplicon diagnostic for a modified soybean event MON87751 and a second amplicon diagnostic for native soybean genomic DNA not comprising the modified soybean event MON87751, wherein the presence of only the first amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed homozygous for the modified soybean event MON87751, and the presence of both the first amplicon and the second amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed heterozygous for the modified soybean event MON87751.

47. A method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: a) contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with a first primer pair that can produce a first amplicon of all or part of the modified soybean event MON87751 and a second primer pair that can produce a second amplicon of a standard genomic sequence known to be single copy and homozygous in the soybean plant, soybean plant part, or soybean seed; b) contacting the sample with a first probe that specifically hybridizes to the first amplicon and / or all or part of the modified soybean event MON87751, and a second probe that specifically hybridizes to the standard genomic sequence; c) performing a DNA amplification reaction using real-time PCR with the sample and determining the cycle thresholds (Ct values) of the first amplicon and the second amplicon; d) calculating the difference (ACt) between the Ct values of the second amplicon and the first amplicon; and e) determining the zygosity of the modified soybean event MON87751, wherein a ACt of about zero (0) indicates homozygosity of the modified soybean event MON87751 and a ACt of about one (1) indicates heterozygosity of the modified soybean event MON87751.

48. The method of claim 46 or 47, wherein the first and second primer pairs comprise SEQ ID NO: 11 combined with SEQ ID NO: 12, and SEQ ID NO: 249 combined with SEQ ID NO: 250.

49. A method of determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: a) contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with a primer pair capable of producing a first amplicon diagnostic for the modified soybean event MON87751 and a second amplicon diagnostic for native soybean genomic DNA not comprising the modified soybean event MON87751; b) performing a nucleic acid amplification reaction with the sample and the set of primer pairs; andc) detecting the first amplicon and the second amplicon, wherein the presence of only the first amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed homozygous for the modified soybean event MON87751, the presence of only the second amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed homozygous for native soybean genomic DNA not comprising the modified soybean event MON87751, and the presence of both the first amplicon and the second amplicon is diagnostic of a soybean plant, soybean plant part, or soybean seed heterozygous for the modified soybean event MON87751.

50. A method for determining the zygosity of a soybean plant, soybean plant part, or soybean seed comprising a modified soybean event MON87751 comprising: a) contacting a sample comprising DNA from the soybean plant, soybean plant part, or soybean seed with a probe set which contains at least a first probe that specifically hybridizes to the modified soybean event MON87751 and at least a second probe that specifically hybridizes to soybean genomic DNA that was disrupted by insertion of the heterologous DNA of soybean event MON87751 and is disrupted by the modified soybean event MON87751 DNA, wherein the second probe does not hybridize to the modified soybean event MON87751 DNA; and b) hybridizing the probe set with the sample under stringent hybridization conditions, wherein detecting hybridization of only the first probe under the hybridization conditions is diagnostic for a soybean plant, soybean plant part, or soybean seed homozygous for the modified soybean event MON87751, and wherein detecting hybridization of both the first probe and the second probe under the hybridization conditions is diagnostic for a soybean plant, soybean plant part, or soybean seed heterozygous for the modified soybean event MON87751.

51. The method of claim 50, wherein the probe set comprises SEQ ID NO: 13 and SEQ ID NO: 16.

52. The method of any one of claims 46-51, wherein the modified soybean event MON87751 is a further modified soybean event MON87751.

53. A population of transgenic soybean plants, wherein each transgenic soybean plant of the population comprises a modified soybean event MON87751.

54. The population of claim 53, wherein each transgenic soybean plant of the population exhibits resistance to a Lepidopteran insect pest species.

55. The population of transgenic soybean plants of claim 53 or 54, wherein the modified soybean event MON87751 is a further modified soybean event MON87551.

56. A method of modifying a soybean plant, the method comprising: a) introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site-specific nuclease into at least one cell of an explant of a soybean plant comprising soybean event MON87751, or a plant part thereof, to produce a modified soybean event MON87751 via a genome editing technique; and b) developing or regenerating a modified soybean plant from the explant, wherein the modified soybean plant comprises the modified soybean event MON87751.

57. The method of claim 56, wherein the site-specific nuclease is a zinc-finger nuclease (ZFN), a meganuclease, an RNA-guided endonuclease, a TALE-endonuclease (TALEN), a recombinase, or a transposase.

58. The method of claim 56 or 57, wherein the site-specific nuclease is an RNA-guided endonuclease or a CRISPR / Cas nuclease.

59. The method of claim 58, wherein the introducing step (a) comprises introducing the recombinant DNA construct into the at least one cell of the explant, and wherein the recombinant DNA construct further comprises an expression cassette encoding a first guide RNA (gRNA).

60. The method of claim 59, wherein the recombinant DNA construct further comprises an expression cassette encoding a second guide RNA (gRNA).

61. The method of claim 58, wherein the introducing step (a) further comprises introducing a first guide RNA (gRNA) or a second recombinant DNA construct comprising an expression cassette encoding a first guide RNA (gRNA) into the at least one cell of the explant.

62. The method of claim 61, wherein the introducing step (a) comprises introducing at least two guide RNAs (gRNAs) comprising the first gRNA and a second gRNA into the at least one cell of the explant.

63. The method of claim 61, wherein the second recombinant DNA construct further comprises an expression cassette encoding a second guide RNA (gRNA).

64. The method of claim 61, wherein the introducing step (a) comprises introducing a first gRNA and second recombinant DNA construct comprising an expression cassette encoding a second guide RNA (gRNA) into the at least one cell of the explant.

65. The method of any one of claims 56-64, wherein the site-specific nuclease has a first target site in the genome of the soybean plant at or near soybean event MON87751.

66. The method of claim 65, wherein the site-specific nuclease has a second target site in the genome of the soybean plant at or near soybean event MON87751.

67. The method of any one of claims 56-66, wherein the introducing step (a) comprises introducing a second site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a second site specific nuclease into at least one cell of the explant, and wherein the second site-specific nuclease has a second target site in the genome of the soybean plant at or near soybean event MON87751.

68. The method of any one of claims 59-64, wherein the first gRNA has a first target site in a flanking DNA sequence, 5' flank, 3' flank, junction sequence, or insertion sequence of soybean event MON87751, or a complement thereof.

69. The method of any one of claims 59-64 and 68, wherein the first gRNA has a first target site comprising a target sequence that is: i. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or ii. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%,at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or iii. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 1 1, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof.

70. The method of claim 69, wherein the first gRNA has a second target site comprising a target sequence that is: i. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or ii. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least10, at least 1 1 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or iii. at least 90%, at least 91%, at least 92%, at least 93%>, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof.

71. The method of any one of claims 59-64 and 68-70, i. wherein the first gRNA has a first target site comprising a target sequence that is:

1. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or2. at least 90%, at least 91%, at least 92%, at least 93%>, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%or 100% identical to at least 10, at least 1 1 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or3. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof; and ii. wherein the second gRNA has a second target site comprising a target sequence that is:

1. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 27 or 47, or a complement thereof; or2. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99. 1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%or 100% identical to at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 28 or 48, or a complement thereof; or3. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% or 100% identical to at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 consecutive nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or a complement thereof.

72. The method of any one of claims 66, 67, 70, or 71, wherein the modified soybean event MON87751 comprises a deletion or excision of intervening genomic DNA between the first target site and the second target site, relative to the soybean event MON87751.

73. The method of any one of claims 56-72, further comprising: c) selecting the modified soybean plant comprising the modified soybean event MON87751; and d) sexually crossing the modified soybean plant with itself or a second soybean plant to produce one or more modified progeny soybean plants.

74. A method of introducing a target site into a soybean plant, the method comprising: a) introducing a cognate target site into the soybean event MON87751 locus of at least one cell of a soybean plant or soybean plant part comprising the soybean event MON8775 1 or an explant thereof via a targeted genome editing technique, wherein the cognate target site is identical or similar to an originator target site for a sitespecific nuclease present in the soybean event MON87751 locus; andb) developing or regenerating a modified soybean plant comprising a modified soybean event MON87751 comprising the cognate target site.

75. The method of claim 74, further comprising: c) introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site specific nuclease into at least one cell of an explant of a soybean plant comprising the modified soybean event MON87751 or a plant part thereof, to produce a further modified soybean event MON87751 via a targeted genome editing technique, wherein the target site of the site-specific nuclease includes the cognate target site and the originator target site; and d) developing or regenerating a second modified soybean plant comprising the further modified soybean event MON87751.

76. A method of introducing a target site into a soybean plant, the method comprising: a) introducing a cognate target site into the soybean event MON87751 locus of at least one cell of a soybean plant or soybean plant part comprising the soybean event MON87751 or an explant thereof via a targeted genome editing technique to produce a modified soybean event MON87751 comprising the cognate target site, wherein the cognate target site is identical or similar to an originator target site for a site-specific nuclease present in the soybean event MON87751 locus, and b) introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site specific nuclease into at least one cell of an explant of a modified soybean plant comprising the modified soybean event MON87751, or a plant part thereof, to produce a further modified soybean event MON87751 via a targeted genome editing technique, wherein the target site of the site-specific nuclease includes the cognate target site and the originator target site; and c) developing or regenerating a second modified soybean plant comprising the further modified soybean event MON87751.

77. The method of claim 75 or 76, wherein the further modified soybean event MON87751 of the second modified soybean plant comprises a deletion or excision of intervening genomic DNA between the originator target site and the cognate target site, relative to the soybean event MON87751 or modified soybean event MON87751.

78. The method of claim 75-77, further comprising: selecting the second modified soybean plant or a progeny plant of the second modified soybean plant comprising the further modified soybean event MON87751, and sexually crossing the second modified soybean plant or the progeny plant with itself or another soybean plant to produce one or more modified progeny soybean plants comprising the further modified soybean event MON87751.

79. The method of claim 74 or 76, wherein the modified soybean event MON87751 is a further modified soybean event MON87551.

80. A method of producing a progeny soybean plant comprising a modified soybean event MON87751 comprising: a) sexually crossing a first modified soybean plant that comprises a modified soybean event MON87751 with itself or a second soybean plant; b) collecting one or more seeds produced from said cross; c) growing said seed to produce one or more progeny plants; and d) selecting at least a first progeny plant or seed comprising a modified soybean event MON87751.

81. A method of modifying an explant of a soybean plant or plant part, the method comprising: introducing a site-specific nuclease or a recombinant DNA construct comprising an expression cassette encoding a site-specific nuclease into at least one cell of an explant of a soybean plant or plant part comprising soybean event MON87751 to produce a modified soybean event MON87751 into the at least one cell of the explant.

82. The method of claim 81, wherein the modified soybean event MON87751 is a further modified soybean event MON877 1.

Images